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Abstract  
 
The University of Manchester 
Dong Hyun Kim: September 2010 
Degree of Doctor of Philosophy in the Faculty of Engineering and Physical Sciences 
Investigation of HIV Anti-viral Drug Effect on HPV16 E6 Expressing Cervical Carcinoma 
Cells Using Advanced Metabolomics Methods  
 
Metabolomics approaches have recently been used to understand the complex molecular 
interactions of biological systems. One popular area in which these methods are being 
developed is to understand the biochemical changes during abiotic and biotic stresses; for 
example, how a cell may respond to a drug. Since metabolites are the end products of gene 
expression, these can be used to indicate the result of the activities and interaction of the cell 
or organism with its environment. The investigation of the level and compositional changes 
of metabolites against metabolic stresses such as chemotherapeutic treatment (drug exposure) 
are required to understand more fully abiotic perturbation to biological systems. The aim of 
this project was to understand the metabolic effect that the anti-viral drugs indinavir and 
lopinavir (currently used by HIV patients) have on HPV-related cervical cancer cell lines by 
measuring changes in metabolism using a wide range of analytical techniques; including 
Fourier transform infrared (FT-IR) and Raman spectroscopies, and gas and liquid 
chromatography-mass spectrometry (GC and LC-MS). The analyses and interpretation of the 
large volumes of complex multidimensional data generated by metabolomics approaches 
were performed with a combination of multivariate data analysis techniques such as principal 
components analysis (PCA) and canonical variates analysis (CVA), as well as univariate 
approaches such as 	-Way analysis of variance (ANOVA). By combining biochemical 
imaging, metabolite fingerprinting and footprinting, and metabolite profiling, with multi- and 
uni-variate analyses, the actions and effects of the anti-viral drugs were investigated. FT-IR 
spectroscopy was initially used to generate global biochemical finger- and foot-prints, and 
Raman spectroscopy was employed to investigate intracellular distribution of metabolites, 
and other cellular species, as well as the localisation of drug molecules within cells. FT-IR 
spectroscopy ascertained that the intra- and extra-cellular metabolomes were being directly 
influenced in a fashion that correlated with increasing anti-viral dosing; these effects were 
phenotypic rather than measurements of the drug level. Raman imaging spectroscopy 
indicated that the indinavir but not lopinavir was being compartmentalised within the cell 
nucleus, but only in HPV early protein 6 (E6) expressing cells. This observation was further 
confirmed by fractionation of cell samples into nuclear and cytoplasmic fractions and 
assessing the indinavir concentrations via LC-MS.  Finally, LC-MS and GC-MS metabolite 
profiling were employed to investigate changes in the intracellular metabolome in response to 
the anti-viral compounds across a range of physiologically relevant concentrations and in the 
presence and absence of the E6 oncoprotein. General effects of both anti-viral compounds 
included the regulation of metabolites such as glutathione, octenedionoic and octadecenoic 
acids, which may be involved in stress related responses, reduced levels of sugars and sugar-
phosphates indicating a potential arrest of glycolysis, and reduced levels of malic acid 
indicating potential decreased flux into the TCA cycle; all indicating that central metabolism 
was being reduced. Finally, LC-MS based quantification indicated that in the presence of E6, 
lopinavir was actively removed from the cell, whereas the indinavir intracellular 
concentration increased concomitantly with the level of dosing. These investigations have 
revealed that metabolomics approaches are an apt tool for the study of anti-viral effects 
within cell cultures, but improvements need to be made with respect to the major limitation of 
metabolite identification.    
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CHAPTER 1 
 
1.  Introduction 
 
1.1. Cancer 
Cancer is a collection of diseases with the common feature of uncontrolled cell growth. 
Carcinogenesis, the process of the development of cancers, is a multistage mechanism caused 
by the accumulation of abnormalities in significant regulatory pathways (Cohen and Ellwein 
1991, King and Robins 2006, McKinnell et al. 1998). It is initiated in a single cell, but the 
altered cell must then achieve sufficient proliferation to produce the large numbers of cells 
that constitute a given cancer (Cooper 1992). Therefore, multiple cellular lesions are required 
to generate a cancer. All cell types are susceptible to cancer, especially those comprising 
epithelial or boundary tissues although mesenchymal cells (e.g. leukaemias/lymphomas) can 
also be affected but usually to a lesser degree. With respect to the aetiology of a cancer, de-
regulated expression of oncogenes and mutations or deletions in tumour suppressor genes are 
clearly important. The proliferation of normal cells is specifically regulated by so-called 
‘proto-oncogenes’ which, when mutated, can lead to uncontrolled cell growth. Mutated proto-
oncogenes are then termed oncogenes. Furthermore, other genes called tumour suppressors 
may function to repair cell damage and/or induce either growth inhibition or the death of 
damaged cells. Clearly loss of function of such genes is associated with the genesis of many 
cancers. The correct diagnosis of cancer is important for treatment decisions since invasion 
and metastasis distinguish many cancers from benign growths. Generally speaking, the 
acquisition of invasive properties distinguishes cancer cells from normal cells, while 
metastasis to other parts of the body is the major cause of clinical problems and death 
(Cooper 1992, King and Robins 2006). 
 
1.1.1. Cancer Initiation and Progression 
The mutation and selection of more rapidly growing cells with increasing invasiveness and 
metastatic potential are an important multistep mechanism for the development of a 
malignant neoplasm (Figure 1.1) (Cooper 1992). Tumour initiation is the first process in the 
development of a neoplasm by a genetic alteration (mutation) resulting in the uncontrolled 
proliferation of a single cell. Subsequent stages of tumour development are termed promotion 
- 18 - 
 
Initiation Mutation
Cell proliferationPromotion
Mutation
Selection for rapid growth
Mutation
Selection
Initial tumour cell
population
Variant cell with
increased growth
potential
Variant tumour
cell population
Still more rapidly
growing variant cell
More rapidly
growing variant
tumour cell population
Progression
and progression during which the cells undergo proliferation and acquire additional mutations 
which confer growth or survival advantages to the evolving tumour.  Some mutations may be 
detrimental to growth although these will be rapidly selected out of the rapidly evolving 
population of a cell.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1. Selective expansion and tumour progression. The development of a malignant neoplasm occurs by a 
multistage process, carcinogenesis, which involves mutation and selection for more rapidly growing cells within 
the tumour cell population. 
 
Thus mutated cells with enhanced growth characteristics have a selective advantage whereby 
they quickly outgrow other cells in the developing tumour due to their increased growth 
potential. This process is called clonal selection where new clones of tumour cells with 
increased proliferative potential continually evolve during the development of the disease.  
Thus, the repetition of the clonal selection step during tumour progression allows tumour 
cells to grow more and more rapidly (Cooper 1992, Foulds 1958, Nowell 1976). 
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1.1.2. Cancer Invasion and Metastasis 
There are more possibilities to cure benign neoplasms and carcinomas in situ, small tumours 
that remain confined to their site of origin and so have not yet invaded adjacent connective 
tissues can be removed by localised surgical procedures. However, once surrounding normal 
tissue has been invaded, all of the tissues that contain cancer cells have to be removed for 
effective surgery (Cooper 1992). Likewise, the occurrence of secondary tumours, no longer 
adjoining to the primary site of tumours, is known as metastasis. Once a cancer has 
metastasised to distant sites in the body, surgery is not usually an option and various 
combinations of surgery and/or chemotherapy are needed to prevent the disease spreading.  
 
A good example of early detection is provided by use of the so called Papanicolaou (Pap) test 
to detect the premalignant early stages of cervical disease. This has enabled a massive 
reduction in cervical cancer related mortality in developed countries which have cervical 
cytology screening programs. This allows the detection of early stage cervical disease which 
greatly improves treatment outcome. However, in most other cancers >50% have 
metastasised at the time of diagnosis with the inevitable increase in disease associated 
mortality (Cooper 1992, Fidler 1990).  
 
Basement membranes include type IV collagen as the major component (Sinha et al. 1991), 
as well as a large number of other constituents such as laminin and fibronectin (McKinnell et 
al. 1998). Therefore, since human tumours (Fidler 1997, Shields et al. 1984) generate type IV 
collagenase, the tumour cells readily invade underlying connective tissue through the 
basement membrane in the first step in progression from carcinoma in situ to metastatic 
carcinoma (Figure 1.2)(Cooper 1992). The cancer cells then continue to proliferate and 
spread through the normal tissue surrounding the site of the primary tumour. The second step, 
one of the most important processes, is that tumour cells can enter into the blood and 
lymphatic systems and these are the major routes of tumour metastasis. Thus, the invasion by 
a tumour into the normal tissue surrounding its site of origin allows the cancer cells to 
penetrate blood and lymphatic vessels, resulting in them being carried throughout the body. 
Once in the circulatory system the cancer cells can be transported to any site in the body. 
They can then grow in a new organ by again penetrating through the capillaries and invading 
the adjacent tissue (Cooper 1992, Gupta and Massague 2006).  
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Figure 1.2. Invasion and metastasis. Cancer cells invade underlying normal tissue and destruct the basement 
membrane, and eventually penetrate blood and lymphatic vessels. Cancer cells are then transported to distant 
sites in the body, leading to metastatic tumours. 
 
1.2. Viral pathogens 
Since many kinds of viruses cause serious diseases in humans and/or domestic animals, and 
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others damage crop plants, they are of great interest in terms of understanding their 
mechanisms and developing anti-virals, vaccines and improved medical care (Strauss and 
Strauss 2002). The initial pathogenesis in the life cycle of a virus is its attachment and entry 
into specific receptors on living cells (Tardieu et al. 1982) which provides the capability of 
subverting the biochemical apparatus of the cell to ensure viral replication (Challand and 
Young 1997). The viron, which is the mature and extracellular virus particle, contains a 
genome that may be DNA or RNA wrapped in a protein coat called a capsid or nucleocapsid. 
These proteins interact with the specific receptors on the surface of the host cell in which the 
viruses replicate and there is a lipid envelope surrounding the nucleocapsid in some viruses. 
This capsid or envelope functions as a protective device for the viral genome whilst the viron 
is in the extra-cellular environment. The information required for viral replication is 
contained within its genome which, on infection, is released into the cytoplasm sometimes 
still in association with protein (“uncoating”). The viral genome then redirects the cellular 
biosynthetic machinery to replicate many copies of itself and to encapsulate these in new 
mature virions. Cellular energy and protein production systems are essential for this 
replicative process. (Strauss and Strauss 2002, Wagner and Hewlett 1999). 
 
1.2.1. Classification of Viruses 
There are >2,500 groups of different viruses recognised and characterised. Since a common 
origin of viruses is unclear, it is impossible to undertake a true Linnaean classification. 
However, a logical classification is valuable in the sense that it has allowed the understanding 
of the detailed properties of individual viruses. Generally, the viruses can be classified based 
upon basic properties as well as specific features of their replication cycle, which provide a 
useful set of parameters (Wagner and Hewlett 1999). Therefore, there are three broad classes 
of viruses which may have independent evolutionary origins (Flint et al. 2000, Haaheim et al. 
2002, Strauss and Strauss 2002). 
 
The first class contains DNA as the genome, which can be single or double stranded with 
direct copying of DNA → DNA as the method of genome replication. For production of viral 
mRNAs and proteins, the transcription of the viral DNA is performed by either cellular 
and/or viral RNA polymerases, depending on the virus type. Furthermore, replication of the 
viral DNA genome is carried out by DNA polymerases that can be of either viral or cellular 
origin. Replication of the genomes of most DNA viruses within eukaryotes, such as human 
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papillomavirus, and assembly of progeny viruses, is carried out in the nucleus; however 
certain viruses such as the poxviruses are replicated in the cytoplasm. 
 
The second class of viruses contains RNA as their genome and direct RNA → RNA copying 
is the method of replication. These viruses can be divided into three subgroups; plus-strand 
RNA, minus-strand RNA and antisense virus. Plus-strand RNA viruses such as yellow fever 
virus (family Flaviviridae) and poliovirus, have a genome which is a messenger RNA. 
Minus-strand RNA viruses like the measles virus (family Paramyxoviridae) and rabies virus 
(family Rhabdoviridae), have anti-messenger sense RNA as their genome. Lastly, antisense 
viruses such as arenaviruses (family Arenavitidae) and some of the genera belonging to the 
family Bunyaviridae have a genome that has regions of both messenger and anti-messenger 
sense.  
 
The third class of viruses incorporate an RNA → DNA copying step in their life cycle and 
uses the enzyme reverse transcriptase. They are thus called retroviruses and their genetic 
information alternates between being contained in RNA and DNA. Retroviruses (e.g. HIV, 
family Retroviridae) contain the RNA phase in the viron and have two copies in a single-
stranded RNA genome. Thus, their genome replicates through a DNA intermediate (RNA → 
DNA → RNA). The hepadnaviruses (e.g. hepatitis B virus, family Hepadnaviridae) contain 
circular and largely double stranded DNA as their genome. Thus, the replication of their 
genome occurs through an RNA intermediate (DNA → RNA → DNA).  
 
All viruses, except retroviruses, are haploid, thus they contain only one copy of the genomic 
nucleic acid whilst retroviruses are diploid and contain two identical copies of the single-
stranded genomic RNA (Strauss and Strauss 2002). 
 
1.2.2.1. D%A Viruses 
A simple schematic representation of the replication of a DNA virus is shown in Figure 1.3 
(Strauss and Strauss 2002). The first step of the replication is the attachment of DNA virus to 
a cellular membrane receptor. After the virus DNA enters into the cell and is transported to 
the cell nucleus, it is transcribed into mRNA by host RNA polymerase. Host ribosomes then 
translate viral mRNAs in the cytoplasm and viral proteins are newly synthesised. The 
structural and non-structural viral proteins are carried back to the nucleus and either the host 
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DNA polymerase or a new viral-encoded polymerase replicates the DNA genome in the 
nucleus. Finally, progeny viral structures are assembled and released from the cell (Strauss 
and Strauss 2002). 
 
 
 
Figure 1.3. General replication scheme for a DNA virus 
 
1.3. Cervical Cancer and Human Papillomavirus (HPV) 
Each year in the UK, over 2,700 women are diagnosed with cervical cancer which leads to 
approximately 1,000 deaths per annum (UK Cervical Cancer Statistics, Cancer Research UK. 
www.cancerresearchuk.org). Globally an estimated 493,000 women are affected by cervical 
cancer resulting in 273,500 deaths each year (National Cervical Cancer Coalition. www.nccc-
online.org). Indeed in many low resource countries it is the greatest cause of women’s cancer-
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related mortality.  
 
Cancer of the cervix which is the lower part of the uterus (Figure 1.4A) most commonly 
originates in the so-called transformation zone of the cervix where the columnar endocervical 
cells of the cervical canal undergo transition to the squamous epithelial cells of the ecto- 
cervix. Cervical cancer does not develop rapidly whereby normal cervical cells gradually 
pass through various pre-cancerous stages that can ultimately develop in to a frank carcinoma. 
There are two main histological types of cervical cancer; squamous cell carcinoma and 
adenocarcinoma. Cervical cancers and cervical pre-cancers are differentiated by their 
appearance as determined via microscopic visualisation (Figure 1.4B). Squamous cell 
carcinomas (SCC’s), accounting for 80% to 90% of cervical cancers, consist of flattened thin 
cells which have the characteristics of the squamous epithelial cells that cover the surface of 
the endocervix (Figure 1.4A). The remaining 10% to 20% of cervical cancers are 
adenocarcinomas which are derived from and resemble the columnar mucus-producing 
glandular cells of the endocervix (www.cancer.org). It is widely accepted that high risk types 
of HPV, most frequently HPV16, are the main aetiological agent for invasive cervical cancer 
(McMurray et al. 2001, Snoeck 2006, Walboomers et al. 1999, zur Hausen 1996). 
 
The papillomaviruses are small DNA viruses that belong to the Papillomaviridae, and cause 
benign squamous epithelial tumours in their natural hosts. There are >100 different types of 
HPV associated with a variety of clinical lesions with approximately 20 of these being 
associated with anogenital tract lesions (de Villiers 1989). Of these HPVs, low-risk types 
(e.g., HPV6 and 11) have low tumourigenic potential and usually cause benign warts. By 
contrast, the high-risk types (e.g., HPV16, 18 and 16 others) are more often found in 
association with pre-malignant cervical lesions and invasive cancers (Scheffner et al. 1990, 
zur Hausen 1996). Accounting for >60% of disease, HPV16 and 18 are the most prevalent 
high-risk types associated with cervical cancer although to date there have been 16 other high 
risk types identified (Dalstein et al. 2009, Harper et al. 2004, Munoz et al. 2003).  
 
Expression of high risk HPV E6 and E7 viral oncoproteins are largely responsible for the 
oncogenic properties of HPV (zur Hausen 2000). One of the most intensively studied 
properties of the E6 protein is its ability to compromise the function of the p53 tumour 
suppressor protein (Huibregtse et al. 1991). In association with the cellular E3 ubiquitin 
ligase E6-associated protein (AP), E6 binds to the p53 protein. E6 mediated activation of 
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E6AP then catalyses the ubiquitination and subsequent proteasomal degradation of p53 
(Huibregtse et al. 1993) (see Figure 1.5). Indeed this strategy of inappropriate activation of 
the proteasome is used by many other viruses to subvert the function of a variety of cellular 
proteins that would prove detrimental to viral persistence (Banks et al. 2003, Thomas et al. 
1999, zur Hausen 1996). This implies that selective inhibition of proteasomal function could 
prove to be an effective strategy for the treatment of HPV infections. 
 
 
 
 
Figure 1.4. (A) Cervical cancer illustration (http://www.mayoclinic.org/cervical-cancer/details-cervical-
cancer.html); (B) Images of normal (top) and malignant (bottom) cells from a tissue biopsy of the cervix. 
Magnification × 100 (Dukor 2002). 
 
 
Figure 1.5. Viral ubiquitin-ligase complexes. The human papillomavirus E6-E6-associated protein (E6AP) 
ubiquitin-ligase complex directs the degradation of the p53 tumour suppressor protein. E6 interacts directly with 
p53 and the E6AP ubiquitin ligase, thereby redirecting E6AP to p53 together with the E2 enzyme UbcH7 family 
members. 
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Hampson et al. (2006) have recently reported that the anti-viral drugs, indinavir and lopinavir 
(Figure 1.6), which are currently used as human immunodeficiency virus (HIV) protease 
inhibitors, could also inhibit E6-mediated proteasomal degradation of p53 and selectively kill 
E6-dependant cervical carcinoma cells in vitro. Therefore, this is an excellent model system 
to investigate drug-cell interactions using advanced metabolomics methods.  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6. The chemical structures of indinavir (A) and lopinavir (B) 
 
1.4. Metabolomic Analysis 
Since the completion of genome sequences of a wide variety of organisms, the determination 
of the functions of the putative genes encoded by the newly sequenced DNA has become a 
pressing issue. This is because it has tremendous importance for the validation of potential 
new targets for drug therapy and for the discovery of new biomarkers of human disease as 
well as gene function analysis (Weckwerth and Morgenthal 2005). 
 
To date, the molecular level information that aids our understanding of complicated 
interactions in biological systems has concentrated largely upon transcriptomic studies. 
However, since transcriptomics has very high costs, few studies involve the high levels of 
replication that are required to meet adequate rigid statistical requirements (Fiehn 2001). 
Two-dimensional (2D) gel electrophoresis (GE), which is comparatively inexpensive, was 
introduced by (O'Farrell 1975), and this and other proteomic techniques have been 
increasingly investigated to understand biological systems. However, technical limitations of 
2D-GE, especially in terms of its lack of reproducibility, clearly reveal that this is not a 
method which can be applied to the analysis of a wide range of proteins in a high-throughput 
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manner (Heijne et al. 2003). Furthermore, it is difficult to identify proteins present in small 
concentrations when compared to highly abundant proteins in current 2D systems, these 
result from there being no protein amplification techniques, such as the polymerase chain 
reaction (PCR) commonly used to amplify DNA and RNA. Also, the fact that some proteins 
are highly hydrophobic and others have a wide charge range means it is difficult to separate 
proteins in 2D gels thereby making it impossible to analyse the full complement of proteins 
present within a cell or tissue (Fiehn 2001, Gygi et al. 2000, Huber 2003). The limitations of 
these approaches show that transcriptomic and proteomic studies cannot alone serve as 
techniques that aid the full understanding of various responses of biological systems to 
genetic and environmental changes, and metabolic stresses.  
 
Recent post-genomic science or systems biology aims at the comprehensive analysis of the 
integrated information from static genes (genome) to dynamic mRNA (transcriptome), 
proteins (proteome) and metabolites (metabolome), in order to understand complex molecular 
interaction in biological systems. Metabolomics is the field of quantifying and identifying all 
of the metabolites present in the cell or organism at a given time under specific conditions. 
This can be expanded to dynamic temporal measurements as an organism undergoes change 
in its environment. Therefore, metabolomics is one of the most recently developed fields for 
holistic approaches, complementing other ‘omics’, such as genomics, transcriptomics and 
proteomics (Fiehn et al. 2001, Weckwerth 2003).  True integrative systems biology has to be 
performed with all these omics studies together, but metabolomics is best suited for analysing 
the intra- and extracellar effects of perturbation with drugs. 
 
Although metabolomics is a complementary field it has particular advantages over 
transcriptomics and proteomics. Small changes in the levels of individual enzymes, which 
cannot be clearly detected by transcriptomics and proteomics, may cause significant effects 
on the concentrations of a variety of metabolites (Urbanczyk-Wochniak et al. 2003). 
Furthermore, the metabolome is the end product of gene expression, or metabolic activities of 
cells and, so reflects more accurately the responses of the cell or organism to both gene 
expression and its environment; i.e., phenotype. Also, since metabolic fluxes are not 
regulated by gene expression alone and changes caused by transcriptome and proteome do 
not always accompany mutated phenotypes such as the metabolome, some physiological 
perturbations, which do not result in changes of the concentrations of enzymes, could be 
detected by metabolic approaches (Goodacre et al. 2004, ter Kuile and Westerhoff 2001). 
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Therefore, the development of metabolomics will greatly enhance our current knowledge of 
biological systems and, at a more general level, functional genomics (Dunn and Ellis 2005).  
 
Despite the above advantages, metabolomics presents unique challenges. There is still a great 
deal of room for technical improvement in areas such as the large-scale detection of the huge 
range of metabolite chemistries that exist within complex tissues, as well as introducing 
routine processes for the dissemination of metabolomic data and research findings (Fiehn et 
al. 2007a, Fiehn et al. 2008), analysis (Goodacre et al. 2007) and reporting (Fiehn et al. 
2007b). For the continued development and application of metabolomics in order to 
understand biological systems, it will be crucial to provide a platform that allows a 
comparison of the results obtained by different laboratories while, at the same time, 
integrating the metabolomic data with other functional genomic information (Bino et al. 
2004). However, metabolic approaches using gas chromatography-mass spectrometry (GC-
MS) and nuclear magnetic resonance (NMR) are the most robust platforms for generating 
comparable data in different research institutes currently (Allwood et al. 2009, Ward et al. 
2010). 
 
1.4.1. Conventional Classification of Metabolic Approaches 
The ultimate objective of metabolomics is to analyse the full metabolic complement within 
the target organism. However this is currently impossible because many thousands of 
metabolites exist across a large spectrum of chemistries in organisms and thus there is no 
single appropriate analytical technique for the simultaneous detection of all metabolites, 
either qualitatively or quantitatively. Therefore, different metabolic strategies according to 
various analytical aims have been developed in order to solve specific questions of biological 
systems. The definitions of various metabolomics approaches as proposed by Fiehn to meet 
the above demands are as follows (Fiehn 2001, Fiehn 2002). 
 
(a) Metabolite Target Analysis: Is a strategy where analysis is restricted to a specific 
chemical class of metabolites, metabolite pathway, or the direct detection of an individual 
metabolite generated by a particular enzyme system. In order to prevent interferences from 
major metabolite components, extensive sample purification steps are often undertaken to 
improve the sensitivity and accuracy of quantification. This strategy is most suitable for 
purposes of monitoring specific compounds in extremely complex matrices, such as 
phytohormones (Duffield and Netting 2001, Ribnicky et al. 1998). 
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(b) Metabolite or Metabolic Profiling: In order to investigate the metabolome, it may not be 
essential to determine all of the perturbations which occur in all branches of metabolism. 
Therefore, this strategy can be focused on the identification and quantification of a selected 
number of pre-defined metabolic pathways or metabolites with similar chemistries. The latter 
is largely dictated by the chosen metabolomics platform. Sample preparation is typically non-
targeted thus allowing the detection and quantification of a wide range of metabolites, sample 
complexity is reduced by applying chromatographic separations prior to detection by MS or 
NMR spectroscopy. This metabolite profiling strategy is widely used across all areas of 
biological (plants, microbes, animals, environmental) metabolomics as well as in the clinical 
context of drug research for biomarker discovery in biomedicine and drug development by 
tracing the metabolic fate of an administered drug.  
 
(c) Metabolic Fingerprinting: This is a high-throughput approach for the classification of 
samples on the basis of relative changes across all of the detectable metabolite features 
without regard to their identification. In certain cases, such as FT-IR spectroscopy, the 
instrument may not be capable of metabolite identification. NMR and MS techniques can also 
be applied to metabolic fingerprinting where as a last step features that have been proven to 
be statistically significant are targeted for identification. Metabolic fingerprinting is typically 
used for large scale screening, however it can also be applied to functional genomics studies 
where the investigator is largely interested in only those metabolites that have been altered as 
a result of gene expression. This approach is also apt for the identification of major 
alterations in biochemical pathways as well as for biomarker discovery for diagnostic use in 
both industrial and clinical scenarios. 
 
(d) Metabolomics: The influence of a mutation by a single genetic alteration may be directed 
to changes in metabolite levels from seemingly unrelated biochemical pathways because of 
pleiotropic effects. In order to elucidate these kinds of events, a comprehensive quantitative 
analysis of all metabolites in a biological system at a given time and under certain conditions 
is needed. Such a strategy is called metabolomics. In order to avoid excluding any metabolite 
of a biological system, well established non-targeted sample preparation procedures and 
analytical techniques must be applied. High sensitivity, selectivity, matrix independence, and 
universality, must be secured to improve the resolving power of the analytical method used in 
metabolomics. Also, since metabolomic data sets are complex, as dictated by the number of 
metabolites detected within the biological samples, highly effective informatics tools are 
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needed to store, normalise, compare, and evaluate the acquired data in order to understand 
interactions and responses between genetic alterations in biological systems. Additionally, 
identification and quantification of as many metabolite features as is possible must be 
achieved and comparison of the analytical results with models of theoretical biochemical 
networks must also be attempted. Currently, metabolomics is limited by the fact that no single 
analytical technique has the ability to quantify and identify all metabolites. Therefore 
typically the approach adopted is to analyse the samples across a number of analytical 
platforms to reveal as great a portion of the metabolome as possible. 
 
(e) Metabonomics:  This is a term used synonymously with metabolomics.  Metabonomics is 
defined as “the quantitative measurement of the dynamic multiparametric metabolic response 
of living systems to pathophysiological stimuli or genetic modification” (Nicholson et al. 
1999). Metabonomics has largely been used in drug safety testing and the generation of 
metabolic databases for both control and diseased animals and humans, as well as the above 
mentioned applications (Lindon 2004). 
 
(f) Metabolic Footprinting: The investigation of intracellular metabolites is a powerful 
method for the understanding of biological systems. However, the measurement of a 
complete set of intracellular metabolites is time consuming and the rapid turnover of 
intracellular metabolites results in numerous technical difficulties which require rigid 
methods for the rapid quenching of metabolism, as well as extraction and separation from the 
extracellular space. Therefore, the measurement of extracellular metabolites secreted and 
excreted from cells or organisms into growth medium is an effective method for example for 
the investigation of ‘unknown’ mutants by genetic modification. This strategy is called 
metabolic footprinting. The classification of microbial mutants for functional genomics has 
been carried out using metabolic footprinting (Allen et al. 2003, Kell et al. 2005). 
 
(g) Metabolic Flux Analysis: This is a well established tool for the investigation of cellular 
metabolism and so it has been used for the analysis of the pathways of intermediary 
metabolism in a variety of organisms. The aim of this analysis is the detailed quantification of 
all metabolic fluxes in (central) metabolism of an organism and so a stoichiometric model is 
employed for the calculation of intracellular fluxes in order to identify the major intracellular 
reactions and to apply mass balances around intracellular metabolites. For example, it can 
help to detect which of several pathways is preferred by the cells to consume a particular 
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substrate. This strategy has been used in bioprocess engineering to monitor cell viability and 
improve strain activity (Lee et al. 1999, Provost and Bastin 2006, Wiechert 2001).  
 
1.4.2. Sampling and Sample Preparation 
In metabolomics, sampling and sample preparation are one of the most important processes in 
order to reduce experimental errors. These errors, or variances, can lead to the detection of 
metabolic changes that are not related to the original objective being studied. Therefore, 
sample preparation has to be accurate and unbiased. In addition rapid protocols are needed 
for reproducible metabolomics experiments and these must consider sampling time, cell or 
tissue cycles, and the section and size of the sample need to be taken into account. In 
microbial metabolomics, since the sample is small and the environment is well controlled, the 
experiments are generally quite reproducible. However, in the case of plant metabolomics, it 
is more difficult to maintain reproducibility because variation in biochemical status might 
occur according to shade and light, diurnal and dietary influences, the growth stage of a plant, 
geographical variation, seasonal variation and harvesting procedure (Boyes et al. 2001, 
Cheng and Ma 2004, Dunn et al. 2005, Ma and Cheng 2003, Noteborn et al. 2000). 
Furthermore, the most and largest variation may occur in human metabolomics due to 
differences in diet, diurnal changes, sex and oestrus cycle, disease, lifestyle, time of sampling, 
drug dosing vehicle and cell cycle (Beckwith-Hall et al. 2002, Bollard et al. 2001, Boydston-
White et al. 2006, Brindle et al. 2002, Dunn et al. 2005, Goodacre 2007, Jernstrom et al. 
2003, Solanky et al. 2003). 
 
There are different strategies of sampling and sample preparation depending on the kind of 
samples being studied. Invasive strategies have usually dealt with blood, serum and 
intracellular metabolites in plants and microbes, whereas non-invasive sampling can be 
performed using urine, volatile components and metabolic footprinting. Extracellular 
metabolites such as urine or growth media (in the case of metabolic footprinting) contain 
great information over a period of metabolic activity (Dunn et al. 2005). In the case of 
intracellular metabolites, careful quenching and extraction from the sample should be 
employed. Although extraction of intracellular metabolites provides metabolic information at 
specific time and conditions, it is difficult to be completely reproducible. The most important 
thing in metabolic approaches is how to stop the inherent enzymatic activity of biological 
samples rapidly. Inadequate methods for quenching metabolism may result in inaccurate and 
biased analysis from biological samples, which is most significant in metabolomics 
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experiments. For example, if quenching fails to stop the activity of phosphatases, ATP and 
fructose-1,6-bisphosphate are converted to ADP and fructose-6-phosphate, respectively. If 
this reaction proceeds, then the true level of the intermediates is lost. Usually, freeze 
clamping, freezing in liquid nitrogen or acidic treatment using perchloric or nitric acid can be 
performed for rapid inhibition of enzymatic activity (ap Rees and Hill 1994). However, these 
methods have some disadvantages. Freezing methods occasionally lead to loss of metabolites 
(Wittman et al. 2004), production of metabolites from responses to injury, irreversible 
absorption of metabolites to cell walls or the recovery of enzymes by partially thawing 
biological samples. Furthermore, serious reduction of metabolites and degradation of some 
compounds which are unstable in low pH can occur by acidic treatment (Bouchereau et al. 
2000). 
 
The strategies of sample extraction which will be applied should be considered according to 
the metabolites of interest under study. Extraction using polar and non-polar solvents are 
most frequently used and is often coupled with mechanical methods for cell breakage by 
sonication, microwave (Fujikawa et al. 1992, Jaki et al. 2006) or grinding using a mortar and 
pestle or ball mill often with the addition of liquid nitrogen (Jarrell et al. 1992, Weil et al. 
1988). However, since microwave disruption heats biological samples, it seems unsuitable for 
metabolic approaches because many secondary metabolites are influenced by high 
temperature (Jaki et al. 2006). After the disruption of cell walls, polar (methanol, ethanol, 
acetonitrile, acetone and water), non-polar (chloroform, hexane and ethyl acetate), and acidic 
and basic (perchloric acid and potassium hydroxide) solvents, singly or in combination have 
been used for extraction followed by the removal of the cellular residue (Roessner et al. 
2000). The efficiency of these methods using the above solvents has been investigated by 
(Jiye et al. 2005, Lin et al. 2007, Villas-Boas et al. 2005). Other chemical methods for 
extraction have been studied and evaluated including those for yeast using boiling buffered 
ethanol, which can be applied to other fungi and be helpful for the determination of the true 
level of metabolites (Gonzalez et al. 1997). For Escherichia coli metabolite quenching using 
cold (-40 °C) methanol offers great promise (Maharjan and Ferenci 2003, Winder et al. 2008). 
Also, an integrated sampling procedure for simultaneous quenching and quantitative 
extraction of intracellular metabolites has been studied (Schaub et al. 2006). In addition, the 
storage of sample is important because the continued freezing and thawing of samples may 
result in effects on stability and composition of metabolites (Al-Jowder et al. 1997, Dunn et 
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al. 2005). Finally, liquid and solid samples should be stored at -80 °C or dried to prevent any 
enzymatic activity until analysis.  Metabolites have been seen to degrade even when under 
continual storage at -80 °C without freeze-thaw occurring (Dunn et al. 2005, Fiehn 2002, 
Gika et al. 2008b), and thus both metabolic quenching and preservation during sample 
storage are considered as extremely important factors within metabolomics investigations.  
 
Generally there is no further separation and isolation of metabolites from the sample extracts. 
These extracts are simply analysed after dilution or deproteinisation which is conventionally 
achieved via solvent precipitation (Daykin et al. 2002). However, for metabolite target 
analysis, the analysis of pharmaceuticals and related metabolites, or to remove bulk 
components such as sugars from samples prior to the analysis of lower concentration 
metabolites, methods for further isolation such as solid phase extraction (SPE) or liquid-
liquid extraction (LLE) are required (Rossi and Sinz 2002). 
 
1.4.3. Metabolomic Technologies and their Applications 
In order to gain a variety of metabolic data from a cell or organism, the analytical techniques 
used have to be comprehensive, selective and sensitive. There are a wide range of techniques 
such as FT-IR, Raman and NMR spectroscopies, direct infusion (DI)-MS, capillary 
electrophoresis (CE)-MS, GC-MS, and LC-MS, which enable the detection of a great number 
of individual chemical components meeting the above mentioned requirements. However, 
there is no single technique suitable for profiling the whole metabolome due to their complex 
physical and chemical diversity. Application of a combination of technologies is required to 
overcome this drawback. 
 
1.4.3.1. Fourier Transform Infrared (FT-IR) Spectroscopy 
For chemical characterisation purposes, the vibrational portion of the IR region, including 
wavelengths between 2.5 µm and 15 µm, is often employed. In particular, the mid-IR region 
between 5 µm and 10 µm has been widely used for analysis in biological materials (Allwood 
et al. 2010, Allwood et al. 2006, Winder et al. 2004, Winder et al. 2006). The relationship of 
the IR region to others included in the electromagnetic spectrum is illustrated in Figure 1.7 
(Pavia et al. 1979).  
 
FT-IR is based on the principle that when IR light is applied to a sample or chemical 
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compound, the functional groups within the chemical compounds, which have covalent bonds, 
will absorb various frequencies of electromagnetic radiation in the IR region of the spectrum 
(Figure 1.8) and vibrate in many different ways such as stretching or bending motions. These 
absorptions of particular frequencies can be used to identify compounds in the sample and 
changes of specific bands or intensities can be used to understand biological processes (Ellis 
and Goodacre 2006). 
 
 
 
 
Figure 1.7. A portion of the electromagnetic spectrum showing the relationship of mid-wavelength infrared to 
other types of radiation. 
 
A schematic of the basic components of an FT-IR instrument are shown in Figure 1.9. The 
radiation generated from the IR source is passed through an interferometer to the sample 
where a proportion of the IR is absorbed prior to the signal from the non absorbed IR being 
detected. As high-frequency contributions have been eliminated by a filter, the detected signal 
is amplified and the data are then converted to a digital form by an analog-to-digital converter. 
The data are finally transferred to a computer where it is Fourier transformed (Stuart 1997). 
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Figure 1.8. Virtual energy levels for infrared and Raman spectroscopies; Molecules are excited by a photon from 
the ground state to vibration states (infrared), virtual (Raman) or electronic excited states (resonance Raman). 
For infrared, the molecules absorb specific frequencies and vibrate in various vibration modes. For the Raman 
effect, when the molecules relax, they return to different vibrational states.  
 
 
 
Figure 1.9. The components of an FT-IR spectrometer 
 
A Michelson interferometer, which is the most common interferometer used, consists of two 
perpendicular plane mirrors, one of which can travel in a direction perpendicular to the plane 
(Figure 1.10). A semi-reflecting film, known as the beamsplitter, bisects the planes of these 
two mirrors. The beamsplitter material has to be chosen according to the region of IR 
radiation to be examined. Materials such as germanium or iron oxide are coated on to an IR-
transparent substrate such as potassium bromide or caesium iodide to produce beamsplitters 
for the mid- or near-IR regions. Thin organic films, such as poly(ethylene terephthalate), are 
used in the far-IR region (Stuart 1997). With respect to IR sources for FT-IR spectroscopy, a 
Nernst or Globar source is employed for the mid-IR region. If the far-IR region is required to 
be examined, then a high-pressure mercury arc lamp can be used. 
 
Two detectors are commonly used for FT-IR spectroscopy. A pyroelectric device 
incorporating deuterated triglycine sulphate (DTGS) in a temperature-resistant alkali halide 
window is the detector commonly employed for routine use, whereas mercury cadmium 
telluride (MCT) can be used for more sensitive work, although it requires cooling by liquid 
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nitrogen (Stuart 1996). Unlike these single element detectors, the multiple element detector, 
focal-plane array (FPA) detector offers an instrumental multiplex/multichannel advantage. 
Specifically, the multiple detector elements enable the collection of spectra across a 
biological section or cells. The spectra are generated in a pixel format and are collected 
simultaneously. The interferometer portion of the system allows all spectral frequencies to be 
measured concurrently. Therefore, large IR images of biological samples can be rapidly 
generated with an FPA system (Lewis et al. 1995). 
 
 
 
Figure 1.10. A simple Michelson interferometer layout 
 
FT-IR spectroscopy has been used widely to investigate metabolic changes in biological 
processes as well as to identify the components of biological systems in the field of 
metabolomics (Allwood et al. 2010, Allwood et al. 2006, Ellis and Goodacre 2006, Fabian et 
al. 2006, Gidman et al. 2003, Johnson et al. 2004, Winder et al. 2004, Winder et al. 2006). 
These techniques make it possible to identify and characterise microbial cells (Naumann et al. 
1991) as well as to determine the biochemical differences between normal and diseased cells; 
as demonstrated for cervical cancer and leukaemia cells by (Cohenford and Rigas 1998, 
Schultz et al. 1996). In addition, FT-IR spectroscopy is a powerful tool for global, sensitive 
and highly reproducible biochemical analysis and is very rapid due to the automated high-
throughput analysis of biological samples and minimal sample preparation requirements 
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(Winder et al. 2006). This reagentless, non-invasive and reproducible technique is resulting in 
manifold applications across a wide range of biosciences (Deleris and Petibois 2003, Ellis et 
al. 2004). However, FT-IR has some disadvantages. A main issue is the strong intensity of IR 
absorption of water in the spectrum. This can be circumvented in one of several ways 
including dehydration of samples, electronic subtraction of the water signal or the application 
of attenuated total reflectance (ATR) spectroscopy (Harrigan and Goodacre 2003, Hartmann 
et al. 2004, Orsini et al. 2000, Winder and Goodacre 2004). 
 
FT-IR microspectroscopy, the combination of FT-IR spectroscopy and microscopy, is an 
emerging technique that provides spatially resolved spectroscopic information close to the 
cellular level on minute quantities of microscopic structures within a given sample. FT-IR 
microspectroscopy provides direct information on chemical composition allowing chemical 
mapping of intact biological systems including tissue sections as well as single cells. Recent 
developments in this technique have enabled quantitative determination of relatively small 
amounts of material, the molecular nature, the orientation of the analysed substances, and 
most significantly the distribution of biomolecules of interest (i.e., DNA, RNA, lipids, 
proteins) within the cell or tissue section (Lascha et al. 1998, Yang et al. 2005). Also, 
chemical mapping using FT-IR microspectroscopy could be used to investigate the metabolic 
effects that chemotherapeutic treatment causes on various cell lines as well as the distribution 
of the drug inside the cell. This information would provide insights to aid our understanding 
of abiotic perturbation to biological systems. 
 
1.4.3.2. Applications of FT-IR Spectroscopy 
FT-IR spectroscopy has developed into a powerful tool for the identification of disease status 
without previous treatments of the cell or tissue such as staining. As IR spectra of normal 
cells or tissues are compared with those taken from diseased cells or tissues, marker bands 
characteristic for diseased status can be identified (Schultz et al. 1996). In addition to 
determining such marker bands, disease diagnosis can be performed using fingerprinting data 
of the IR spectrum coupled to advanced data processing techniques like cluster analysis in 
order to overcome very subtle differences between healthy and atypical cells or tissues. This 
powerful disease pattern recognition (Petrich et al. 2000) approach has the potential to 
complement established strategies of tissue section diagnosis (Fabian et al. 2006, Schultz et 
al. 1996). Also, FT-IR spectroscopy has great potential for rapid, low-cost and accurate 
cancer screening. Since earlier detection of cancer can provide better prognosis, high 
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throughput screening becomes a significant process in cancer therapy. Potential applications 
in cervical cancer screening have been recently reviewed by (Walsh et al. 2007).  
 
Not only is FT-IR spectroscopy used as a tool for disease diagnosis, but it can also be 
employed to follow the response of patients to chemotherapeutic drugs (Krishna et al. 2006, 
Sulé-Suso et al. 2005). Sule-Suso et al. (2005) reported a rapid and effective method for 
prediction of tumour cell sensitivity to chemotherapy as well as for revealing the correlation 
between cell death and the specific band ratio depending on various concentrations of the 
drug. A further paper by Krishna et al. (2006) presented the use of FT-IR spectroscopy to 
identify multidrug resistance phenotypes in cancer cell lines. The authors reported a method 
for the discrimination between resistant and sensitive phenotypes using cluster analysis in 
order to enhance the efficiency of the therapy and thus lead to more effective treatment plans 
for individual patients. 
 
In addition to applications of FT-IR spectroscopy in biomedical areas, this approach has also 
been applied for the identification of microorganisms in microbiology (Essendoubi et al. 
2005, Winder et al. 2004), characterisation of gene insertion mutants and pathogenic 
interactions in planta (Allwood et al. 2010, Allwood et al. 2006, Brown et al. 2005), 
concentration measurements of plasma within biological fluids, cells and tissues (Petibois et 
al. 2006), and toxicology studies (Harrigan et al. 2004). 
 
1.4.3.3. Raman Spectroscopy 
The irradiance of an intense laser source onto a biological sample generates informative 
Raman spectra. There are three types of light scattering which are evident in Raman spectra 
and these are known as Rayleigh scattering, Stokes and anti-Stokes Raman scattering (Figure 
1.8). When the incident light interacts with molecules in the sample, the light will be 
scattered. If the scattered photon has the same wavelength as the incident light, this process 
will be called Rayleigh or elastic scattering. Unlike Rayleigh, when the energy of the 
scattered photon has less than that of the incident light due to the excitation of a molecular 
vibration, this is termed Stokes scattering; by contrast when the energy of the scattered 
photon is increased this process is termed anti-Stokes (Harrigan and Goodacre 2003). That is 
to say, the loss or gain in photon energies is attributed to the difference of vibrational energies 
between the incident light and scattered photon which interact with molecules. Bands 
indicated by wavenumber (inverse of wavelength in cm-1) shifts from incident frequencies 
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generate the resultant Raman spectra (Mahadevan-Jansen and Richards-Kortum 1997). 
Therefore, the rich information present within Raman spectra produced by the chemical bond 
of functional groups in a molecule can permit quantitative and qualitative analysis in order to 
understand biological systems.  
 
A schematic diagram of a modern Raman microspectrometer is shown in Figure 1.11. The 
Raman excitation light from the laser source is directed on to microscopic or macroscopic 
biological samples through a series of mirrors. The microscope objective both focuses the 
excitation laser onto the sample and collects the Raman scattered light in a backscattering 
geometry. The Raman scattered light from the microscope is redirected by a beamsplitter and 
mirror combination and passes through a notch filter and then is finally focused into a 
spectrograph attached to a cooled charge-coupled device (CCD) (Shafer-Peltier et al. 2002). 
The CCD concept was suggested by (Boyle and Smith 1970) and the first experimental 
device was verified by (Amelio et al. 1970). Commercially available CCD detectors provide 
extremely low detector noise and substantial advantages over InGaAs and other NIR 
detectors (Baraga et al. 1992).  
 
Raman spectroscopy is a well established analytical tool in order to characterise chemical 
molecules in samples and to investigate biological systems. Also, the spectra generated by 
this approach represent the chemical fingerprints of a sample. Raman spectroscopy has 
several advantages over other analytical techniques such as mass spectrometry. Like FT-IR 
spectroscopy this technique is rapid, non-invasive and requires minimal sample preparation 
without the use of any dye, label or derivative. In addition, the sample is not damaged if an 
appropriate laser wavelength and power are used (Verrier et al. 2004). 
 
Raman spectroscopy has been widely used to analyse biochemical molecules in tissues and 
cells on both the macroscopic and microscopic scale. Raman microspectroscopy has provided 
information on concentration, structure, and interaction of biochemical molecules within 
intact cells and tissues under their microenvironment without destructive homogenisation and 
extraction. Furthermore, Raman spectroscopy can be performed in vivo using optical fibre 
technology which allow real time measurements (Buschman et al. 2001). Raman 
spectroscopy has great potential for biomedical applications since it can provide very detailed 
information on chemical composition, thus allowing the diagnosis of diseases as well as the 
accompanying chemical changes according to disease progression. Prospects for in vivo 
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Raman spectroscopy in the field of biomedicine have been well reviewed by (Stone and 
Matousek 2008). 
 
 
 
Figure 1.11. A schematic diagram of a modern Raman spectrometer 
 
The chemical mapping approach of Raman microspectroscopy, which is an optical 
microscope coupled to a Raman spectrometer, is a powerful tool for analysing the chemical 
distribution and the response of metabolic stresses on cells or tissues. The spectrometer 
provides the analytical light source and the spectral detection elements, whilst the microscope 
offers focussing and data collecting optics for both spectral and white light image information 
from the sample. A Raman spectrum is obtained at a point of the cell or tissue in these 
mapping type experiments. The spectrum is collected from the first point, the incident light is 
moved in a raster pattern across the grid in a diffraction-limited spot size (1 µm × 1 µm) then 
another spectrum is taken until the area of the sample assigned by the operator has been 
covered (Clark and Sasic 2006) (Figure 1.12). Therefore, subtle changes in chemical 
composition and distribution within the cell or tissue can be monitored using this technique. 
The chemical mapping approach not only enables visualisation of spatially resolved chemical 
information but also can detect any small chemical changes in order to understand biological 
systems. 
 
Compared to FT-IR, Raman spectroscopy has a great advantage regarding the interference of 
water. Water is not a significant factor in Raman spectra because water molecules have strong 
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asymmetric features which only generate very weak Raman bands, water molecules also have 
a small Raman cross-section, thus water only has a small effect on the spectra of the sample 
being studied. Therefore, biofluids can be directly measured using Raman spectroscopy (Ellis 
and Goodacre 2006, Pichardo-Molina et al. 2007, Premasiri et al. 2001). However, Raman 
microspectroscopy is limited in terms of the low intensity of Raman signals detected from 
biological molecules due to a strong fluorescence background. This disadvantage can be 
overcome with long measurement times, and the use of high laser powers as the excitation 
source and surface enhanced Raman scattering (SERS) (Beljebbar et al. 1999, Harrigan and 
Goodacre 2003, Wang et al. 2010). 
 
 
 
Figure 1.12. The procedure of chemical mapping; After the spectrum is taken from one certain point of the 
sample, the incident light from the laser source and spectrometer is moved in a stepwise manner in steps as 
small as 1µm and another spectrum is collected. This process is continued until the area of the sample assigned 
by the operator has been covered. 
 
1.4.3.4. Applications of Raman Spectroscopy 
Raman spectroscopy has been widely accepted as an industrial analytical tool for many years 
but recent developments in Raman instrumentation have made it possible to measure a 
variety of biomolecules from cells or tissues for early detection of diseases and the 
development of new drugs. Raman spectroscopy has emerged as a promising diagnostic tool 
for disease detection in the field of biomedicine. Various diseases have been detected by 
comparing the differences of Raman spectra between normal and diseased cells or tissues 
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because disease progression results in quantitative and compositional changes of metabolites 
(Buschman et al. 2001, Hawi et al. 1996, Shafer-Peltier et al. 2002). Biomedical applications 
of Raman to cancer detection and disease diagnosis have been well reviewed in (Ellis et al. 
2007a, Ellis and Goodacre 2006, Hedegaard et al. 2010, Mahadevan-Jansen and Richards-
Kortum 1997). In addition, Raman spectroscopy has been investigated in order to develop 
effective chemotherapeutic agents and to assess the combination of various drugs against 
serious diseases; this has involved the response to chemotherapy and the distribution of the 
drugs inside cells or tissues (Beljebbar et al. 1999, Kang et al. 2006). In microbiology, 
identification and characterisation of single yeast cells has been performed using Raman 
microspectroscopy. It is a crucial application in this field because the identification of yeast is 
highly relevant to the medical field (e.g., different Candida strains) as well as various areas of 
food preparation (e.g., wine, beer, bakery products) (Huang et al. 2004, Rosch et al. 2005). In 
addition, classification and identification of various microorganisms has been carried out thus 
permitting the appropriate course of antimicrobial treatment (Choo-Smith et al. 2001, Gaus et 
al. 2006, Kirschner et al. 2001, Rosch et al. 2007). As a more practical application of this 
technique, monitoring the mode of action of antibiotics has been performed thus allowing the 
discovery of new antibiotics as well as characterising their effect within bacterial cells 
(Lopez-Diez et al. 2005).  
 
1.4.3.5. Mass Spectrometry (MS) 
Mass spectrometry particularly when combined with chromatography has been widely used 
in the field of metabolomics in order to profile a variety of metabolites in plants, 
microorganisms and mammalian cells because MS-based approaches can provide sensitive, 
selective and rapid quantitative and qualitative analyses. The instrumentation for detecting 
the mass-to-charge ratio (m/z) and intensity of the various ionised analytes produced by 
ionisation from a chromatographic fraction or sample extract is simply termed a MS. In this 
process the most important step is ionisation as ions can be much more easily analysed than 
neutral molecules. Although all varieties of MS consist of several parts, there are three key 
components; an ionisation source, a mass analyser and a detector. All these components are 
operated under vacuum to provide the optimal environment for the transmission of ions to 
analyser and detector (Gross 2004, Niessen 1998). Chromatography coupled MS-based 
techniques have very high sensitivity and so have a great potential to discover new 
biomarkers for the diagnosis of diseases and observation of disease progression, metabolites 
can also be identified through a combination of matching retention time or retention index, 
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mass spectral interpretation or comparative matching to mass spectra of pure compounds 
collected under the same conditions within library databases (Kopka et al. 2005, Moco et al. 
2006, Wagner et al. 2003).  The huge complexity of metabolites in plants, microorganisms 
and mammalian cells, has lead to MS commonly being coupled to chromatographic 
instrumentations such as gas chromatography (GC), liquid chromatography (LC), or capillary 
electrophoresis (CE) which aid in reducing the sample complexity by separating out the 
various sample components prior to their MS detection. 
 
Linear Time-of-Flight (TOF)/MS is widely used for the identification of various analytes. 
The concept of TOF/MS is based upon the theory that the mass of the ion is related to its 
flight velocity along the flight tube and therefore the arrival time at the detector of a mass ion 
is proportional to its mass, the mass ions reach the detector in order of increasing m/z 
(Allwood and Goodacre 2010, Guilhaus et al. 1997). In linear TOF/MS ionised metabolites 
(analytes) are accelerated by an electric field along the flight tube prior to them reaching 
typically a micro channel plate (MCP) based detector (Allwood and Goodacre 2010).  
Occasionally analytes of the same mass possess slightly different flight velocities which 
results in mass ion peak broadening. This problem can be overcome by employing a 
reflectron (Re)TOF/MS (Figure 1.13) which provides not only a greater distance for ions to 
travel within the flight tube thus improving resolution, but also equalises the time of flight of 
the ions through the reflectron. The reflectron consists of a series of rings for creating a 
constant electrostatic field in which the mass ions are retained and reflected toward the 
detector. Higher mass ions with greater flight velocities penetrate deeper into the reflectron 
field and are held for longer, whereas lower mass ions of the same m/z penetrate a shorter 
distance into the electrostatic field and, correspondingly, are retained for shorter time. Thus, 
during this refocusing different energy mass ions of the same m/z can arrive into the detector 
at the same time (Allwood and Goodacre 2010, Gross 2004, Guilhaus et al. 1997). 
 
The quadrupole mass analyser has been commonly applied to GC and LC for many years. 
The quadrupole analyser, as the name suggests, consists of four parallel, cylindrical metal 
rods which are arranged symmetrically. Each opposing rod pair is connected electrically, 
radio-frequency (RF) and direct-current (DC) charges are applied, the RF and DC 
components on each pair of rods is 180° out-of-phase (Figure 1.14) (Allwood and Goodacre 
2010). The effect of these applied voltages is to generate an oscillatory motion in the paths of 
the ions passing through the analyser. On entering the electric quadrupole field, the ions 
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Figure 1.13. A schematic illustration of reflectron time of flight (ReTOF); (A) reflectron time of flight mass 
spectrometry-V mode arrangement; (B) reflectron time of flight mass spectrometry-W mode arrangement; (C) 
illustration of how the reflectron equalises the velocities from different energy mass ions of the same mass-to-
charge (m/z).  
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All other ions will either hit the rods or exit between them and are lost, positive ions are 
attracted to negatively charged rods whilst the converse is observed for negative ions, through 
this process mass filtering of a specified m/z range is achieved. Therefore, the quadrupole 
analyser can be considered to be a mass filter which allows only a narrow range of mass ions 
to pass to the detector (Allwood and Goodacre 2010, Ashcroft 1997, Splitter and Turecek 
1993).   
 
More recent MS developments have lead to quadrupole mass filters being linked directly with 
TOF/MS, a technique referred to as quadrupole (Q)-TOF/MS. Post ionisation, analytes enter 
and are filtered within the quadrupole to isolate the ion of interest, this ions’ m/z is then 
detected via TOF/MS. A secondary function can be applied, here the ion after having been 
filtered through the quadrupole enters a collision cell where a stream of, typically, helium gas 
fragments the ion via collision induced dissociation (CID), and the fragments are then 
detected within the TOF/MS. This process is termed as tandem-MS (MS/MS) analyses and 
via the study of fragmentation patterns and comparison to analytical standards leads to 
unambiguous metabolite identification, especially where matching of RT is achieved via 
upfront chromatography which is necessary to differentiate isomers that otherwise produce 
identical MS/MS fragments, for example glucose-6-phosphate and fructose-6-phosphate 
(Figure 1.15) (Allwood and Goodacre 2010, Glish and Vachet 2003). 
 
 
Figure 1.14. A schematic diagram of the quadrupole analyser 
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Figure 1.15. A schematic diagram of tandem mass spectrometry 
 
1.4.3.6. Gas Chromatography-Mass Spectrometry (GC-MS) 
GC-MS is a hyphenated analytical technique combining gas chromatography, which provides 
high separation efficiency permitting the resolution of the complex metabolite mixtures 
present in biological samples, and mass spectrometry, that detects the m/z of separated 
compounds for their identification. GC involves the separation of metabolites through a 
column (stationary phase) by a carrier gas (mobile phase), the carrier gas is typically 
chemically inert; helium or nitrogen are commonly employed in metabolomics. Separated 
metabolites are then introduced in to an electron impact (EI) ionisation source prior to 
introduction to the separation and detection by TOF or quadrupole MS. EI involves impacting 
a metabolite with a stream of high-energy electrons in order to convert a metabolite to an 
analyte mass ion (Figure 1.16). EI is considered as a hard ionisation method because it results 
in high levels of analyte fragmentation rather than producing intact parent ions. Post 
ionisation, the mass ions are accelerated into a quadrupole MS or more typically a TOF/MS 
detector where they are separated according to m/z.  
 
Finally, the separated ions are detected typically via a MCP which when struck by a mass ion 
produces an electrical charge that is further amplified through electron cascades within the 
MCP micropores. The various mass ions detected are counted into bins across a scan window, 
the greater the ion count for each bin, the greater the intensity or concentration of the mass 
ion. Via recording the time from when the ions are accelerated to when they strike the 
detector, the m/z can be calculated since it is proportional to the ions’ TOF. The recorded data 
are stored and processed upon a personal computer. By combining all of the mass spectral 
scans recorded across a chromatographic peak a mass spectrum (a plot of intensity versus m/z) 
can be generated that is representative of the analytes eluting within that peak (Allwood and 
Goodacre 2010, Pavia et al. 1979).  
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GC-MS is widely used for metabolic profiling of biological samples such as plants, 
microorganisms and mammalians due to its high reproducibility, sensitivity and selectivity 
resulting from the chromatographic separation and a sensitive detector. Although it has a 
great potential in metabolomics, there is practical limitation related to the analysis of many 
interesting classes of compound including sugars, nucleotides, amino acids and organic acids 
etc. Whereas volatile or low molecular weight metabolites can be analysed directly without 
any sample preparation, non-volatile or high molecular weight polar compounds mentioned 
above cannot be analysed directly due to their lack of volatility. This means that such polar 
metabolites require addition of volatile groups via chemical derivatisation to make them 
amenable to GC separations. 
 
 
 
                                                  
                                              
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.16. Ionisation chamber; ionisation is typically 70eV. 
 
The most common derivatisation procedure applied in metabolomics is as follows. The dried 
extract is dissolved in pyridine, to which methoxyamine hydrochloride is added for 
methoxymation under heating. This reaction is followed by the addition of 	-methyl-
	(trimethylsilyl)-trifluoracetamide (MSTFA) followed by further heating (Lenz and Wilson 
2007). The MSTFA reaction effectively replaces the OH groups within a compound with 
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volatile trimethylsilyl (TMS groups). It is critical that extracts are fully dried in advance of 
derivatisation since water inhibits the process of silyl ether formation (Dunn et al. 2005). 
MSTFA has similar silyl donor power to 	,O-bis(trimethylsilyl)acetamide (BSA) and 	,O-
bis(trimethylsilyl)trifluoroacetamide (BSTFA) but is more volatile. Therefore, this reagent is 
more appropriate for the GC analysis. Also, the silylation power of MSTFA can be enhanced 
by using catalysts such as trimethylchlorosilane (TMCS), potassium acetate, 
trimethylbromosilane (TMBS) and trimethyliodosilane (Blau and Halket 1993). The choice 
of reagent for greater silylation power is very important since it prevents the biased analysis 
resulting from there being underivatised metabolites remaining within the sample. It is 
valuable in this sense that sample stability is maintained.  
 
The derivatised samples are separated through high resolution capillary columns (~30 - 60m) 
with small volume injection (typically 1 µl). Splitless injection is more widely used for non-
targeted metabolomics analysis which requires maximum qualitative metabolite coverage 
from complex mixtures of samples which have a wide range of boiling points, for example in 
GC-MS based plant metabolite fingerprinting (e.g. (Allwood et al. 2009)). However, splitless 
injection can result in typical problems such as monosaccharide overloading due to the large 
sample volume that is injected.  This problem can be averted by employing split injection. 
Split injection is commonly employed in metabolite profiling experiments where the 
investigator wants to quantify and identify accurately as many metabolite components as is 
possible without causing overloading and a loss in accuracy, for example in semi-quantitative 
GC-MS based metabolite profiling in serum (e.g. (O'Hagan et al. 2005)). During split 
injection, a typical split ratio between 1:10 – 1:50 is applied thus reducing the volume of 
sample entering the column by ten to fifty-fold which may result in the loss of detection of 
certain low concentration sample components (Robards et al. 1994). Ideally without 
limitations on instrument time, a splitless analysis should be performed to allow for the 
detection of low concentration metabolites, this is then followed by split injection based 
analysis to give accurate quantification of bulk metabolite components such as mono- and di- 
saccharide’s which are overloaded within the splitless dataset (Allwood et al. 2009). GC 
chromatograms are complicated, a large proportion of the chromatographic peaks consist of 
many closely eluting and co-eluting metabolite species, some of which may form more than 
one product during derivatisation. The extent of this problem can be reduced by increasing 
GC separation times via reduction of the temperature ramp rate, thus co-eluting components 
are given a greater space in time to separate, although at a cost of sample throughput. More 
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commonly perhaps is the application of chromatographic deconvolution software such as the 
automated mass spectral deconvolution and identification system (AMDIS) (Meyer et al. 
2010). Chromatographic deconvolution employs the pure mass spectra to define the 
metabolite components that co-elute within a single chromatographic peak; although the 
accuracy of this approach is reliant upon the data being collected using high speed scan rate 
detectors such as the TOF/MS. A negative feature of deconvolution is that it frequently results 
in outlying deconvolutions. For example, deconvolution and library matching is performed 
upon a sample by sample basis, frequently it is seen that a metabolite may appear in a single 
sample within an experimental class and then is absent in all other samples. This may 
represent metabolic heterogeneity or may be the result of an outlying deconvolution.  By 
disregarding metabolite features that appear in less than 80% of samples within a class, this 
problem can be minimised, although sample class-by-sample class manual visualisation and 
interpretation of the data must also be performed at great time expense (Allwood et al. 2009, 
Lisec et al. 2006).   
 
Applications of GC-MS are wide ranging from plant and microbial metabolomics to 
biomedical areas, especially related to diseases (Horning and Horning 1971, Pauling et al. 
1971). The screening of organic acids from urine was one of the first applications of GC-MS 
in terms of targeted metabolite profiling in order to detect patients with organic acidurias 
(Tananka and Hine 1982). During the last decade, GC-MS was developed into a powerful 
technique for metabolomics applications in the plant sciences, much of this developmental 
work was performed by the Willmitzer group at Max Plank Institute for Molecular Plant 
Physiology (Fiehn 2001, Fiehn 2002, Kopka et al. 2005, Lisec et al. 2006) who were inspired 
by the work of (Sauter et al. 1988). These methods have been taken and extensively applied 
within clinical and pharmaceutical metabolomics. Biofluids such as urine and serum  are still 
commonly analysed to observe drug induced metabolic responses, both within drug 
development and clinical biomarker discovery (Boudonck et al. 2009, Staack et al. 2004). 
Other applications have employed GC-MS for the chemical diagnosis of diseases such as 
Lesch–Nyhan syndrome, Parkinson’s disease and acute coronary syndrome (Michell et al. 
2008, Ohdoi et al. 2003, Vallejo et al. 2009).   
 
1.4.3.7. Liquid Chromatography-Mass Spectrometry (LC-MS) 
LC-MS is a powerful technique for not only the quantification of metabolites but also the 
identification of known compounds in biological samples. LC provides a universal separation 
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due to its ability to purify a wide range of chemical classes that differ greatly in physical and 
chemical properties.  The chemical classes range from non-polar compounds such as lipids to 
polar metabolites such as amino acids. Although GC-MS can detect a range of volatile 
compounds, non-polar fatty acids, or primary metabolites, LC-MS is more suited to the 
analysis of both primary and secondary metabolites within a single analyses, although this is 
very much dependant on the extraction methodology that is employed.  Since LC-MS, like 
GC-MS, is fully automated it is particularly amenable to high-throughput metabolomics 
analysis. 
LC is the term normally used to describe the separation of components in solution based 
mixtures by different affinities of the mixtures components with a liquid mobile phase 
gradient flowing through a liquid stationary phase. Differences in compound polarity within 
the sample mixtures leads to their separation, since certain components will have high affinity 
for the stationary phase and thus will be retained for longer and elute more slowly (i.e., at a 
later retention time (RT)), whereas others will have high affinity to the mobile phase and will 
elute quickly. 
 
After an appropriate column (i.e., materials in a packed column and column size) and eluent 
system are selected, the following important step is the choice of the eluent mode. There are 
two eluent modes commonly used; i.e., isocratic elution and gradient elution. A separation in 
which a mobile phase of single composition is constant throughout a procedure is termed 
isocratic elution. A drawback of isocratic elution is that the mode often leads to peak 
broadening and flattening for late eluting peaks. However, this disadvantage can be overcome 
by using a gradient elution in which the mobile phase composition is changed during the 
chromatographic separation process. For instance, polar organic solvents such as acetonitrile 
or methanol may be employed for a polar elution gradient starting at 5% acetonitrile or 
methanol in water and ending at 95% acetonitrile or methanol in water; solvents such as 
toluene may be used for a nonpolar gradient (Snyder et al. 1997). In reverse-phase LC, there 
are two components of the mobile phase typically termed ‘A’ and ‘B’; ‘A’ is normally a 
highly aqueous solvent which elutes polar compounds first whilst maximising non-polar 
compound retention to the stationary phase, whilst ‘B’ is typically a strong organic solvent 
which rapidly elutes the non-polar sample compounds from the columns' stationary phase. 
The increasing organic eluent of the mobile phase decreases the retention of the late eluting 
non-polar compounds, thus they elute faster giving narrower and sharper peaks. In addition, 
as the concentration of the organic composition increases, the tailing part of a peak is pushed 
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forward, thus giving better peak shape since the peak tailing effects are reduced (Meyer 2004, 
Snyder et al. 1997).  
 
Adsorption chromatography is the most commonly employed LC technique in metabolomic 
analysis, as the name suggests it is based upon the adsorption of the samples’ metabolites 
directly onto a solid stationary phase. The retention and separation of sample components is 
relative to the metabolite and stationary phase polarities (Horvath et al. 1981, Meyer 2004, 
Snyder et al. 1997). Silica packed columns are commonly used for adsorption 
chromatography in which polar R groups (e.g., amine or nitrile groups) or non-polar 
hydrocarbons (e.g., C8H17 or C18H37) are bonded to the silica stationary phase particles. There 
are two typical chromatographic approaches; i.e., normal-phase (NP)-LC and reversed-phase 
(RP)-LC. NP-LC employs polar stationary phase materials and thus gradient elution with a 
non-polar solvent elutes non-polar metabolites first. On the other hand, RP-LC employs non-
polar stationary phase materials and thus gradient elution with a polar aqueous solvent elutes 
polar compounds first (Meyer 2004, Snyder et al. 1997). Due to the high stability of RP-LC, 
it has been the most commonly used technique in metabolomics, and several research groups 
have developed robust and repeatable analytical methodologies for metabolomic studies such 
as on both plant, microbial and human samples (Coulier et al. 2006, De Vos et al. 2007, Dunn 
et al. 2008, von Roepenack-Lahaye et al. 2004, Zelena et al. 2009). 
 
High performance (originally high pressure) liquid chromatography (HPLC), coined by 
Horváth in 1970, is a commonly used technique of column chromatography which combines 
the different types of stationary phase (columns) with a high pressure pump that pushes the 
mobile phase and analyte molecules into the column, and a detector that provides a specific 
RT of metabolites. Most compounds that dissolve in liquid can be analysed with high 
resolution separation and detection, even in very low concentrations; i.e., parts per trillion 
(Meyer 2004, Snyder et al. 1997). 
 
The typical cycle of a HPLC system is described in Figure 1.17. Briefly, the HPLC 
instrument consists of several units such as solvent reservoirs, a solvent degasser, pressure 
pump, gradient valve, sample injector, column and detector. The reservoirs hold the solvent 
used for the mobile phase, and the injector and line washes. A solvent degasser prevents 
bubbles in the mobile phase and a high pressure pump provides the solvent delivery system 
which generates a designed flow rate (typically millimetres per min). A gradient valve mixes 
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solvents A and B at previously programmed ratios and time gaps, thus the prescribed gradient 
elution steps by the operator can be achieved (Meyer 2004).   
 
 
 
 
 
Figure 1.17. A schematic diagram of high and ultra high performance liquid chromatography and the analysis of 
a single sample with a reversed phase column. (A) A schematic representation of HPLC instrumentation. (B) 
Initially 100 % solvent A (HPLC grade water with 0.1 % formic acid) is introduced to the unit and the sample is 
injected into the mobile phase. Solvent B (HPLC grade acetonitrile with 0.1 % formic acid) is then introduced to 
the mobile phase in steps until the composition reaches 100 % solvent B. Polar compounds of the samples firstly 
elute from the column with highly aqueous solvent A and as the ratio of solvent B increases, non-polar 
compounds of the sample initially retained on the stationary phase by hydrophobicity, start to elute with the 
increasing organic mobile phase composition. After the initial gradient, there is a final hold period with 100 % 
solvent B for several minutes and then the system purges with clean solvents in order to remove any sample 
remaining in the sample injector, syringe, column and lines prior to running the next sample. 
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If a compound within a mixture or biological sample can be clearly resolved and is not 
overlapped with peaks from any other sample components, it can be isolated, potentially 
identified and quantified, and if necessary fractionated for further analysis. The identification 
can be achieved by comparing the RT of the component within the sample to that of a pure 
standard compound eluted under the same chromatographic conditions.  
 
Furthermore, the quantification of a compounds’ concentration within the samples can be 
carried out by creating a calibration curve of the serially diluted standard compound of 
known concentration based upon the detected chromatographic peak areas (Allwood et al. 
2006, Kimura and Rodriguez-Amaya 2002). However, there are usually so many co-eluting 
and possibly overlapping peaks from complex biological samples which can interfere with 
HPLC-based identification and quantification, that it is a necessity to employ MS or NMR 
analysers in order to perform these purposes (Tolstikov et al. 2003).  
 
As discussed above, the separation of complex compounds through HPLC is largely affected 
by three major factors: the polarity of the sample component being studied; the mobile phase 
composition; the chemical properties of the stationary phase. However, there are several 
important parameters related to the efficiency of HPLC separation and the development of 
ultra high performance liquid chromatography (UHPLC or UPLC). The first consideration for 
these parameters is column length and particle size. If a column bed is stable and uniformly 
packed, the chromatographic separation power depends on the column length and particle 
size. Longer columns often provide enhanced resolution of the chromatographic separation 
but analysis times and system back pressure for a given flow rate increases as the column 
length increases (Romanyshyn and Tiller 2001). Stationary phase particle sizes also influence 
the system back pressure and column separation efficiency. The system back pressure and 
separation efficiency are inversely proportional to the particle diameter thus as the particle 
size decreases, the system back pressure and separation efficiency increases (Nguyen et al. 
2006, Novakova et al. 2006). The column separation efficiency can be estimated by 
calculating the number of theoretical plates or height equivalent to the theoretical plate 
(HETP). Since HETP is inversely related to the number of theoretical plates, as the number of 
theoretical plates increases or HETP decreases, the column efficiency increases (Figure 1.18). 
That is to say, as particle size decreases or column length increases, the column separation 
efficiency increases. According to the graph in Figure 1.18 showing the relationship between 
column stationary phase particle size, flow velocity and the HETP, in modern HPLC and 
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UHPLC, small particles less than 2 µm are commonly employed to maximise the 
chromatographic separation power whilst maintaining short column lengths so to provide 
reduced system back pressures and shorter sample analysis times (Novakova et al. 2006). 
 
The internal diameter (i.d.) of a column is also an important parameter which affects 
detection sensitivity and the separation selectivity in gradient elution. It also determines the 
volume of sample analytes loaded onto the column. Larger columns (i.d. 10 mm) are 
normally used for industrial applications and analytical scale columns (i.d. 4.6 mm) are most 
commonly used columns for standard HPLC applications such as quantitative analysis; 
narrow-bore columns (i.d. 1-2 mm) are used for applications which require more sensitive 
detection methods like MS (Meyer 2004, Snyder et al. 1997). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.18. Van Deemter plot illustrating the relationship between the height equivalent to the theoretical plate 
(HETP) and flow velocity with changing column stationary phase particle size. The lower the HETP value, the 
better the efficiency of column separation. As the velocity of the mobile phase increases, the HETP value first 
decreases indicating the increasing separation efficiency of the stationary phase particles with diameter of 3 and 
5 µm. However, the separation efficiency of 3 and 5 µm particle sizes reaches an optimum and then rapidly 
decreases with increasing flow velocity, whereas 1.7 µm particles reach and preserve high chromatographic 
separation efficiencies under increasing flow rates and thus faster analysis times. 
 
Another significant parameter is the pump pressure which provides a consistent and 
reproducible flow rate of the mobile phase. Normally, as flow rate increases, the column 
separation efficiency decreases since the time of interactions between sample analytes and 
stationary phase decreases (Nguyen et al. 2006). However, modern HPLC has been enhanced 
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with much higher pressures up to 15,000 psi and thus smaller particle sizes in the columns 
(<2 µm) can be used (Novakova et al. 2006). As can be seen in Figure 1.18, since the 
separation efficiency with smaller than 2 µm particles is preserved with increasing mobile 
phase flow rate, sample analysis time and chromatographic resolution of the sample 
separation can be extended to new limits. This new technique has been termed UHPLC, due 
to its enhanced separation efficiencies, faster analysis times and reduced use and waste of 
solvents. In addition, the technique combined with maintaining high temperatures of column 
and mobile phase can provide the reduction of analysis times (Gika et al. 2008a). The 
reduction of mobile phase viscosity caused by high temperature operation can reduce sample 
analysis times with higher flow rates, although may result in the loss of heat labile 
metabolites.   
 
Visible radiation and absorbance detectors are commonly linked to HPLC or UHPLC. Visible 
radiation methods measure overall physical properties of the column eluent such as light 
scattering or refractive index and absorbance methods respond to the properties of solute by 
UV or fluorescence spectroscopy and photodiode array (PDA) detection (Meyer 2004, 
Snyder et al. 1997). UV or fluorescence spectrophotometric detectors are often employed for 
specific classes of compounds which are UV or fluorescence active (e.g., certain amino acids 
such as tyrosine and phenylalanine, and flavonoids such as the kaempferols and quercetins). 
PDA detectors have been frequently linked online to HPLC or UHPLC prior to MS, 
especially in the field of plant metabolomics (De Vos et al. 2007, Hanhineva et al. 2008, 
Moco et al. 2006, Mullen et al. 2006, Vorst et al. 2005). It is frequently found that for the 
identification of metabolites from complex sample matrices, it is essential to employ MS 
and/or NMR spectroscopy based detectors. 
 
HPLC and UHPLC are commonly linked to TOF and Q-TOF varieties of MS detector.  
However, as opposed to employing the hard EI ionisation technique commonly applied in 
GC-MS, the popularity of LC-MS has come from the application of soft ionisation methods 
appropriate to both metabolite and peptide analysis, for example atmospheric pressure 
chemical ionisation (APCI) and more so electrospray ionisation (ESI). During ESI, the 
eluting chromatographic fractions from LC are passed via a capillary and probe to the 
electrospray needle which has a high electrical charge applied to it resulting in charge transfer 
to the sample solute, thus the sample exits the needle as a fine spray of highly charged 
droplets. The charged droplets enter a stream of nebulisation gas (typically N2) within a 
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heating tube resulting in solvent evaporation and the production of gaseous ions (Figure 1.19). 
These gaseous ions are next extracted under vacuum through firstly the sample cone and then 
secondly the extraction cone, the gaseous ions are then focused into a fine stream through a 
hexapole lens and on into the MS detector.  Since ESI and APCI are soft ionisation methods 
that do not highly fragment the analyte, as observed in EI, thus direct metabolite 
identification is difficult and relies typically upon measurements of accurate mass and the 
generation of the numerous possible elemental compositions for that mass. In order to 
identify the analytes, LC is linked to tandem mass spectrometry (MS/MS), as largely 
performed with Q-TOF/MS. In Q-TOF/MS the analyte is typically filtered within the 
quadrupole, fragmented within a collision cell via CID, prior to TOF/MS detection. 
Confirmation of metabolite identification has to be performed by comparison and matching 
of LC RT and the sample analyte MS/MS spectra to those of pure analytical standards 
analysed under identical conditions (Allwood and Goodacre 2010, Dunn and Ellis 2005, 
Sumner et al. 2007). 
 
 
 
 
Figure 1.19. A schematic diagram of an ESI source 
 
Applications of LC-MS in biomedical areas have been commonly and constantly undergoing 
new developments. The technique has been employed for monitoring and screening human 
biofluids (Wagner et al. 2007, Zelena et al. 2009). Wagner et al. (2007) profiled mercapturic 
acids in human urine in order to develop LC-MS metabolic profiling methods for the early 
detection of risk factors from diseases or other harmful effects. For long-term metabolomic 
studies of human serum, Zelena et al. (2009) have assessed the reproducibility of UPLC-MS 
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methods by comparing different batches of UPLC columns and variations in MS performance 
over repeat analyses to assess suitable analytical block sizes between instrument cleaning and 
performance checks. It has been shown that columns from different production batches did 
not affect experimental reproducibility between two identical sample test sets. With respect to 
the block size indicating the suitable number of sample injections, fewer than 90 injections in 
the testing of the analytical block size experiment were recommended for appropriate MS 
reproducibility. LC-MS has been also mainly used to discover new biomarkers for a number 
of diseases including constant neutral loss (CNL) by screening of human urine (Wagner et al. 
2006). Also, the quantitative analysis of two low molecular weight organic compounds and 
an endogenous peptide was performed with human plasma and supernatants of cell cultures 
in order to develop LC-MS methods in biomedicine (Carrascal et al. 1998). LC-MS has also 
been applied to biomarker discovery in disease diagnosis, especially in cancer (Bondar et al. 
2007, Winther and Reubsaet 2007). LC-MS based metabolomics has been applied in the areas 
of drug discovery and development as well as drug metabolism and uptake (Chen et al. 2007a, 
Plumb et al. 2003). Plumb et al. (2003) detected xenobiotic metabolites derived from the 
GSK-X candidate pharmaceutical in the urine of Sprague-Dawley rats through the 
combination of LC-MS and multivariate data analyses such as PCA. In this research, clear 
separation between drug exposed and non-exposed groups was shown in PCA scores and 
loadings plots were used to determine differences between the control and test groups. The 
analyte species identified within the PCA loadings were confirmed as drug metabolites that 
were not present in the control samples. The drug metabolite data can be further interpreted to 
construct models on the metabolism of the drug candidate that potentially aid understanding 
of the drugs’ mode of action. Alternatively, LC-MS has also been employed to investigate 
disease development. In order to investigate 2-amino-1-methyl-6-phenylimidazo[4,5-
b]pyridine (PhIP) induced carcinogenesis, a high-resolution LC-MS/MS technique combined 
with multivariate data analysis was used for the profiling of the compound which led to the 
construction of a comprehensive map of PhIP metabolism, which made it possible to 
understand its role related to carcinogenesis (Chen et al. 2007b). 
 
1.4.4. Data Interpretation (Multivariate Analysis) 
Metabolomics approaches generate large amounts of multidimensional data regardless of 
which analytical technique is used. Such huge data sets contain much information some of 
which is relevant to the biological processes being studied and some which is not, thus it is 
very important to analyse the data sets accurately in order to decipher the relevant 
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information. This complexity and high dimensionality of data requires careful precise 
comparative analysis of different sample types (healthy/diseased, mutant/wild type, 
control/drug exposed, cell/patient, etc.) since important alterations in levels or compositions 
of metabolites need to be discovered. Since one or more peaks or bands in multi-dimension 
spectral data sets are correlated to the metabolites which have biological relationships with 
each other, the simplification of such data sets reduction of their dimensionality to 1- or 2-
dimensional scores maps is extremely valuable (Daykin and Wulfert 2006). Therefore, 
computer-based statistical applications can determine which samples are similar or different 
based upon the reduced dimensional variables (Goodacre et al. 2004). The reduced 
dimensional variables (often termed latent variables) that are of greatest interest can then be 
interpreted to identify which peaks or bands in the dataset contribute the most highly to it. 
Such analysis methods have been shown to provide better visualisation and more accurate 
interpretation of metabolomics data sets. 
 
1.4.4.1. Unsupervised Methods  
Determining the relationship between samples is the main goal of unsupervised methods. 
Analytical data may be grouped either by clustering methods or by projecting the high 
dimensional data on to lower dimensional space. Since there is no training in respect to which 
samples belong to (i.e., specific experimental classes), these methods are carried out in an 
unsupervised manner (Otto 1999). 
 
Principal component analysis (PCA) (Jolliffe 1986) is one of the oldest, simplest and most 
widely used multivariate techniques. This technique is an unsupervised method employed to 
reduce the dimensionality of spectroscopic or metabolomics data, where the original data 
matrix is projected on to a smaller variable subspace. PCA can be used to determine the 
variance in multi-dimensional data sets according to a set of underlying orthogonal variables 
known as principal components (PCs). The original variables (metabolite signals) can be 
described as a particular linear combination of the PCs (Sumner et al. 2003). Since PCA is a 
linear additive model, as more PCs are used more of the variance within the data set is 
explained. Often, a small set of PCs (e.g., 5 PCs) can explain as much as 95 % of the total 
explained variance. Those selected PCs construct a particular space (two or three dimensions, 
e.g. PC1 vs. PC2) where the data can be plotted and the dimension of the data set is reduced 
which most of the variance is explained. Therefore, PCA provides a rapid means of 
visualising and comparing the data set, making it possible to identify their similarities and 
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differences in the PCA scores space. By analysis of the PCA loadings it is possible to 
decipher which of the original metabolite signals contribute the most highly to the most 
significant PCs in respect to the separation of sample classes. 
 
1.4.4.2. Supervised Methods  
The key idea behind supervised methods is that there are some patterns (e.g., metabolic finger 
and footprints) that have desired responses that are known (e.g., whether an animal has been 
given a drug or placebo, or has a disease or a susceptibility to it) (Goodacre et al. 2004).  
Therefore, supervised methods can be applied for finding a model or mapping that will 
correctly associate variables identified from the data set with a priori knowledge on the 
experimental class structure (i.e., biological classification, or analytical or biological 
replicates).  
 
Canonical variates analysis (CVA; also known as discriminant function analysis (DFA), 
(Manly 1994)), is a powerful supervised methods usually applied to reduced dimensionality 
data from PCA; this combination is known as PC-CVA. The basic principle of CVA is similar 
to that of PCA but the goal of CVA is to find the linear combinations of the latent variables 
which maximise the ratio of the between-group to within-group variance, rather than 
maximising the total variance (Alsberg et al. 1998). PCA is first used to reduce the 
dimensionality of the data and then on the basis of the retained PCs and a priori information 
on the experimental class structure, PC-CVA is used to discriminate the samples by 
maximising the variance between the groups and minimising the variance within the groups; 
i.e., the Fisher ratio (Krzanowski 2000, Manly 1994). 
 
Partial least squares regression (PLSR) (Martens and Naes 1989) is also a supervised learning 
method. PLSR is a linear regression based method that can be used to investigate the linear 
relationships from multivariate datasets. In the studies described within this thesis, PLSR is 
used for quantitative predictions and is performed to search for linear combinations called 
latent variables in multivariate spectral data sets in order to explain maximum covariance 
between the data sets and drug concentrations. 
 
1.4.4.3. Cross Validation 
Cross-validation is possibly the most important step in formulating supervised learning 
models such as PC-CVA and PLSR since there is a possibility that these algorithms will over 
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fit the data. That is to say, the model has learnt the training data perfectly and is not able to 
generalise. This problem can be overcome by performing cross-validation. Data splitting is 
used to partition available data into two portions for the cross-validation purpose; i.e. a 
training set and cross-validation set. One portion of the data (the training set) is used to 
develop a predictive model and the other (cross-validation set) to evaluate the model’s 
performance (Brereton 2003, Picard and Berk 1990).  After the model is cross validated a 
third data set is often used to test further the stability of the model. 
 
1.5. Aims 
Cervical cancer is the second most common cancer in women worldwide and high-risk types 
of human papillomavirus (HPV) (~13) have been shown to be associated with over 99 % of 
cervical carcinomas (Harper et al. 2004, Munoz et al. 2003). Since most surgical procedures 
for treating the disease carry an increased risk of infertility, it is clear that simple non-surgical 
therapies such as self-administered drugs or creams are required against HPV for better 
preservation of obstetric function.  
 
It has been recently reported that the anti-viral drugs, indinavir and lopinavir, which are 
currently used as human immunodeficiency virus (HIV) protease inhibitors, could also inhibit 
E6-mediated proteasomal degradation of mutant p53 in E6-transfected C33A cells (Hampson 
et al. 2006). However, the molecular mechanisms of these protease inhibitors against HPV 
related cervical carcinomas have not yet been investigated. Thus in this thesis, advanced 
metabolomics methods were employed to help elucidate modes of action and drug cellular 
targets. For this purpose, the phenotypic effects of indinavir and lopinavir on HPV16 E6 
expressing C33A cervical carcinoma cells and control C33A cells which do not express E6 
were investigated using a variety of analytical instruments such as FT-IR and Raman 
spectroscopies, and UHPLC-MS. Metabolomic approaches for investigation of the 
phenotypic effects of indinavir and lopinavir on these cell lines could help us to understand 
the modes of action of the drugs against HPV.  
 
The specific aims of this work are: 
1. To investigate intra- and extra-cellular components based on a combination of metabolic 
fingerprinting and footprinting using FT-IR spectroscopy in order to understand the 
phenotypic response of HPV16 E6 expressing cervical carcinoma cells exposed to the HIV 
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anti-viral drugs, indinavir and lopinavir.  
 
2. To investigate the level and compositional changes in intracellular components of cervical 
carcinoma cells upon exposure to a series of indinavir and lopinavir concentrations with MS 
based metabolic profiling.  In addition, LC-MS was employed to quantify the level of the 
drugs inside the cells and in combination this will contribute to an understanding of the 
mechanism of these drugs against HPV on human cervical cell lines. 
 
3. To investigate the intracellular distribution of the drugs and other cellular components 
within a single cervical carcinoma cell using Raman chemical mapping and LC-MS in order 
to determine site of action of these drugs within the cells. 
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CHAPTER 2 
 
2. Combining Metabolic Fingerprinting and Footprinting to 
Understand the Phenotypic Response of HPV16 E6 Expressing 
Cervical Carcinoma Cells Exposed to the HIV Anti-viral Drug 
Lopinavir 
 
This chapter has been published as follows: 
Kim, D.-H., Jarvis, R. M., Xu, Y., Oliver, A. W., Allwood, J. W., Hampson, L., Hampson, I. N. 
& Goodacre, R. (2010). Combining metabolic fingerprinting and footprinting to understand 
the phenotypic response of HPV16 E6 expressing cervical carcinoma cells exposed to the 
HIV anti-viral drug lopinavir.  Analyst, 135, 1235-1244 
 
2.1. Abstract 
Recently, it has been reported that the anti-viral drug, lopinavir, which is currently used as a 
human immunodeficiency virus (HIV) protease inhibitor, could also inhibit E6-mediated 
proteasomal degradation of mutant p53 in E6-transfected C33A cells. In this study, C33A 
parent control cells and HPV 16 E6-transfected cells were exposed to lopinavir at 
concentrations ranging from 0 to 30 µM. The phenotypic response was assessed by Fourier 
transform infrared (FT-IR) spectroscopy directly on cells (the metabolic fingerprint) and on 
the cell growth medium (the metabolic footprint). Multivariate analysis of the data using both 
principal components analysis (PCA) and canonical variates analysis (PC-CVA) showed 
trends in scores plots that were related to the concentration of the drug. Inspection of the PC-
CVA loadings vector revealed that the effect was not due to the drug alone and that several IR 
spectral regions including proteins, nucleotides and carbohydrates contributed to the 
separation in PC-CVA space.  Finally, partial least squares regression (PLSR) could be used 
to predict the concentration of the drug accurately from the metabolic fingerprints and 
footprints, indicating a dose related phenotypic response. This study shows that the 
combination of metabolic fingerprinting and footprinting with appropriate chemometric 
analysis is a valuable approach for studying cellular responses to anti-viral drugs. 
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2.2. Introduction 
Each year in the UK, over 2,700 women are diagnosed with cervical cancer which leads to 
approximately 1,000 deaths per annum (UK Cervical Cancer Statistics, Cancer Research UK. 
www.cancerresearchuk.org). Globally an estimated 493,000 women are affected by cervical 
cancer producing 273,500 deaths from this disease each year (National Cervical Cancer 
Coalition. www.nccc-online.org). Indeed in many low resource countries it is the greatest 
cause of women’s cancer-related mortality.  
 
It is known that the human papilloma virus (HPV) is the major cause of cervical cancer (zur 
Hausen 1996). There are >100 different types of HPV associated with a variety of clinical 
lesions with approximately 20 of these being associated with anogenital tract lesions (de 
Villiers 1989). Of these HPVs, low-risk types (e.g., HPV6 and 11) have low tumourigenic 
potential and usually cause benign warts. By contrast, the high-risk types (e.g., HPV16 and 
18) are more often found in association with pre-malignant cervical lesions and invasive 
cancers (Scheffner et al. 1990, zur Hausen 1996). Accounting for >60% of disease, HPV16 
and 18 are the most prevalent high-risk types associated with cervical cancer although to date 
there are 16 other high risk types known (Dalstein et al. 2009, Harper et al. 2004, Munoz et 
al. 2003). 
 
In developed countries national anti-HPV vaccination programmes are currently being 
implemented as a means of preventing HPV infection and subsequent disease. However, 
these only cover types 16 and 18 which mean that there is still a significant proportion of 
high risk HPV related cervical disease that will not be protected by this strategy. Furthermore, 
many women are already persistently infected with high risk types of HPV which drastically 
reduces the effectiveness of vaccination. Thus, since cervical cancer can take from 10-20 
years to develop, this means these women will be at risk from this disease for many years to 
come. 
 
Surgery is still the preferred treatment of choice for HPV related pre-cancerous cervical 
intraepithelial neoplasia (CIN) (Harper et al. 2004, Villa et al. 2005). However, since most 
surgical procedures of this type carry an increased risk of infertility, this is usually reserved 
for so-called high grade CIN (CIN3). This leaves many women diagnosed with low grade 
disease (CIN1/2) with the unsatisfactory situation of being referred for increased surveillance. 
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It is clear that a simple, preferably self-administered non-surgical therapy would provide 
several advantages such as better preservation of obstetric function which would enable this 
treatment to be offered for low grade disease (Kyrgiou et al. 2006). 
 
Expression of high risk types of the E6 and E7 viral oncoproteins are largely responsible for 
the oncogenic properties of HPV (zur Hausen 2000). One of the most intensively studied 
properties of the E6 protein is its ability to compromise the function of the p53 tumour 
suppressor protein (Huibregtse et al. 1991). In association with the cellular E3 ubiquitin 
ligase E6-associated protein (AP), E6 binds to the p53 protein. E6 mediated activation of 
E6AP then catalyses the ubiquitination and subsequent proteasomal degradation of p53 
(Huibregtse et al. 1993). Indeed this strategy of inappropriate activation of the proteasome is 
used by many other viruses to subvert the function of a variety of cellular proteins that would 
prove detrimental to viral persistence (Banks et al. 2003, Thomas et al. 1999, zur Hausen 
1996). This implies that selective inhibition of proteasomal function could prove to be an 
effective strategy for the treatment of HPV infections. 
 
Metabolic fingerprinting is a high-throughput analytical technique which mostly uses 
spectroscopic methods for the classification of samples on the basis of their origin or 
biological relevance (Ellis and Goodacre 2006). In metabolic fingerprinting generating 
quantitative data on specific metabolites is not the strategy, as this necessitates time 
consuming sample clean-up steps and chromatography usually linked to mass spectrometry 
(Hollywood et al. 2006). Physicochemical analytical techniques such as FT-IR spectroscopy, 
nuclear magnetic resonance spectroscopy, or direct infusion mass spectrometry can provide 
sufficient resolution to handle a significant quantity of biological information reflecting 
biochemical differences between samples (Fiehn 2001). Therefore, these methods are often 
used for screening in functional genomics experiments (Kaderbhai et al. 2003), for the 
identification of major alterations in biochemical pathways as well as for diagnostic usage in 
industrial or clinical applications (Fiehn 2002).  
 
The investigation of intracellular metabolites is a powerful method for the understanding of 
complex biological systems; but global analysis of the complete set of intracellular 
metabolites is not yet achievable with a single technique. Furthermore, this approach is time 
consuming, and rapid metabolite turnover leads to technical difficulties requiring robust 
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methods for the rapid quenching of metabolism and extraction from cells. An alternative yet 
complementary approach can be the measurement of extracellular metabolites that are 
secreted and/or excreted from cells or organisms into their growth media. This overall 
strategy is called metabolic footprinting, which was demonstrated in studies involving the 
classification of microbial mutants for functional genomics (Allen et al. 2003, Kell et al. 
2005). 
 
FT-IR spectroscopy has been used widely to investigate metabolic changes in biological 
processes as well as to identify the components of biological systems in the field of 
metabolomics (Ellis and Goodacre 2006). These techniques make it possible to identify and 
characterise microbial cells (Naumann et al. 1991) as well as to determine the biochemical 
differences between normal and diseased cells; as demonstrated for cervical cancer and 
leukaemia cells in (Cohenford and Rigas 1998, Schultz et al. 1996). In addition, FT-IR 
spectroscopy is a powerful tool for global, sensitive and highly reproducible biochemical 
analysis and is very rapid due to the automated high-throughput analysis of biological 
samples and minimal sample preparation requirements (Winder et al. 2006). This reagentless, 
non-invasive and reproducible technique is resulting in manifold applications across a wide 
range of biosciences (Deleris and Petibois 2003, Ellis et al. 2004) and has great potential for 
rapid, low-cost and accurate cancer screening. Since earlier detection of cancer can provide 
better prognosis, high throughput screening becomes a significant process in cancer therapy. 
Potential applications in cervical cancer screening are well reviewed in (Walsh et al. 2007). 
Not only is FT-IR spectroscopy used as a tool for disease diagnosis, but it can also be 
employed to follow the response of patients to chemotherapeutic drugs, and can identify drug 
resistant phenotypes such that the best drug or combinations of drugs can be chosen for each 
patient (Krishna et al. 2006, Sulé-Suso et al. 2005). 
 
Hampson et al. have recently reported that the anti-viral drug lopinavir, which is currently 
used as a human immunodeficiency virus (HIV) protease inhibitor, could also inhibit E6-
mediated proteasomal degradation of p53 and selectively kill E6-dependant cervical 
carcinoma cells in vitro (Hampson et al. 2006). In order to contribute to an understanding of 
the mechanism of these drugs against HPV on human cervical cell lines, in this study we 
investigate the level and compositional changes in intra- and extra-cellular metabolites of 
control and HPV16 E6 expressing cervical carcinoma cells upon exposure to a series of 
physiologically relevant lopinivir drug concentrations. 
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2.3. Materials and Methods 
 
2.3.1. Cell Line and Culture Medium 
HPV-negative human C33A cervical carcinoma cells (termed “C33AP cells”) were 
maintained in RPMI 1640 medium (Invitrogen, Paisley, UK) supplemented with 10% fetal 
bovine serum (FBS) and 2 mM L-glutamine (Sigma-Aldrich Company Ltd, Dorset, UK) 
(complete medium) at 37 °C, 5% CO2. C33A cells stably transfected with HPV16 E6 (termed 
“C33AE6 cells”) and pcDNA3.1 were derived and cultured as previously described 
(Hampson et al. 2001). 
 
2.3.2. Protease Inhibitor 
Lopinavir was provided as a generous gift from Abbott Laboratories, Park Road, Abbott Park, 
IL 60064-6187, USA. Lopinavir was dissolved in DMSO (Sigma-Aldrich Company Ltd, UK) 
at a working stock concentration of 20 mM.  
 
2.3.3. Sample Preparation 
C33AP and E6 cells were seeded in T75 culture flasks and then incubated at 37 °C, 5% CO2. 
Before cells reached confluence, the complete medium was removed and 800 µl of trypsin 
(0.25%, 2.5 g/l) were added in order to detach the adherent cells from the flask. Cells were 
then incubated for 3 min at 37 °C, 5% CO2. After this incubation period, cells were 
resuspended in 10 ml of the complete medium and were counted.  
 
For fingerprint analysis, 1 × 106 cells were seeded in to 33 T75 culture flasks to give three 
biological replicates at each drug concentration and allowed to adhere overnight at 37 °C, 5% 
CO2. 0, 3, 6, 9, 12, 15, 18, 21, 24, 27 and 30 µM of lopinavir, (0 = control DMSO) were 
added to the relevant flasks and cells were incubated for 24h at 37 °C, 5% CO2. The growth 
medium was decanted and cells were washed once with 5 ml of PBS which was warmed to 
37 °C in advance. Next 500 µl of ice cold MeOH (-48 °C) were added for quenching 
metabolism and cells were scraped from the surface of the culture flasks and then transferred 
to 1.5 ml microcentrifuge tubes. For FT-IR spectroscopy (see below) 20 µl of each sample 
were pipetted onto a 96 well zinc selenide (ZnSe) plate (Bruker Ltd., Coventry, UK) and 
dried for 10 min at 60 °C. The procedure of cell preparation for fingerprint analysis using FT-
- 67 - 
 
Split to 33 T75 flasks
for 3 biological replicates
Washed × 3 
using PBS
Pipetted (20 µl)
ZnSe plate
FT-IR spectroscopy
×33
Lopinavir Scraped
×33 ×33
×33
Dried for 10min 
at 60°C
IR spectroscopy is shown in Figure 2.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1. The procedure of cell preparation for metabolic fingerprint analysis using FT-IR spectroscopy. 
 
For footprint analysis, 1 × 105 cells were seeded in to 12 6-well culture dishes to give three 
biological replicates and allowed to adhere overnight at 37 °C, 5% CO2. 0, 3, 6, 9, 12, 15, 18, 
21, 24, 27 and 30 µM of lopinavir, including control DMSO, were added to the relevant well 
and cells were incubated for 24h at 37 °C, 5% CO2. After this incubation period, 1 ml of the 
growth medium was collected and centrifuged at 3000 × g for 10 min at 4 °C to remove any 
cells and cell debris. For FT-IR spectroscopy the supernatants were collected and 40 µl of 
each were pipetted onto a ZnSe plate and dried for 20 min at 60 °C. The procedure of 
footprint analysis using FT-IR spectroscopy is illustrated in Figure 2.2. 
 
2.3.4. High Throughput Screening (HTS) FT-IR Spectroscopy 
FT-IR analysis was carried out on Bruker Equinox 55 infrared spectrometer equipped with a 
motorised microplate module HTS-XTTM utilising a deuterated triglycine sulphate (DTGS) 
detector (Bruker Ltd.) as detailed in (Winder et al. 2006). 
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Figure 2.2. The procedure of footprint analysis using FT-IR spectroscopy 
 
FT-IR spectra were recorded directly from the dried cell solutions and the growth media in 
transmission mode. The blank zero position of the plate was used to collect the reference 
spectrum for the background before each measurement. All spectra were obtained in the 
4000-600 cm-1 range using 64 co-added scans at 4 cm-1 resolution. A total of 396 spectra 
from fingerprinting and footprinting were collected and each spectrum took 60 s to obtain. 
These analytical settings were maintained during all measurements. 
 
2.3.5. Data Analysis 
ASCII data were exported from the OPUS 5.5 FT-IR operation software package and 
imported into Matlab version 7 software (The Mathworks, Inc., Matick, MA, USA) for 
further spectral analysis. To reduce non-biological variances arising from CO2 vibrations, the 
CO2 peaks at 2400-2275 cm
-1 and 680-660 cm-1 were removed and filled with a set trend. FT-
IR spectra were next scaled via extended multiplicative scatter correction (EMSC) (Martens 
et al. 2003). 
 
Matlab was programmed using in-house routines and was then used to perform principal 
components analysis (PCA), principal components-canonical variates analysis (PC-CVA) and 
partial least squares regression (PLSR) analysis on FT-IR spectral data sets from both the 
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finger- and footprinting of C33A cells. Briefly, PCA is one of the oldest and most widely 
used multivariate techniques, it is employed to reduce the dimensionality of spectroscopic 
data whilst maintaining the majority of its variance, and is often utilised as an initial step 
prior to cluster or discriminant analysis (Goodacre et al. 1998, Jolliffe 1986, Sumner et al. 
2003). Matlab was used to carry out PCA according to the NIPALS (nonlinear iterative partial 
least squares) algorithm (Wold 1966). CVA (also known as discriminant function analysis 
(DFA)), was then used to discriminate the samples on the basis of the retained principal 
components (PCs) and a priori information on the experimental class structure (Krzanowski 
2000, Manly 1994). Since the class structure within this experiment was based on the 
analytical replicates (see below) this does not bias the analysis and allows any natural trend 
differences between drug level treatments or cell types to be observed. Validation of the PC-
CVA model for finger- and footprint analyses was performed according to the methods 
described in (Jarvis and Goodacre 2004, Kaderbhai et al. 2003, Radovic et al. 2001). Briefly, 
the training set, which consisted of the first two biological replicates including all three 
analytical replicates, was used to construct a PC-CVA model. After which the test dataset 
were projected first into the PCA space used in the first model, subsequently the retained PCs 
were projected into CVA space. For comparison between the training and test data sets, the 
independently generated PCA and PC-CVA score plots were superimposed, co-clustering of 
the respective class groups within the test and training set indicated the validity of the PCA 
and PC-CVA models. Finally, 95% confidence circles were constructed around the PC-CVA 
group means using the χ2 confidence intervals using two degrees of freedom (Krzanowski 
2000) in order to investigate the statistical significance and to visualise the close 
superimposition of test and training dataset clusters. Since the chi-squared estimate was based 
on two independent variables (i.e. PC-CV1 and 2), two degrees of freedom were used.  
 
To investigate the relationships between the spectra and the series of drug concentrations, 
partial least squares regression (PLSR) analysis was used (Martens and Naes 1989, Wold et al. 
1984) as detailed in (Ellis and Goodacre 2001, Goodacre 2003, Goodacre and Kell 2003). 
PLSR analysis is generally performed for predictive linear modelling, and in this research 
was used to model the relationship between the spectral variations of C33A cervical cancer 
cells and the variable concentrations of anti-viral drug, lopinavir. Validation was achieved 
using a k-fold cross-validation with all the samples of each concentration level being left out 
once except the lowest and the highest concentration. 
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2.4. Results and Discussion 
 
2.4.1. Fingerprint Analysis 
The C33AP and E6 cells grown in both the absence and presence of lopinavir, were analysed 
by FT-IR spectroscopy. Typical transmission-generated FT-IR spectra of C33A human 
cervical cancer cells exposed to lopinavir for the two different cell lines are illustrated in 
Figure 2.3. All components of the cells such as a range of amino acids, lipids and nucleic 
acids contribute to the FT-IR spectra. The band assignments of FT-IR spectra were obtained 
from available literature (Conti et al. 2007, Fabian et al. 2006, Naumann 2001, Walsh et al. 
2007, Zhou et al. 2001) and are shown in Table 2.1. We attempted to collect the spectrum of 
lopinavir at the maximum concentration used in this work (30µM); however, no infrared 
absorbance was seen and so no FT-IR spectrum was recovered and this confirms that there 
was no direct contribution of the drug to the spectra of cell solutions (data not shown). 
 
Due to the qualitative similarity and complexity of the spectra from the two cell lines, a 
visible inspection of differences would be very difficult and so an initial multivariate analysis 
was carried out with PCA, as described above, to investigate basic biological differences 
between the two different cell types. 
 
 
 
 
 
 
 
 
 
 
Figure 2.3. Typical transmission-generated FT-IR spectra of C33A parent and E6-trasfected cells that have been 
grown in both the absence and presence of lopinavir. 
 
The resultant PCA scores plots and loadings plots are shown in Figure 2.4. As can be seen in 
Figure 2.4A and B, a clear separation between the two cell types is observed, indicating a 
high feasibility for an investigation of the inherent differences between the C33AP and E6 
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cells in terms of their biochemistry. Since the control and transfected cells are isogenic, and 
thus have the same genetic background, the only difference between the two cell types is the 
presence of the E6 oncogene and its protein. Therefore, this result from PCA clearly 
illustrates that the metabolic fingerprinting approach has great enough resolution to detect 
clear metabolic changes caused by E6; that is to say the effects of E6 oncoproperties are 
captured in the metabolome of a cancer cell. 
 
To investigate which spectral regions discriminated between C33AP and E6 cells, PCA 
loadings vectors were calculated and plotted (Figure 2.4C and D). These loadings plots 
revealed that the PC1 loadings (Figure 2.4C), which account for the greatest variation within 
the IR data set and which revealed a drug concentration related trend, predominately revealed 
a band at ~1080 cm-1 as making the greatest contribution, with some contribution from a 
sharper band at ~970 cm-1. In the PC2 loadings (Figure 4.5D), which largely discriminates 
between C33AP (red) and E6 (blue) cells, the bands at ~1750, ~1125 and ~1025 cm-1 
positively contributed to the PCA scores plot clustering. As can be confirmed in Table 2.1, the 
bands at ~1080 cm-1 and ~970 cm-1 can be attributed to phosphate vibrations from nucleotides 
and the peaks at ~1125 and ~1025 cm-1 could arise from a range of vibrations (Table 2.1) 
from carbohydrates including sugars within the cells. These large variations in nucleotide and 
carbohydrate content between the two cells are due to the biological differences which occur 
by virtue of the expression of the E6 oncogene in the C33A cervical carcinoma cell line. As 
discussed above, E6 oncogene encoded high risk E6 proteins of approximately 150 amino 
acid polypeptides, which bind and functionally inactivate the p53 tumour suppressor proteins 
and also facilitate the degradation of other cellular proteins.  
 
Although one of the major roles of E6 is to reduce the effective protein levels of p53 in order 
to abolish its tumour suppressor function, it is clear that it also directs the degradation of 
many other cellular proteins such as E6TP1, Scribble and the DNA-repair protein O6-
methylguanine DNA methyltransgerase (Banks et al. 2003, Mantovani and Banks 1999b, 
Scheffner et al. 1990) which are adenosine triphosphate (ATP) dependant processes. Indeed 
the E6 protein is known to affect the function of many cellular targets (Howie et al. 2009) 
with the conclusion that this will cause large biological perturbations in the level of various 
cellular components which result in the large spectral changes observed between the parent 
and E6 cells. 
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Table 2.1. Tentative FT-IR band assignment for C33A cells 
 
Wavenumber 
(cm
-1
) 
Assignment FT-IR Vibrational Modes 
Protein   
~3400 - ~3300 Amide A str. mode of N-H 
~1690 - ~1620 Amide I ν(C=O) 
~1590 - ~1530 Amide II δ(N-H) & ν(C-N) 
~1340 - ~1240 Amide III  
<ucleotide   
~1225  PO2
- (asymmetric phosphate) 
~1080  PO2
- (symmetric phosphate) 
Lipid   
~2924 & ~2850 Membrane lipids Symmetric CH2 str. mode of CH2 
chains 
~2958 & ~2873 Membrane lipids Asymmetric CH3 str. mode of 
CH3 end groups 
~1746  C=O 
~1463  CH2 bending 
~1165  Ester CO-O-C str. 
Carbohydrate   
~1200 - ~900  νs(C-O) coupled to the δ(C-O-H) 
  νs(C-O-C) 
  νs(C-O) 
~1030 Sugar (glycogen)  
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Figure 2.4. PCA scores plots (A, B) from PC1 (44.9%), PC2 (31.1%) and PC3 (13.1%), and loadings plots (C; 
PC1), (D; PC2) extracted from scores plot (A) showing the differences between the spectra of C33A parent and 
E6-transfected cells; red: parent cells, blue: E6 cells; first two letters indicate the type of cells and the name of 
the drug, lopinavir, last number represents the drug concentrations (µM).  
 
In successive multivariate analyses, individual PC-CVA was carried out as described above to 
investigate the anti-viral drug effect on each cell line separately. The first 9 PCs for C33AP 
cells and 10 PCs for C33AE6 cells, which accounted for 99.3% and 99.4% of the total 
explained variance (TEV), respectively, were used by the CVA algorithm, with knowledge of 
the biological replicates; cluster analysis validation was applied as detailed above. The 
resultant PC-CVA ordination plots are shown in Figure 2.5A and B for C33AP and E6 cells 
respectively. As can be clearly seen, trends in the individual PC-CVA scores plots reveal that 
metabolic relationships between drug concentrations and spectra are more significant for the 
E6 cell line, but less so for the parent. As seen in Figure 2.5B, the scores of E6 cells exposed 
to low concentrations of lopinavir are observed in the top left hand corner, as the 
concentration of the anti-viral drug increases, the cluster spreads from left to right. It is 
therefore valuable in the sense that this trend is directly relative to the lopinavir 
concentrations. This result clearly shows that the metabolic fingerprinting data from C33A 
A B 
C D 
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human cervical cancer cell lines using FT-IR spectroscopy contain valuable information for 
studying the phenotypic effect of the anti-viral drug. 
 
 
 
 
 
 
 
 
 
 
Figure 2.5. PC-CVA ordination plots (parent cells, A; E6 cells, B) showing the anti-viral effect on C33A parent 
and E6-transfected cells exposed to different concentrations of lopinavir. 9PCs for parent cells and 10 PCs for 
E6 cells, accounting for 99.3% and 99.4% of the TEV, respectively, were used to construct the ordination plots. 
Green circles represent the 95% confidence region about the group sample population, and the blue circles 
represent the 95% confidence interval about the group centroid. Arrows are drawn as a visual guide indicating 
the relationship between the spectra and the concentrations of lopinavir. 
 
Again, to determine whether any specific IR bands accounted for this trend, the PC-CV1 
loadings vector from the spectra of E6 cells was calculated and plotted in Figure 2.6. As can 
be seen in this figure, the band from ~1170 to ~1020 cm-1 is predominant within the PC-CV 
loadings and is negatively correlated to the anti-viral drug concentration. Also, the loadings 
vectors highlighted other peaks that made a significant contribution at ~1653 and ~1543 cm-1, 
that are positively correlated to the anti-viral concentration. As discussed above, the band 
from ~1170 to ~1020 cm-1 can be related to nucleotides and carbohydrates, and also peaks at 
~1653 and ~1543 cm-1 can be attributed to protein (amide I and II) content within the cells.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6. Loadings plot for PC-CV1 of E6 cells (See Figure 2.5B for respective scores plot). 
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There could be several explanations for the observed correlation between the level of some 
intracellular components and the concentration of lopinavir. As can be seen in Figure 2.7A 
and B, which plots the level of amide I and II against drug concentration there is a negative 
correlation with respect to protein contents. From this observation we can hypothesise that as 
the drug concentration increases and the proteolytic functions of E6 are inhibited, more p53 
and other unidentified E6 target proteins are stabilised in E6 expressing cells. The increase in 
the level of the p53 protein produced by inhibition of the effects of E6 by lopinavir has 
already been confirmed by Hampson et al. (Hampson et al. 2006) and it is very unlikely that 
this will be the only E6 targeted protein to be stabilised by this treatment. 
 
However, since the comparative cellular level of p53 is very small (Mantovani and Banks 
1999a), it will clearly be below the threshold of detection by the instrument. In addition it is 
also known that HPV oncoproteins can indirectly promote the stabilisation of specific 
proteins (e.g., p16INK4a) which implies that the net effect of blocking the function of E6 with 
lopinavir will consist of a balance between virally stabilised and destabilised proteins that are 
present. This provides a potential explanation for the observed drop in total cellular proteins 
in lopinavir treated C33AE6 cells where the overall effect of the drug produces a drop in 
cellular protein levels. Another intriguing possibility could be that lopinavir is inducing down 
regulated expression of proteins associated with enhanced toxicity of the drug in the C33AE6 
cells. Indeed it is known that stable ectopic expression of a single oncogene in carcinoma cell 
lines can cause “oncogene addiction” whereby the cells become dependent on the expression 
and continued function of the oncogene exhibiting enhanced sensitivity to agents that 
specifically target its functions (Mitsiades et al. 2007). 
 
A potential explanation for the negative correlation between both the carbohydrates and 
nucleotides band (1170 - 1020 cm-1) against drug concentration shown in Figure 2.7C, could 
be differences in carbohydrate metabolism. For example, it has been described that lopinavir 
can induce insulin resistance in vitro (Noor et al. 2006) which inhibits glucose and 2-
deoxyglucose uptake into primary rat adipocytes in vitro (Yan and Hruz 2005). Thus the 
documented influence of lopinavir on carbohydrate metabolism could produce a reduction in 
the levels of carbohydrate based nucleotides which coincides with the up-regulation of 
cellular proteins such as p53. 
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Figure 2.7. Box plots of proteins (amide I; A: amide II; B) and, nucleotides and carbohydrates (C) against drug 
concentrations (µM) for E6-transfected cells. Amide I and II regions are ~1653 and ~1543 cm-1, respectively, 
nucleotide and carbohydrate regions are ~1170 to 1020 cm-1, respectively. The blue bottom and top of the box 
are the lower and upper quartiles (the 25th and 75th percentile), respectively; the red band in the box represents 
the median (the 50th percentile); The ends of the whiskers represent the minimum and maximum of all the data; 
red cross represents any data not included between the whiskers. These box plots were plotted with particular 
wavenumber integrations in which the values (Y-axis) can be anything between 0 and 1.  
 
 
From these PC-CVA results, it is confirmed that the FT-IR spectra from C33AE6 cells contain 
biological information related to the concentration of lopinavir. Therefore, supervised 
learning analysis using PLSR was used to attempt to quantify the level of the drug. PLSR was 
conducted using k-fold cross-validation as described in the Data Aanlysis section. For the best 
model with the lowest prediction error in a test set (the arrow indicated in Figure 2.8A (model 
selection)), seven latent variables were used. The plot of PLS predicted versus actual 
concentrations of the drug shows relatively good prediction for both the training set (R2=0.88) 
and test set (Q2=0.74) as shown in Figure 2.8B and C, and the residual errors are randomly 
distributed (Figure 2.9D) suggesting a stable model. Like for the PC-CVA result (Figure 2.5), 
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it was also found that the predictions of the anti-viral drug concentrations from spectra using 
PLS are much better for the C33AE6 cell line than the parent (Appendix A). Thus it could be 
inferred that the spectra of C33AE6 cells have a more consistent response against increasing 
doses of the anti-viral drug. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.8. Estimates from PLS versus the actual concentration of lopinavir present in the growth media. (A) 
Model selection, number of PLS components against root mean square error of cross-validation (RMSECV); 
seven latent variables were used for the best model with the lowest prediction error in a test set. (B) Auto 
prediction of the training set, R2, the percentage of the variations explained by the module based on training sets. 
(C) Prediction of the test set, Q2, the percentage of the variations explained by the module based on cross-
validation sets. (D) Residues plot, actual concentration minus prediction.  
 
2.4.2. Footprint Analysis  
Growth media from C33AP and E6 cells grown in the absence and presence of lopinavir, 
were also analysed by FT-IR spectroscopy. Typical footprint spectra for these are shown in 
Figure 2.9. Clearly all the components of RPMI 1640 medium such as a range of amino acids, 
vitamins and sugars (formulation of RPMI 1640 medium, American Type Culture Collection. 
www.atcc.org) contribute to the FT-IR spectra. However, it has been shown for yeast and 
bacterial cells that the metabolic footprint contains useful information relating to the overflow 
of metabolism (Allen et al. 2003, Kaderbhai et al. 2003, Kell et al. 2005) and so we decided 
to investigate the metabolic footprint from E6 and parent cells in the presence and absence of 
lopinavir. 
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Figure 2.9. Typical transmission-generated FT-IR spectra of the growth media for C33A parent and E6-
trasfected cells that have been grown in both the absence and presence of lopinavir. 
 
Due to the low concentrations of metabolites secreted into the growth medium relative to the 
high levels of normal medium components, it is difficult to detect metabolic changes by 
simple visual inspections of the data. Therefore, PCA was carried out for initial analysis of 
the spectra produced from the growth media of both the C33AP and E6 cells. The resultant 
PCA scores plot and loadings plot are shown in Figure 2.10. Figure 2.10A shows that 
separate clusters from the media of C33AP and E6 cells are revealed which indicates 
metabolic differences in terms of the level and compositional changes of extracellular 
metabolites secreted from these two cell types, irrespective of drug level exposure. It is also 
notable that the C33AE6 cells are more tightly clustered than the parent cells and this could 
be due to the addition of the E6 oncogene and its protein causing a common response to the 
addition of the lopinavir. 
 
As can be seen from the PC1 loading plot in Figure 2.10B this separation is related to the 
variations of protein (amide II) and carbohydrate contents originating from ~1590 and ~1200 
to ~1000 cm-1, respectively. These data are the first demonstration of the overall effects of the 
HPV16 E6 protein on the secreted metabolic signature of cancer cells. 
 
To determine the specific anti-viral drug effect on extracellular metabolites secreted from 
each cell line, individual PC-CVAs were carried out separately and are shown in Figure 2.11A 
and B for C33AP and E6 cells respectively. Similar to the fingerprint analysis, trends in the 
individual PC-CVA score plots show that metabolic relationships between the footprinting 
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spectra and anti-viral drug dose are more obvious for the C33AE6 cell line and less so for the 
C33AP cell line. Based upon the previous fingerprint analysis, it is suggested that the changes 
in intracellular metabolites are in line with those observed for extracellular components in 
terms of the increasing dose of lopinavir. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.10. PCA scores plot (A) from PC 1 (75.9%) and PC2 (12.9%), and loadings plot (B) showing the 
differences between the spectra from footprint media of the growing C33A parent and E6-transfected cells 
exposed to lopinavir; red: parent cells; blue: E6 cells; first letter indicates the type of cells, last number 
represents the drug concentrations (µM). 
 
As can be seen in Figure 2.11B, the scores of the medium from C33AE6 cells exposed to low 
concentrations of lopinavir are located in the top left hand corner and as the dose of the anti-
viral drug increases the cluster spreads from left to right. As previously mentioned in the 
fingerprint analysis, we hypothesise that the trend in the footprint from C33AE6 cells is 
attributed to the inhibitory activity of anti-viral drug, lopinavir against the functions of E6, 
rather than the drug itself since the previous analysis of this drug by FT -IR produced no IR 
absorbance spectrum. 
 
PLSR on the IR spectra from the media of C33AE6 cells was also conducted with k-fold 
cross-validation as described in the Data Analysis section. Eight latent variables were 
selected for the best model (Figure 2.12A) with the lowest prediction error in a test set. The 
plot of PLS predicted versus actual concentrations of the drug shows very good prediction for 
both the training set (R2=0.95) and test set (Q2=0.86) as shown in Figure 2.12B-C (again with 
small residuals; Figure 2.12D) indicating that consistent responses occurred with increasing 
concentrations of drug. 
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Figure 2.11. PC-CVA ordination plots (the medium of parent cells, A; the medium of E6-transfected cells, B) 
showing the anti-viral effect on extracellular metabolites secreted from C33A parent and E6-transfected cells 
exposed to different concentrations of lopinavir. 10 PCs for parent cells and 12 PCs for E6 cells accounting for 
99.1% and 99.3% of the TEV, respectively, were used to construct the ordination plots. Green circles represent 
the 95% confidence region about the group sample population, and the blue circles represent the 95% 
confidence interval about the group centroid. Arrows are drawn as a visual guide indicating the relationship 
between the spectra and the concentrations of lopinavir. 
 
Moreover, these predictions from the footprint were slightly better than those from the 
fingerprint (Figure 2.8) and this may result from there being no cells within the footprint 
samples, thus the sample film thickness was more uniform compared to the metabolic 
fingerprint which contained cells. 
 
2.5. Conclusion 
Lopinavir is a well-known highly effective anti-viral drugs used routinely for the treatment of 
HIV. Yet despite there being observed efficacy against HPV the prospective mechanism of 
action of this drug against HPV infection has not been fully investigated. As discussed it has 
been reported that the drugs have an inhibitory effect on E6-mediated proteasomal 
degradation of the p53 tumour suppressor protein in C33AE6 cells. Thus, investigation of the 
changes of intra- and extracellular metabolites caused by lopinavir on C33AE6 and parental 
control cells could increase understanding of the mode of action of the drug. The objective of 
this study was to provide valuable data with which to support the prospective new use of 
lopinavir as a topically applied alternative to surgery for the treatment of HPV related pre-
cancerous lesions of the cervix. 
 
Our study shows that the spectral data sets obtained from human C33A cervical cancer cell 
lines, in combination with multivariate statistical methods such as PCA, PC-CVA and PLSR, 
do contain valuable information pertinent to the anti-viral effect of lopinavir. 
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Figure 2.12. Estimates from PLS versus the actual concentration of lopinavir present in the growth media. (A) 
Model selection, number of PLS components against root mean square error of cross-validation (RMSECV); 
eight latent variables were used for the best model with the lowest prediction error in a test set. (B) Auto 
prediction of the training set, R2, the percentage of the variations explained by the module based on training sets. 
(C) Prediction of the test set, Q2, the percentage of the variations explained by the module based on cross-
validation sets. (D) Residues plot, actual concentration minus prediction. 
 
We report that PCA scores plots from both metabolic fingerprint and footprints reveal 
excellent separation between C33AP and E6 cells and the PCA loadings vectors show that 
several regions derived from proteins, nucleotides and carbohydrates contribute to the 
separation. Trends according to individual PC-CVA score plots from fingerprinting also 
reveal that metabolic relationships between drug concentrations and spectra are more 
significant for the C33AE6 cells and less so for the C33AP. This indicates that the C33AE6 
cells have a bigger drug response. Since the PC-CVA scores plot obtained from the growth 
media of C33AE6 cells also shows a very similar trend to that from the fingerprint, it is 
clearly demonstrated that the changes of extracellular metabolites are well correlated to those 
of intracellular components in terms of response to lopinavir. This is valuable since it means 
that this approach could be used to analyse cellular response within the footprint in a non-
invasive fashion and so the cells do not need to be harvested and dried, thereby allowing time 
course experiments to be conducted. Finally, PLSR revealed good predictions for the 
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concentration of the drugs from the metabolic fingerprinting and footprinting being indicative 
of a dose-related phenotypic response that was not due to the spectral contribution of the drug 
itself. 
 
In conclusion we have demonstrated that the combination of metabolic fingerprinting and 
footprinting with appropriate chemometric analysis is a valuable approach for studying 
cellular responses to anti-viral drugs. 
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CHAPTER 3 
 
3. The Effects of HIV Protease Inhibitors on the UPLC-TOF/MS-
based Metabolic Profiling of HPV16 E6 Expressing Cervical 
Carcinoma Cells 
 
This chapter will be submitted as follows: 
Kim, D.-H., Allwood, J. W., Moore, R.E., Correa, E., Xu, Y., Jarvis, R. M., Oliver, A. W., 
Marsden-Edwards, E., Hampson, L., Hampson, I. N. & Goodacre, R. (2011). The effects of 
HIV protease inhibitors on the UPLC-TOF/MS-based metabolic profiling of HPV16 E6 
expressing cervical carcinoma cells. in preparation 
 
3.1. Abstract 
 
Recently, it has been reported that anti-viral drugs, such as indinavir and lopinavir (originally 
targeted for HIV), also inhibit E6-mediated proteasomal degradation of mutant p53 in E6-
transfected C33A cells. In order to understand more about these drugs’ mode-of-action(s) the 
effect of these drugs on the metabolome of HPV16 E6 expressing cervical carcinoma cell 
lines was investigated using mass spectrometry (MS)-based metabolic profiling. C33A parent 
and E6-transfected cells were exposed to indinavir (0, 0.05, 0.15, 0.5 and 1.0 mM) and 
lopinavir (0, 7.5, 15, 22.5 and 30 µM) at physiologically relevant conditions and the 
metabolite profiling was then performed by ultra performance liquid chromatography 
(UPLC)-MS using a Waters Acquity UPLC Synapt HDMS. Using a combination of 
multivariate analyses, such as principal components analysis (PCA), PC-canonical variates 
analysis (PC-CVA) and Bayesian networking (BN), along with univariate 	-way ANOVA, 
MS data were investigated for analytical and biological reproducibility and to reveal key 
metabolite differences between the various sample groups associated with anti-viral drug 
effects. This approach revealed both distinct and common effects of these two drugs on the 
metabolome of these two different cell lines. Metabolites which commonly increased in 
response to both drugs included phenylalanine whereas those which commonly decreased as 
anti-viral concentration increased included 2-methylenebut-3-enenitrile, 2-octenedioic acid, 
(iso)butyrylcarnitine and 2’-deoxy-guanosine 5’-phosphate. In terms of specific effects on 
cells expressing E6, metabolites that specifically responded to lopinavir included the 
putatively identified 6-acetyl-2-hydroxy-cyclohepta-2,4,6,-trien-1-one or 9-hydroxynon-7-en-
3,5-diynoic acid, 2,3-dihydrothiophene, 2,5-dihydrothiophene or but-3-yne-1-thiol and 
methionine, and unambiguously confirmed proline and indoline. Finally, the LC-MS drug 
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quantification showed that intra-cellular levels of lopinavir were approximately two-fold 
lower in the E6-transfected cells than in parent cells, indicating that it could be subjected to 
enhanced membrane pump excretion in the presence of E6. On the contrary, indinavir 
concentrations were always greater in the E6-transfected cells than the parent cells which 
may be a reflection of the extremely high levels of dosing applied with indinavir or may be a 
reflection of the localisation of the indinavir to the cell nucleus in the E6 transfected but not 
the parent cells.     
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3.2. Introduction 
Cervical cancer is the major gynecological cancer among women diagnosed in the UK. Each 
year in the UK, over 2,800 women are diagnosed and approximately 1,000 deaths are caused 
by the cancer (UK Cervical Cancer Statistics, Cancer Research UK. 
www.cancerresearchuk.org). The global figures are even more astounding, with an estimated 
473,000 women affected by cervical cancer and 253,500 deaths each year (National Cervical 
Cancer Coalition. www.nccc-online.org). Indeed in many low resource countries it is the 
greatest cause of women’s cancer-related mortality.  
 
Human papilloma virus (HPV) is the major cause of cervical cancer (zur Hausen 1996) and 
there are over 100 different types of HPV associated with a variety of clinical lesions with 
approximately 20 of these being associated with anogenital tract lesions (de Villiers 1989). Of 
these HPVs, the high-risk types (e.g., HPV16 and 18) are more often found in association 
with pre-malignant cervical lesions and invasive cancers (Scheffner et al. 1990, zur Hausen 
1996). HPV16 and 18 are the most widespread high-risk types associated with cervical cancer, 
accounting for over 60% of cases although there are 16 other high risk types reported 
(Dalstein et al. 2009, Harper et al. 2004, Munoz et al. 2003). Although anti-HPV vaccines 
have been implemented these generally only cover the high risk types (16 and 18) which 
mean that there is still a significant proportion of other high risk HPVs related cervical 
disease that will not be protected by this strategy. In addition, since there are many women 
persistently infected with high risk types of HPV and cervical cancer can take from 10-20 
years to develop, alternative therapies are required for preventing HPV infection. Whilst 
surgery has been employed widely for the treatment of HPV related pre-cancerous cervical 
intraepithelial neoplasia (CIN) (Harper et al. 2004, Villa et al. 2005), most surgical 
procedures of this type carry an increased risk of infertility, which leads to a need for simple, 
preferably self-administered non-surgical therapy providing several advantages such as better 
preservation of obstetric function which would enable this treatment to be offered for low 
grade disease. (Kyrgiou et al. 2006). 
 
Expression of high risk types of the E6 and E7 viral oncoproteins are largely responsible for 
the oncogenic properties of HPV (zur Hausen 2000). One of the most intensively studied 
properties of the E6 protein is its ability to compromise the function of the p53 tumour 
suppressor protein (Huibregtse et al. 1991). In association with the cellular E3 ubiquitin 
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ligase E6-associated protein (AP), E6 binds to the p53 protein. E6 mediated activation of 
E6AP then catalyses the ubiquitination and subsequent proteasomal degradation of p53 
(Huibregtse et al. 1993). Indeed this strategy of inappropriate activation of the proteasome is 
used by many other viruses to subvert the function of a variety of cellular proteins that would 
prove detrimental to viral persistence (Banks et al. 2003, Thomas et al. 1999, zur Hausen 
1996). This implies that selective inhibition of proteasomal function could prove to be an 
effective strategy for the treatment of HPV infections. 
 
In order to understand complex molecular interactions in biological systems there has been 
great interest in the recent post-genomic and systems biology fields. These include the 
comprehensive analysis of the integrated information from genes (genome), mRNA 
(transcriptome), proteins (proteome) and metabolites (metabolome). Metabolomics is an 
emerging field for quantifying and identifying all of the small molecules present in the cell or 
organism at a given time under specific conditions, which is complementary to the other 
‘omics’ approaches (Dunn et al. 2010, Fiehn 2001, Goodacre et al. 2004, Weckwerth 2003).  
 
Although metabolomics is a complementary field, it has particular advantages over other 
‘omics’ approaches. The metabolome is the end product of gene expression, or metabolic 
activities of cells and so reflects more accurately the responses of the cell or organism to both 
gene expression and its environment; i.e., phenotype (Goodacre et al. 2004, ter Kuile and 
Westerhoff 2001). Metabolite profiling is a powerful analytical tool focused on the 
identification and quantification of a selected number of pre-defined metabolic pathways or 
small molecules with similar chemistries, which is largely dictated by the chosen 
metabolomics platform (Fiehn 2001). Sample preparation is typically non-targeted thus 
allowing the detection and quantification of a wide range of metabolites and sample 
complexity is also reduced by applying chromatographic separations prior to detection by 
mass spectrometry (MS) or nuclear magnetic resonance (NMR) spectroscopy. Metabolite 
profiling is used widely across all areas of biological (plants, microbes, animals, 
environmental) and clinical metabolomics (Biais et al. 2009, Gika et al. 2008a, Winder et al. 
2008, Zelena et al. 2009) as well as in the clinical context of drug research for biomarker 
discovery (Ong et al. 2009) and drug development by tracing the metabolic response of an 
administered drug (Tiziani et al. 2009).  
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Although FT-IR and Raman spectroscopy are reagentless and non-invasive tools for global, 
sensitive and highly reproducible metabolome analyses with minimal sample preparation, 
there is the limitation that specific chemical structures cannot be identified. Since 
spectroscopic techniques, unlike chromatography-MS, do not detect the mass-to-charge ratio 
(m/z) and thus molecular weight that can then be related to the elemental composition of 
compounds within biological samples such as the C33A cervical cancer cells being studied in 
this thesis, it is difficult to investigate which specific molecules are associated with the anti-
viral drug effect and further understand the mechanism of the drugs. LC-MS is a powerful 
analytical technique not only for the quantification of metabolites but also for the 
identification of known compounds in biological samples; LC is employed for the separation 
followed by electrospray ionisation (ESI)–MS for mass detection (Allwood and Goodacre 
2010). Whilst GC-MS can detect a range of volatile compounds, non-polar fatty acids, or 
primary metabolites (when derivatised), LC-MS is more suited to the analysis of both 
primary and secondary metabolites within a single analysis, although this is very much 
dependant on the extraction methodology and choice of column and method of LC that is 
employed.  Since LC-MS, like GC-MS, is fully automated it is particularly amenable to high-
throughput metabolomics analysis. Thus, LC-MS has been used widely to investigate 
metabolic changes in biological processes as well as to discover new biomarkers using MS 
based analyses, as for example the application of full and constant neutral loss (CNL) 
scanning to the screening of human urine (Wagner et al. 2006). Also, this technique was 
employed for the quantitative analysis of  low molecular weight organic compounds and an 
endogenous peptide in human plasma and supernatants of cell cultures in order to develop 
LC-MS methods in biomedicine (Carrascal et al. 1998). Many other applications are 
employing LC-MS for biomarker discovery in order to diagnose diseases, and this is 
especially the case for cancers (Bondar et al. 2007, Kind et al. 2007, Winther and Reubsaet 
2007). LC-MS based metabolomics has been also applied in the areas of drug discovery and 
development as well as drug metabolism and uptake (Chen et al. 2007a, Chen et al. 2007b, 
Plumb et al. 2003). Therefore, we plan to exploit metabolic profiling employing LC-MS in 
order to understand biological consequences of cellular exposure to anti-viral drugs.  
 
Typically the data generated from metabolomics experiments are difficult to interpret and 
visualise and so a combination of multivariate and univariate analyses are performed 
(Goodacre et al. 2007).  Typical algorithms that are used include cluster approaches as well as 
discriminant analyses. However the links between metabolites can often be hard to 
- 88 - 
 
understand using these approaches and validation of models is important (Broadhurst and 
Kell 2006, Westerhuis et al. 2008).  By contrast, a Bayesian network (BN) is a multivariate 
statistical technique which recently has started to be applied to metabolomics-based 
investigation (Gavai 2009, Li and Chan 2004). A BN is basically a graphical model of a 
probability distribution over a set of variables of a given problem domain (Jensen 2001, 
Neapolitan 2003), providing a compact and intuitive representation of their relationships. 
Nodes on the graph represent variables from the problem (e.g., metabolites) and an edge (line) 
linking two nodes indicates a statistical correlation between them. This statistical correlation 
falls broadly into one of the two categories: (a) “positive correlation” indicates that the values 
of both variables increase or decrease together, and (b) “negative correlation” indicates that 
as one variable increases, the other decreases, or vice versa. The network structure of a BN 
encodes probabilistic dependencies among domain variables and a joint probability 
distribution quantifies the strength of these dependencies (Heckerman 1995). The resulting 
graphical model (network) has two main uses: 
 
(1) Visualisation of probabilistic relationships: the graphical model provides direct 
and accurate information about the underlying interactions among variables of interest 
(metabolites in our case), and  
(2) Inference: the BN is intrinsically an inference model and can be used to predict 
outputs or to classify new samples. Therefore, anti-viral drug effect on the cells can be 
determined by investigating the underlying relationships between metabolites of 
interest. 
 
We have recently reported that the anti-viral drugs indinavir and lopinavir, which are 
currently used for the treatment of a human immunodeficiency virus (HIV) infection, also 
inhibit the ability of HPV16 E6 to degrade p53 and selectively kill E6-dependant cervical 
carcinoma cells in vitro (Hampson et al. 2006) and that the exposure of these drugs is 
affected by the phenotypic changes (i.e. metabolic alteration) of these carcinoma cells (Kim 
et al. 2010b). However, whilst recent studies show that indinavir is targeted to the nucleus 
(Kim et al. 2010a), the mode of action of these drugs against HPV is largely unknown. 
Therefore, in this study in order to contribute to an understanding of the mechanism of these 
drugs against HPV on human cervical cell lines, we investigate the level and compositional 
changes in intracellular components of control and HPV16 E6 expressing cervical carcinoma 
- 89 - 
 
cells upon exposure to a series of physiological relevant indinavir and lopinavir 
concentrations and quantify the intra-cellular concentration of these drugs. 
 
3.3. Materials and Methods 
 
3.3.1. Cell Line and Culture Medium 
HPV-negative human C33A cervical carcinoma cells (termed “C33AP”) were maintained in 
RPMI 1640 medium (Invitrogen, Paisley, UK) supplemented with 10% fetal bovine serum 
(FBS) and 2 mM L-glutamine (Sigma-Aldrich Company Ltd, Dorset, UK) (complete medium) 
at 37 °C, 5% CO2. C33A cells stably transfected with HPV16 E6 (termed “C33AE6”) and 
pcDNA3.1 were derived and cultured as previously described (Hampson et al. 2001). 
 
3.3.2. Protease Inhibitor 
Indinavir was obtained through the NIH AIDS Research and Reference Reagent Program 
(Division of AIDS, NIAID, NIH): indinavir sulphate (8145). Lopinavir was provided as a 
generous gift from Abbott Laboratories, Park Road, Abbott Park, IL 60064-6187, USA. 
Indinavir and lopinavir were dissolved in sterile distilled water and DMSO (Sigma-Aldrich 
Company Ltd, UK), respectively, at a working stock concentration of 20mM. 
 
3.3.3. Sample preparation 
After incubation in RPMI 1640 medium (Invitrogen, Paisley, UK) supplemented with 10% 
fetal bovine serum (FBS) and 2 mM L-glutamine (Sigma-Aldrich Company Ltd, Dorset, UK) 
(complete medium) at 37 °C, 5% CO2, the complete medium was removed and 800 µL of 
trypsin (0.25%, 2.5 g/l) was added in order to detach the adherent cells from the flask. Cells 
were then incubated for 3 min at 37 oC, 5% CO2. After this period, cells were resuspended in 
10 ml of the complete medium and were counted. Each 1 × 106 of C33AP and C33AE6 cells 
were then seeded in large scale T75 culture flasks (to provide five drug conditions and five 
biological replicates for each drug) and allowed to adhere and reach 80-90% confluence at 37 
oC, 5% CO2. Indinavir (0, 0.05, 0.15, 0.5 and 1.0 mM) and lopinavir (0, 7.5, 15, 22.5 and 30 
µM), or water and DMSO (as controls) were added to the relevant flasks and cells were 
incubated for 24h at 37 °C, 5% CO2; these concentrations were investigated previously and 
found to be physiologically relevant (Hampson et al. 2006, Kim et al. 2010b). Three flasks 
were employed per drug concentration in order to obtain enough biomass to be detected by 
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LC-MS. After the incubation period, the growth media were poured off and the cells were 
washed with PBS warmed at 37 oC (matching the incubation temperature). 3 ml of pure 
methanol (MeOH) (-48 °C) was added for quenching metabolism and cells were scraped from 
the surface of the culture flask whilst being kept on ice. After combining three flasks, cells 
were freeze-thaw extracted and lyophilised (i.e., flash frozen in liquid N2 for 1 min and 
thawed at 4 oC then vortexed for 30 s × 4) and then centrifuged at 3000 × g for 10 min. Next, 
the supernatants (cell extracts) were evaporated at room temperature and each dried extract 
was weighed for normalisation, and subsequently stored at -80 °C prior to analysis. In order 
to compensate for any analytical drift each sample group (i.e. parent + indinavir or lopinavir; 
E6 + indinavir or lopinavir) was prepared on a different week. Before analysis, the samples 
were reconstituted in 20 µl/mg cell DW (dry weight) of 20% aqueous MeOH (HPLC grade). 
In total four groups of samples were prepared and these were analysed as one batch by 
UPLC-MS using an Acquity UPLCTM (Waters Ltd., Manchester, UK) and Synapt HDMSTM 
(Waters Ltd., UK).  
 
In order to assess instrument performance as detailed in (Begley et al. 2009, Sangster et al. 
2006, Zelena et al. 2009) three pooled quality control (QC) samples were prepared; indinavir 
QC to represent equal mix of all indinavir exposed samples, the lopinavir QC to represent 
equal mix of all lopinavir exposed samples and mixed QC to represent equal mix of all the 
samples. 
 
3.3.4. Analytical Methodologies 
For metabolite profiling, UPLC was performed on an ACQUITY UPLCTM system (Waters 
Corporation, Milford, MA, USA). Chromatographic separations were performed on a 1mm x 
100 mm, 1.7 µm ACQUITY HSS T3 C18 column. The column was maintained at 45 ºC and 
samples were eluted with a linear water (0.1 % v/v formic acid)/acetonitrile (0.1 % v/v formic 
acid) gradient over 10 min at a flow rate of 0.25 ml/min as follows: 100 % A (0 min) to 100 % 
B at 7 min to 100 % B at 8 min to 100% A at 8.1 min to 100 % A at 10 min. A 5 µl injection 
of each sample was made. 
 
A hybrid Quadrupole/Travelling Wave IMS-oa TOF device SYNAPT HDMS (Waters, 
Manchester, UK) was operated in positive ion electrospray (ES +ve) mode. Data were 
acquired in V mode with a FWHM (full width at half maximum) of 10,000 with mass 
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accuracy typically within 3 ppm root mean square (RMS). Data were acquired from 50-1000 
Da, using a source temperature of 120 ºC, desolvation temperature of 350 ºC and cone 
voltage of 30 V. Data were centroided during the acquisition and the lockmass applied was 
leucine enkephalin (500 pg/µl in 50 % (v/v) acetonitrile, 0.1 % (v/v) formic acid, infused at 
50 µl/min), [M+H]+ 556.2771. The instrument was calibrated using sodium formate over the 
acquisition mass range of 50-1000 Da and data was acquired in MSE mode (Bateman et al. 
2007, Wrona et al. 2005). In this mode of data acquisition the mass spectrometer is operated 
in a wide-band radio-frequency mode in Q1 with interleaved low and elevated collision 
energies to generate unfragmented and fragmented ions in two discrete functions. Low-
energy data were acquired in Function (1) using a collision energy (CE) of 6 eV on the Trap 
collision cell and 4 eV on the Transfer collsion cell. High-energy data were acquired in 
Function (2) using a ramped CE on the Trap collision cell  of 15 eV-25 eV and a fixed CE on 
the Transfer collision cell of 25 eV. Sample measurements were performed in triplicate, to 
account for any analytical variability. 
 
LC-MS/MS analysis was performed under the same UPLC conditions as applied to the LC-
MS analysis, only linked to a XEVOTM QTof MS system (Waters, Manchester, UK). The MS 
instrument was operated in ES +ve mode. Prior to sample analysis the instrument was 
calibrated with sodium formate from 50-1000 Da and the lockspray employed was leucine-
enkephalin at a concentration of 500 pg/µl with 2 points employed for lockmass; m/z 
556.2771 and a fragment ion from leucine-enkephalin at m/z 120.0813. All instrument 
calibration and setup was performed using IntelliStartTM. Most of the instrument parameters 
were made consistent with those applied to the SYNAPT HDMS with the exception of the 
desolvation temperature which was set at 400 °C. The target mass ion for MS/MS was 
selected by the quadrupole and was then subjected to CID using a CE ramp typically in the 
range 15-35 eV. Sample measurements were compared to those of pure analytical standards. 
Identification was only regarded as unambiguous when the sample data matched that of the 
standard for both UPLC retention time (RT) and MS/MS accurate mass fragment ions. 
 
For drug quantification, LC-MS analysis for the quantification of lopinavir within the 
samples was performed on a Waters ACQUITY UPLC system, whereas for indinavir analyses 
were performed upon a Thermo Accela UHPLC system, both LC systems were operated 
using the same column and under the same conditions as applied for metabolite profiling. For 
quantification of lopinavir, mass detection was achieved using a Q-TOF Micro (Waters 
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Manchester, UK), whereas for indinavir mass detection was performed upon a Thermo LTQ-
Orbitrap XL. Both MS systems were operated in ES +ve mode. Prior to sample analysis the 
Q-TOF micro instrument was calibrated with ampicillin, whereas the LTQ and Orbitrap XL 
was tuned to a calibrant ion in the mid range of mass detection (528 m/z) prior to mass 
calibration with the manufacturers recommended calibration mixture across 100-2000 m/z. 
For both MS systems, data were acquired from 50-1000 Da, using a source temperature of 
120 ºC, desolvation temperature of 350 ºC, desolvation gas flow of 800 l/h and cone voltage 
of 30 V. A number of serially diluted standards for each of the two drug compounds were 
analysed six times each. The sample extracts initially profiled by LC-MS were diluted three 
fold prior to analysis on the Q-TOF micro, and 24 fold prior to analysis on the LTQ-Orbitrap 
XL, thus preventing saturation of the MS detectors. For both samples and analytical standards 
a 5 µl sample injection was performed, within the C33A cell culture samples (50mg extract 
dry weight (DW)/ml), after adjustment to compensate for the extract dilution made prior to 
analysis, this equates to an on column volume that was equal to 0.25mg extract DW. Peak 
areas were extracted for each drug compounds’ parent m/z within Waters MassLynx and 
Thermo Xcalibur software packages for the data collected on Q-TOF Micro and LTQ-
Orbitrap XL respectively. The indinavir and lopinavir extracted peak areas, for both drug 
standards and samples, were transformed to their natural log values, and calibration curves 
were built for the two drug standards. Quantification of the indinavir and lopinavir mass 
peaks within the cell line samples were predicted against the calibration curves constructed 
using the serially diluted drug standards. All stages of the quantification process were 
performed within MatLab version 7.   
  
3.3.5. Data Processing  
Initially the LC-MS profiling data were baseline corrected, aligned, and exact mass retention 
time (EMRT) pairs extracted within Waters MarkerLynxTM XS thus producing an X and Y 
data matrix of samples aligned for each EMRT. Prior to data analysis, an exclusion list of all 
known xenobiotics originating from the dosing drug (including parent metabolites and 
excipients) and solvents used was applied to the data set, such that only EMRT pairs from 
endogenous metabolite species remained for chemometric analysis. For each cell line the 
cellular metabolites of each drug were identified using the MetaboLynxTM XS application 
manager within MassLynx 4.1. Since data were acquired in MSE mode, fragmentation data 
were available for confirmation of the metabolites identified. Excipients from the indinavir 
and lopinavir solutions were identified by comparing drug standard injections to blank 
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injections in MarkerLynx XS. A text file of all these excluded masses was generated and 
employed in the cell profiling MarkerLynxTM XS processing method, thus producing an 
output containing only EMRT pairs that were associated with endogenous metabolites. The 
final output was Pareto scaled prior to statistical analysis. The Pareto scaling can be operated 
by the dividing of dataset by the square root of its standard deviation. This strengthened the 
representation of lower concentration metabolites in the dataset models while minimising the 
noise contribution (Noda 2008, Pears et al. 2005).   
 
3.3.6. Data Analysis 
Data analysis followed the Metabolomics Standards Initiative guidelines (Goodacre et al. 
2007). The resultant data matrix of EMRTs was submitted to multivariate statistical analysis 
in Matlab version 7 software (The Mathworks, Inc., Matick, MA, USA). Principal 
components analysis (PCA) and principal components-canonical variates analysis (PC-CVA) 
were performed on the pre-processed LC-MS data set. Briefly, PCA is one of the oldest and 
most widely used multivariate techniques, it is employed to reduce the dimensionality of 
metabolomics data whilst maintaining the majority of its variance and is used to visualise 
general trends and outliers among the observations. Therefore, it is often utilised as an initial 
step prior to cluster or discriminant analysis (Goodacre et al. 1998, Jolliffe 1986, Sumner et 
al. 2003). PCA was performed according to the NIPALS (nonlinear iterative partial least 
squares) algorithm (Wold 1966). Canonical variates analysis (CVA; also known as 
discriminant function analysis (DFA)), was then used to discriminate the samples on the basis 
of the retained principal components (PCs) and a priori information on the experimental class 
structure (Krzanowski 2000, Manly 1994). Since the class structure within this experiment 
was based on the analytical replicates (see below) this does not bias the analysis and allows 
any natural trend differences between drug level treatments or cell types to be observed. 
Validation of the PC-CVA model was performed according to the methods described in 
(Jarvis and Goodacre 2004, Kaderbhai et al. 2003, Radovic et al. 2001). Briefly, the training 
set, which consisted of the first three biological replicates, was used to construct a PC-CVA 
model. A second PC-CVA model is made with the remaining test set which consisted of the 
last two biological replicates. For comparison between the training and test datasets, the 
independently generated PC-CVA scores plots were superimposed, co-clustering of the 
respective class groups within the test and training sets indicated the validity of the PC-CVA 
models. Finally, 95% confidence circles were constructed around the PC-CVA group means 
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using the χ2 confidence intervals using two degrees of freedom (Krzanowski 2000) in order 
to investigate the statistical significance and to visualise the close superimposition of test and 
training dataset clusters. 
 
In addition to the inspection of loadings matrices from PCA and PC-CVA for the discovery 
of which metabolites were more discriminatory, as a final data mining step univariate data 
analyses were applied. Here, 	-way ANOVA was performed within Matlab 7 software and 
was used to assess levels of significant difference for each EMRT pair between control and 
drug doses within each cell line individually.  
 
Finally, to investigate the relationships between metabolic changes and drug exposure as well 
as correlations of each key metabolite in terms of metabolic pathways, a BN analysis was 
performed; all BN analyses were conducted by Dr Elon Correa. A BN is a graphical map of 
the probabilistic relationships among variables of a given problem domain (Pearl 1988). The 
graphical representation of a BN is a directed acyclic graph. A directed acyclic graph G is an 
ordered pair G = (V;  E) where V is a set whose elements are called vertices or nodes and E is 
a set whose elements are called directed edges, arcs, or arrows. The graph G contains no 
directed cycles; for any vertex v ∈ V, there is no directed path that starts and ends on v. An 
example of a Bayesian network is as follows (This is a modified version of the so-called 
“Asia” problem found in (Lauritzen and Spiegelhalter 1988)). Suppose that a doctor is 
treating a patient who has been suffering from shortness of breath, called dyspnoea. The 
doctor knows that diseases such as tuberculosis, bronchitis and lung cancer are possible 
causes of this. The doctor also knows that other relevant information includes whether the 
patient is a smoker, which increases the chances of lung cancer and bronchitis, and what sort 
of air pollution the patient has been exposed to. A positive X-ray would indicate either 
tuberculosis or lung cancer. (The set of variables for this problem and their possible values 
are shown in Appendix B together with a Bayesian network representing this problem.) 
 
The network structure, also known as network topology, shows how variables correlate to 
each other. More formally, let X = {X1, X2, ..., Xn} be a multivariate random variable whose 
components Xi are also random variables. A corresponding lower-case letter xi denotes an 
assignment of state or value to the random variable Xi. Parents(Xi) represents the set of nodes 
that have a directed edge pointing to Xi. Consider a BN containing n nodes, X1 to Xn, taken in  
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that order. A particular value of X = {X1, X2, ..., Xn} in the joint probability distribution is 
represented by p(X) = p(X1 = x1, X2 = x2, ..., Xn = xn), or more compactly, p(x1, x2, ..., xn). The 
chain rule of probability theory allows the factorization of joint probabilities, therefore: 
p(X) = p(x1) p(x2|x1) … p(xn|xn-1)  
 = 
−∏ 1 1( | ,..., )i i
i
p x x x  (1) 
 
As the structure of a BN implies that the value of a particular node is conditional only on the 
values of its parent nodes, Equation 1 is reduced to: 
 
p(X) = ∏ ( | ( ))i i
i
p X Parents X        (2) 
 
Learning the structure of a BN is an NP-hard problem (Bouckaert 1994, Chickering et al. 
1994). Many algorithms developed to this end use a scoring metric and a search procedure. 
The scoring metric evaluates the “goodness-of-fit” of a structure to the data. The search 
procedure generates alternative structures and selects the best one based on the scoring metric. 
A greedy search algorithm is used to generate alternative structures for the BN. Greedy 
search proceeds at each step by assessing each neighbour of the current state, and moving to 
the one with the highest score if doing so improves the score (Chickering 2002). Starting with 
an empty network, the greedy search algorithm adds to the current network the edge that most 
increases the score of the new resulting network. The search stops when no other edge 
addition improves the score of the network. 
 
To examine the interaction among metabolites further we fitted a Bayesian network to the 
data. Contrary to intuition, the direction of the arrow on a Bayesian network does not 
necessarily imply a cause-effect relationship between the variables. A Bayesian network is 
not a “causal network”. A causal network is a Bayesian network with an explicit requirement 
that the relationships (arrow directions) be causal (Pearl 2000). On this thesis we do not 
construct a causal network. Causal networks are out of the scope of this thesis and are a 
subject for future work. 
 
Therefore, to eliminate the possible misleading cause-effect interpretation from our BN, we 
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intentionally omit the arrow heads from the graphs. In the represntation of BN used in this 
thesis a line linking two metabolites implies that there is a statistically significant relationship 
between them; detected during the network building process. After learning the network 
structure, we also compute the partial correlation coefficient between linked metabolites and 
show this respective correlation beside each link on the network. A partial correlation 
estimates the correlation between two nodes when the effect of all other nodes in the model is 
held constant; this process avoids the detection of metabolites that are not in fact directly 
correlated to each other (Hair et al. 2007). 
 
3.3.7. Metabolite Identification Using LC-MS/MS 
The process of marker identification was made up of four stages. The first stage employed the 
exact mass and accurate isotope ratio data for each EMRT pair to calculate proposed 
elemental composition. This was automatically calculated using the Elemental Composition 
Calculator within MarkerLynx XS. The mass accuracy (in ppm or mDa) and isotope ratio 
accuracy (i-FIT value) of each proposed formula were provided allowing the quality of the 
elemental composition results to be assessed. In the second stage, each EMRT pair and its’ 
proposed elemental compositions were searched against predefined online databases 
(Chemspider.com) using either the exact mass or the elemental composition as the search 
criterion. The results from the database search were compared with the proposed elemental 
compositions and where a match was found (elemental composition and database result) the 
structure of the proposed metabolite was obtained from the database. The third stage of 
marker identification was to use MassFragment software (Waters Ltd., UK) to assign the high 
energy MSE fragments according to the structure of the proposed metabolite. The method of 
marker identification is a simple, logical process which employs all of the LC-MS data 
qualities to build confidence in assignments and therefore reduces the incidence of false 
positives. However, for unambiguous confirmation a fourth step is required, where 
comparative LC-MS/MS analysis was performed on both the sample EMRT pairs and an 
authenticated reference standard for the predicted metabolite structures. Matching of both RT 
and MS/MS spectra between the reference standards and sample EMRT pairs is required for 
unambiguous confirmation (Sumner et al. 2007). An example of LC-MS/MS analysis is 
shown in Figure 3.1.  
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C4H8< (-CH2O2)
C4H8< (-CH2O2)
Standard Proline (10 µM)
Mixed QC sample
C4H8<O2 (-CH2)
C5H5O2 (-H5<)
C3H6<O2 (-C2H4)
C5H6< (-H4O2)
C4H8< (-CH2O2)
C3H6< (-C2H4O2)
C4H6<O (-CH4O)
LC-MS Low Energy
LC-MS High Energy
C5H10<O2
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1. LC-MS/MS analysis of m/z 116.0714. LC-MS low (A) and high (B) energy data showing the 
calculated elemental composition (C5H9NO2) and proposed metabolite (proline) (A) and high energy (MS
E) data 
interrogated using online database search results and MassFragment analysis (B), The structures in red boxes 
indicate high confidence in the mass differences although the fragmentation event is deemed unlikely to occur, 
LC-MS/MS sample (C) and proline (D) data showing unambiguous confirmation of metabolite ID by 
comparative LC-MS/MS of a sample exact mass retention time (EMRT) pair and an authenticated reference 
standard. 
 
3.4. Results and Discussion 
 
3.4.1. LC-MS Data Quality 
A total of 332 injections were performed totalling 59 h of analysis. Amongst these were 5 
biological replicates for each cell line/drug treatment permutation, 3 technical replicates of 
A 
B 
C 
D 
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1.0 ppm
-1.5 ppm
-1.6 ppm
each concentration level of drug treatment in each cell line, 6 replicate injections of each drug 
QC, 8 replicate injections of the mixed QC and drug standards. All samples were analysed in 
a randomised manner. Throughout the course of the analysis retention time drift was minimal 
(Figure 3.2A) and 3ppm RMS mass accuracy (Figure 3.2B) was maintained. 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                                                                                   
Figure 3.2. (A) Three overlaid base peak intensity (BPI) chromatograms of triplicate injections of 0.5 mM 
indinavir treated C33A E6-transfected cell extracts showing minimal retention time (RT) drift for technical 
repeats; (B) Mass accuracy of indinavir in triplicate, The mass error for a single representative mass (indinavir 
at 614.36 m/z) was within 3ppm of the true mass across technical repeats. 
 
3.4.2. Multivariate Analysis of LC-MS Profiling Data from C33A Parent and E6-
transfected Cells 
Extracts from the C33AP and C33AE6 cells grown in both the absence and presence of 
indinavir and lopinavir, were analysed by LC-MS. The 3D LC-MS data obtained were 
converted into a 2D matrix by MarkerLynx XS. Each data point in the 2D matrix represents 
an exact mass retention time (EMRT) pair (i.e., a potential marker along with its intensity), 
and the matrix was converted to a tab delimited text file suitable for import into Matlab 
software. PCA was then carried out initially to determine basic biological differences 
between the two different cell types and different drug treatments, and to investigate trends 
determined by the drug dosing. The resultant PCA scores plots are shown in Figure 3.3. As 
can be seen in Figure 3.3A, trends between the cells treated with two different drugs were 
clearly observed, indicating a strong feasibility to investigate relationships between drug 
concentrations and mass spectra in terms of anti-viral effects on their biochemistry. In 
addition, the scores of the cells exposed to low concentrations of both drugs are observed in 
A 
B 
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the left bottom of PCA space (PC1 vs. PC2), as the concentration of the anti-viral drugs 
increases, the clusters spread from the bottom to the top (indinavir exposed cells) or right 
hand side (lopinavir exposed cells). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3. PCA scores plots from C33A parent and E6-transfected cells exposed to indinavir and lopinavir. 
Mixed, indinavir and lopinavir quality controls (QC) are included as an indication of data quality (A), indinavir 
exposed parent and E6 cells with indinavir QC (B) and lopinavir exposed parent and E6 cells with lopinavir QC 
(C) showing the anti-viral drug effect; (A) PC1 (54.08 %), PC2 (21.28 %); blue: indinavir treated parent and E6 
cells; green: lopinavir treated parent and E6 cells; (B) PC1 (51.37 %), PC2 (17.88 %); blue: indinavir challenged 
E6 cells; red: indinavir challenged parents cells; (C) PC1 (64.28 %), PC2 (14.61 %); blue: lopinavir challenged 
E6 cells; red: lopinavir challenged parents cells; first two letters indicate the type of cells and the name of the 
drug, third number indicates the number of biological replicates, last number represents the drug concentrations 
(mM for indinavir, µM for lopinavir); mix QC: equal mix of all the samples; indinavir QC: equal mix of all 
indinavir challenged samples; lopinavir QC: equal mix of all lopinavir challenged samples; Arrows are drawn as 
a visual guide indicating the relationship between the drug concentrations and the mass spectra. The data were 
scaled prior to PCA using Pareto scaling in which the original dimension of the dataset was preserved resulting 
in the extension of the values of X and Y axes in PCA scores plots. 
 
Next, separate PCAs of indinavir and lopinavir challenged samples were performed to 
investigate how differently each drug affects intracellular metabolites on C33AP and E6 cells 
A 
B C 
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(Figure 3.3B-C). As can be seen in Figure 3.3B and C, no clear separation between parent and 
E6 cells exposed to indinavir is observed, whilst scores of C33AP cells treated with lopinavir 
are separated clearly from those of C33AE6 cells treated with lopinavir. However, better 
discrimination between indinavir challenged C33AP and E6 cells in the different PCA space 
(PC1 vs PC3, Appendix C) is observed, indicating inherent differences between the parent 
and E6 cells in terms of their biochemistry due to the presence of the E6 oncogene and its 
protein in C33AE6 cells. We have recently confirmed the phenotypic differences between 
host C33A cells and those expressing E6 using the complementary vibrational technique of 
FT-IR spectroscopy (Kim et al. 2010b). On closer inspection of each PCA, interestingly the 
scores from C33AP and E6 cells exposed to indinavir show similar trends whereas those from 
C33AP and E6 cells exposed to lopinavir reveal markedly different trends, suggesting that the 
cells are interacting with lopinavir in a different way when compared to indinavir. Therefore, 
these results from PCA clearly reveal that metabolite profiling using LC-MS is sensitive 
enough to detect the metabolic changes elicited by each anti-viral drug. 
 
In successive multivariate analyses, individual PC-CVA from the four groups (i.e., parent + 
indinvir or lopinavir; E6 + indinavir or lopinavir) was performed to investigate the common 
metabolic effect of the anti-viral drugs on each cell line and drug treatment separately. This 
supervised multivariate analysis was employed in order to minimize the variance within the 
groups (i.e. same drug concentration) while maximizing the variance between groups (i.e., 
different drug concentration). The first 12 PCs, which accounted for 95.3 % 
(parent+indinavir), 96.5 % (E6+indinavir), 94.8 % (parent+lopinavir) and 95.8 % 
(E6+lopinavir) of the total explained variance (TEV), respectively, were used by the CVA 
algorithm, with knowledge of the biological replicates and application of projection analysis 
validation. The resultant PC-CVA ordination plots are shown in Figure 3.4. As can be seen in 
Figure 3.4A-D, clear trends in the individual PC-CVA scores plots reveal metabolic 
relationships between drug concentrations and mass spectra from extracts of each cell line.  
The scores plots of four different groups have very similar trends and so these trends reveal 
that it is directly related to the indinavir or lopinavir concentrations. This cluster analysis 
clearly shows that the metabolic profiling data from C33A human cervical carcinoma cell 
line using LC-MS contain important information for investigating the anti-viral drug effect.  
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Figure 3.4. PC-CVA ordination plots (parent cells + indinavir, A; E6 cells + indinaivir, B; parent cells + 
lopinavir, C; E6 cells + lopinaivir, D) showing the anti-viral effect on C33A parent and E6-transfected cells 
exposed to different concentrations of indinavir or lopinavir. The first 12 PCs, which accounted for 95.3 % 
(parent+indinavir), 96.5 % (E6+indinavir), 94.8 % (parent+lopinavir) and 95.8 % (E6+lopinavir) of the TEV, 
respectively, were used to construct the ordination plots. Green circles represent the 95 % confidence region 
about the group sample population, and the blue circles represent the 95 % confidence interval about the group 
centroid. Arrows are drawn as a visual guide indicating the relationship between the spectra and the 
concentrations of indinavir or lopinavir, and are not of statistical significance. 
 
3.4.3. Feature selection 
To investigate which mass ions contributed to the separations and trends from each cell line 
and drug treatment suggesting anti-viral drug effects, 2-way orthogonal comparisons were 
made between 0 dose and mid-dose, and 0 dose and high dose samples for each drug 
treatment using PCA. To clarify the drug effect between drug concentrations, mid- (0.15 mM 
for indinavir and 15 µM for lopinavir) and high-dose (1.0 mM for indinavir and 30 µM for 
lopinavir) were chosen, which showed the complete separation from 0 dose in individual PC-
CVA ordination plots (Figure 3.5).  
 
Furthermore, to determine the chemical differences between each two sample groups, a 
scatter plot (S-plot) based upon PC loadings from the 2-way PCA was performed. Examples 
of each 2-way PCA ordination and S-plot are shown in Figure 3.5.  
A B 
C D 
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Figure 3.5. 2-way PCA ordination plot (A) and S-plot (B) showing the anti-viral effect on C33A E6 transfected 
cells exposed to two different doses of indinavir (0 mM vs. 0.15 mM). (A) PC1(69.78 %), PC2 (12.51 %); first 
two letters indicate the type of cells and the name of the drug, third number indicates the number of biological 
replicates, last number represents the drug concentrations (mM); red: 0 mM; blue: 0.15 mM, (B) each point 
represents an EMRT pair. The EMRT pairs observed to show positive or negative values represent the ions 
contributing to the separation of each sample group. The data were scaled prior to PCA using Pareto scaling in 
which the original dimension of the dataset was preserved resuting in the extension of the values of X and Y 
axes in PCA scores plots. 
 
PCA ordination plots from all 2-way comparisons showed clearly separated clusters 
(Appendix D) between non-drug exposed control cells, and mid- and high-dose exposed cells 
which indicate metabolic differences in terms of the level and compositional changes of 
intracellular metabolites caused by the anti-viral drugs. S-plots were constructed to determine 
significant variables contributing to the class separation. EMRT pairs making significant 
positive or negative contributions to the PC1 axis which separates the classes were selected. 
As a result, 225 key mass ions out of 1860 EMRT pairs were selected and cross checked with 
the 830 significant variables selected by univariate 	-way ANOVA (with the false discovery 
rate (FDR) Q <= 0.05). Although multivariate analysis identifies general trends in sample 
data set, it can miss very small but significant changes in the levels of low concentration 
metabolites. However, univariate analysis can detect all significantly altered metabolites 
between groups, some of which are missed by multivariate analysis. Nevertheless, since the 
FDR used in the univariate analysis was 5 %, it means that 5 % of the peaks are likely to be 
discrimitory by chance or coincidental. Thus, 71 of the EMRT pairs were selected by both 
multivariate and univariate analysis and possible adducts species were then removed, and 
finally 32 of the common key mass ions were selected for metabolite identification and 
Bayesian network analysis (Table 3.1). Since potential products from the cellular metabolism 
of the anti-viral compounds were of interest, a list of mass ions present in the LC-MS and 
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LC-MSE spectra collected from pure indinavir and lopinavir anti-viral compounds in solution 
was created, the list of 32 EMRT pairs was then appraised for these anti-viral related mass 
ions, because it can be assumed that fragmentation in the ion source could be correlated well 
with enzymatic modifications since weakest bonds are broken (Smyth 2003, Weston et al. 
2005). None of the anti-viral associated MSE masses were present in the 32 EMRT pairs, that 
is not to say that none of the EMRT pairs could have been derived from the metabolism of the 
anti-viral compounds, but the readily broken bonds generated by MSE were not seen to be 
present in the significant mined cellular EMRT pairs. For identification of key metabolites, 
the proposed elemental composition, C5H9NO2 of m/z 116.0714 [M+H]
+ was calculated 
automatically and was searched against online databases. Following this, MassFragment 
software was used to assign the high energy MSE fragments according to the proposed 
metabolite, proline (Figure 3.1A-B) and then LC-MS/MS analysis was performed on both 
m/z 116.0714 (RT 0.3856) and the standard compound of proline (Figure 3.1C-D). As can be 
seen in Figure 3.1B, m/z 116.0714 was unambiguously confirmed as proline by comparing 
LC-MS/MS fragmentation of sample EMRT with that of the authenticated proline standard. 
Using the same procedure of LC-MS/MS analysis as above, m/z 120.0806 (RT 2.1775) was 
determined as 2,3-dihydro-1H-indole (indoline). 
 
To determine the intracellular concentration of anti-viral drugs, indinavir and lopinavir in 
drug challenged C33AP and E6 cells, sets of serially diluted drug standards of known 
concentration (indinavir, 0.5, 0.75, 1, 2.5, 5, 7.5, 10, 25, 50, 75, 100, 250, 500 µM; lopinavir, 
5, 10, 15, 20, 25 and 30 µM) and extracts from C33AP and E6 cells exposed to indinavir and 
lopinavir (profiling samples) were initially analysed by LC-MS as described above. 
Calibration curves containing a minimum of six data points were then created using data sets 
from the standards of known concentration (analysed six times and averaged for each 
concentration). The linearity of the calibration curves of indinavir and lopinavir (R2) by LC-
MS were 0.9979 and 0.9301, respectively, and so they proved to be suitable for quantification. 
Following this, the extract concentrations of the two drugs for each cell line were determined 
against the calibration curves by comparison of the mass spectral drug intensity (extracted 
peak area for lopinavir or indinavir parent mass ion converted to the natural log value) 
recorded in the cellular extracts. 
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Table 3.1: The significant metabolite features selected by PCA, 	-way ANOVA, and Bayesian Networking 
analyses, were further investigated. Elemental compositions were first generated from the accurate mass data, 
they were next submitted to online databases to identify candidate metabolites. Next the MSE data were 
investigated, where MSE fragmentation data matched those predicted for the candidate metabolite, the feature 
was considered as being putatively identified. A subset of the key significant metabolite features were finally 
unambiguously identified, by LC-MS/MS comparison of those EMRT features within the cell culture derived 
samples to the LC-MS/MS data acquired for authentic reference standards, only where RT and MS/MS 
fragmentation data were exactly matched were sample metabolite features regarded as unambiguously identified.   
 
The drug levels within the cellular extracts are reported in Table 3.2. The quantification can 
only be viewed as relative and the reported values as arbitrary. This relates back to issues in 
relating the predicted extract molar concentration back to the cell weight in each extract. Due 
to limited volumes of material and the requirement to perform sample processing and 
extraction rapidly, neither determination of sample formula weight (FW) or a cell count were 
performed, instead sample normalisation was performed according to the DW of the extract.  
However, it is known that treatment with the anti-viral compounds did not reduce cell growth; 
in total three flasks were pooled (each containing  approximately 5 x 106 cells) to provide 
enough material (~15 x 106 cells) for metabolite extraction. Thus the values presented in 
Table 3.2 can only be related back to the estimated cell number of ~15x106 cells and not to a 
true cell weight, as one would desire, and thus the values can only be considered as arbitrary 
but are still suitable for the relative comparison of anti-viral levels between the different 
C33A cultures.     
 
As can be seen in Table 3.2, intra-cellular levels of lopinavir were approximately two-fold 
lower in the C33AE6 than C33AP cells, suggesting that C33AE6 cells are actively excreting 
the lopinavir anti-viral drug from the cell. It is known that multidrug resistance is a major 
function of cancer cells, which develop resistance to toxic or chemotherapy drugs (McKenna 
and Padua 1997, Persidis 1999). This multidrug resistance has been highly correlated to the 
function of molecular ‘efflux pumps’, which actively excrete chemotherapy drugs from the 
cell (Persidis 1999). Interestingly, it has been reported that p53 mutations and/or a loss of p53 
function strengthens multidrug resistance in neuroblastoma cell lines (Keshelava et al. 2001).  
Thus, it could be hypothesised that since expression of viral E6 proteins in C33AE6 cells 
inappropriately activates the 26S proteasome to degrade p53 (Hampson et al. 2006), very low 
levels of p53 proteins in the cells could cause high-level multidrug resistance, and thus 
lopinavir could be excreted from the cells via the membrane efflux pumps. 
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C33AE6 0µM Lopinavir Challenged ND ND
C33AE6 7.5µM Lopinavir Challenged 8.8 1.18
C33AE6 15µM Lopinavir Challenged 11.54 1.28
C33AE6 22.5µM Lopinavir Challenged 15.32 1.12
C33AE6 30µM Lopinavir Challenged 20.54 1.22
C33AP 0µM Lopinavir Challenged ND ND
C33AP 7.5µM Lopinavir Challenged 15.36 1.09
C33AP 15µM Lopinavir Challenged 26.92 3.16
C33AP 22.5µM Lopinavir Challenged 33.18 2.56
C33AP 30µM Lopinavir Challenged 37.52 2.85
C33AE6 0mM Indinavir challenged ND ND
C33AE6 0.05mM Indinavir challenged 52.96 13.91
C33AE6 0.15mM Indinavir challenged 277.96 19.01
C33AE6 0.5mM Indinavir challenged 343.44 25.98
C33AE6 1mM Indinavir challenged 583.24 67.82
C33AP 0mM Indinavir challenged ND ND
C33AP 0.05mM Indinavir challenged 121.88 29.02
C33AP 0.15mM Indinavir challenged 162.08 30.97
C33AP 0.5mM Indinavir challenged 102.44 19.97
C33AP 1mM Indinavir challenged 195.28 61.90
<D: <ot Detected
Table 3.2 Quantification of indinavir and lopinavir in C33A samples 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Indinavir and lopinavir were absolutely quantified in C33AP and E6 cells that had been previously challenged 
with various concentrations of the two anti-viral compounds.  The profiling extracts were diluted so as to not 
saturate the mass spectrometers detector. Analytical standards for the two anti-viral compounds were serially 
diluted, analysed six times and the data averaged. The extracted peak areas for the anti-viral compounds parent 
masses within both the analytical standards and the sample extracts were transformed to their natural log values, 
calibration curves were constructed for the two anti-viral compounds, the concentration of the anti-viral 
compounds within the cellular extracts were predicted against the calibration curves.   
 
On the contrary, intracellular levels of indinavir were greater in the C33AE6 than C33AP 
cells. Perhaps one would expect that indinavir and lopinavir would act in the same way upon 
the C33AP and E6 cells, however the concentrations of the two anti-viral compounds used for 
treatment differ massively (7.5-30 µM lopinavir, 0.05-1 mM indinavir), even the structures of 
the two anti-viral compounds differ significantly, and it is possible that a culmination of 
structural and dosing differences between the two anti-viral compounds may explain these 
effects within challenged C33AP and E6 cultures. Previous work revealed that the 
concentration of indinavir was approximately eight-fold greater in the nucleus than in the 
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cytoplasm of C33A E6 cells, which demonstrated that indinavir undergoes enhanced nuclear 
accumulation in E6 expressing cells only and this suggests that the nucleus is the most likely 
site of action for this compound against HPV (Kim et al. 2010a). The current data perhaps 
reflects that due to the nuclear localisation of indinavir within C33AE6 cells, the final 
concentration of the drug is maintained at a greater level than in the parent cells where no 
such nuclear localisation has been observed in previous studies. It must also be taken into 
account that the reported concentrations of indinavir within the various cell lines can be quite 
variable; this variability was even observed within the same cell line at the same dosing 
concentration. It is likely that this is an indication of the problems caused due to indinavir 
crystallising within the challenged cell cultures, which relates to the high concentration of 
indinavir that the cells were subjected to, indinavir crystallisation has even been observed 
within HIV patients being treated with high concentrations of indinavir (Grases et al. 2004).  
 
3.4.5. Bayesian network analysis 
To investigate the probabilistic relationships between metabolic changes and drug exposure 
as well as how key metabolites are correlated to each other in terms of metabolic pathways, a 
BN analysis was performed as described above. In order to reduce the complexity of the 
network (in terms of the number of potential nodes), the top 24 key mass ions were selected 
by the network on the basis of > 50% correlation values and these are shown in Table 3.1. 
Next individual PCAs from different cell types and drug treatments were then performed with 
the selected 24 mass ions. The resultant PCA scores and loadings plots are shown in Figure 
3.6. As can be seen in Figure 3.6A-D, each 0 and low-dose, and high-dose group are well 
separated in PCA scores plots (PC1 vs. PC2) from each cell type, indicating the anti-viral 
drug effects can be well explained with these 24 key mass ions which can provide an 
opportunity to perform a correlation network analysis for understanding the anti-viral effect 
on biochemical pathways. In the successive analysis, each loadings plot was inspected to 
determine which mass ions were responsible for the patterns seen among the scores plots and 
how they are correlated. As can be seen in Figure 3.6E-H, the relationships between all 24 
variables are displayed at the same time. Mass ions, which contribute similar information, are 
clustered together, that is to say, they are correlated. For example, m/z 685.1863 is positively 
correlated to m/z 768.1238, which means that as the spectral intensity of m/z 685.1863 
increases or decreases, that of m/z 768.1238 responds in the same way. However, when two 
variables are negatively correlated, they are placed on opposite sides of the origin of the 
loadings plot. For instance, m/z 308.0923 and m/z 367.1521 are negatively correlated, 
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suggesting that when the intensity of m/z 308.0923 increases, that of m/z 367.1521 decreases 
and vice versa. Furthermore, the distance and direction from the origin can provide valuable 
information. The further away a mass ion is from the origin, the greater the contribution it has 
to the variance from each drug concentration. This means, for example, that all 0 dose 
samples from four groups (i.e., C33AP + indinavir or lopinavir and C33AE6 + indinavir or 
lopinavir) make large contributions by m/z 173.0826 and m/z 768.1238 whilst m/z 119.0498 
and m/z 165.0551 make high contributions to the high dose samples. Interestingly, on closer 
inspection, some metabolites are contributed differently according to the different drugs. m/z 
367.1521 is highly contributed to C33AP and E6 cells exposed to low doses of indinavir and 
high doses of lopinavir whereas m/z 267.0804 is clearly affected by high doses of indinavir 
and low doses of lopinavir. In addition, mass ions such as m/z 116.0714, m/z 120.0806 and 
m/z 281.1052 are highly variable in C33AP and E6 cells exposed to high doses of indinavir, 
the C33AP cells exposed to high doses of lopinavir also showed variable responses although 
in lopinavir challenged C33AE6 cells the response was consistent. These different 
contributions of the variables upon each drug exposure suggest that indinavir and lopinavir 
have slightly different interactions with the cells in terms of metabolic changes even though it 
has been confirmed that both drugs have the same inhibitory effect on E6-mediated 
proteasomal degradation of mutant p53 in C33AE6 cells (Hampson et al. 2006).  
 
Based upon the Bayesian network constructed from the data set, a partial correlation 
coefficient between two variables (mass ions) was computed to investigate a statistically 
significant relationship between them after removing the effects of other variables (de la 
Fuente et al. 2004, Hair et al. 2007) and an example of these respective correlations beside 
each link on the network is shown in Figure 3.7. Figure 3.7 clearly shows that many of the 24 
key metabolite variables are significantly correlated to many others, thus they might have 
shared biochemical significance; bearing in mind that correlation does not necessarily mean 
there is a causal link between two metabolites (Camacho et al. 2005). As can be seen in 
Figure 3.7, the dashed lines represent a negative correlation whilst the solid lines show a 
positive correlation. For example, m/z 120.0806 is positively correlated to m/z 173.0826 but 
negatively correlated to m/z 116.0714, suggesting that when the spectral intensity of m/z 
120.0806 increases or decreases, that of m/z 173.0826 has the same tendency to change but 
when the level of m/z 120.0806 decreases, that of m/z 116.0714 increases and vice versa. 
 
Trend plots were employed to determine which mass ions are altered significantly by drug 
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concentrations and these are shown in Figure 3.8. In these plots the peak intensities for the 
selected analytes from the network analysis are compared across the entire concentration 
series, visualising those metabolites which are reduced or elevated. As can be seen in Figure 
3.8, there are several patterns explaining the drug associated level changes of metabolites. In 
indinavir challenged C33AP and E6 cells, the intensities of m/z 80.0505 at RT 0.5956 (2-
methylenebut-3-enenitrile; tentative assignment), m/z 116.0714 at RT 0.3856 (proline; 
confirmed assignment), m/z 173.0826 at RT 2.3923 (2-octenedioic acid; tentative assignment), 
m/z 232.1559 at RT 2.4034 ((iso)butyrylcarnitine; tentative assignment) and m/z 348.0719 at 
RT 0.5226 (2’-deoxy-guanosine 5’-phosphate; tentative assignment) decrease as the drug 
concentration increases.   
 
The intensities of m/z 87.0266 at RT 0.5292 (2,3-dihydrothiophene, 2,5-dihydrothiophene or 
but-3-yne-1-thiol; tentative assignment), m/z 120.0806 at RT 2.1775 (indoline; confirmed 
assignment), m/z 150.0596 at RT 0.5355 (methionine; tentative assignment) and m/z 
165.0551 at RT 0.7716 (6-acetyl-2-hydroxy-cyclohepta-2,4,6,-trien-1-one or 9-hydroxynon-
7-en-3,5-diynoic acid; tentative assignment) and m/z 166.0870 at RT 2.2151 (phenylalanine; 
tentative assignment) increase as the drug concentration increases. In lopinavir challenged 
C33AP and E6 cells, like indinavir challenged cells, the intensities of m/z 80.0505, m/z 
173.0826, m/z 232.1559 and m/z 348.0719 decrease as the drug dose increases whilst the 
intensity of m/z 166.0870 increases as the drug dose increases. However, the interesting 
features are observed in C33AP and E6 cells exposed to lopinavir in terms of the drug 
response against the two different cell lines. With respect to m/z 87.0266, m/z 116.0714, m/z 
120.0806, m/z 150.0596 and m/z 165.0551, their intensities decrease in C33AE6 cells but 
increase in C33AP cells as the drug concentration increases. This trend analysis also confirms 
that indinavir and lopinavir interact differently with cells.  
 
Overall, the concentration of phenylalanine increases in both C33AP and E6 cells as the 
doses of indinavir and lopinavir increase and the concentrations of 2-octenedioic acid, 
(iso)butrylcarnitine and 2’-deoxyguanosine-5’-phosphate decrease in both cells as the doses 
of both drugs increase. The fact that the levels of these four compounds were changed in 
C33AP cells which do not produce E6 oncoproteins as well as C33AE6 could assume that 
these cellular components represent general drug effects on the two different cells.  
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Parent + Indinavir
E6 + Indinavir
Parent + Lopinavir
E6 + Lopinavir
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6. PCA scores plots (A-D) and the biplots for the combinations of PC scores and PC loadings (E-H) 
derived from a Bayesian network analysis showing the anti-viral drug effect on C33A parent and E6-transfected 
cells exposed to different concentrations of indinavir and lopinavir. First two letters indicate the type of cells and 
the name of the drug (I, indinavir; L, lopinavir); last number represents the drug concentrations (mM for 
indinavir, µM for lopinavir). (A-D) Arrows are drawn as a visual guide indicating the relationship between the 
spectra and the concentrations of indinavir and lopinavir. (E-H) red numbers represent loading vectors displayed 
as mass labels corresponding to actual mass ions (see Table 3.1); the length of the vector (red line) 
corresponding to a metabolite (mass ions) approximates its statistical variance. The longer the line, the higher 
the variance is and the more discriminating the mass ion is. 
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Figure 3.7. A partial correlation network with the 24 significant key variables (mass ions) from E6-trasfected 
cells exposed to lopinavir (0, 7.5, 15, 22.5 and 30 µM); dashed lines: negative correlations; solid lines: positive 
correlation; bold line: higher correlation than normal lines; gray lines: still significant but not as high as red, 
blue and bold lines; numbers: correlation coefficients.  
 
 
 
  
 
 
 
 
 
 
 
 
 
Figure 3.8. Trend plots of the 10 most significant metabolites. Blue line: C33A E6-transfected cell, green line: 
C33A parent cell, (A,K) 2-methylenebut-3-enenitrile (tentative assignment); (B,L) 2,3-dihydrothiophene, 2,5-
dihydrothiophene or but-3-yne-1-thiol (tentative assignment); (C,M) proline (unambiguously confirmed 
assignment); (D,N) indoline (unambiguously confirmed assignment); (E,O) methionine (tentative assignment); 
(F,P) 6-acetyl-2-hydroxy-cyclohepta-2,4,6,-trien-1-one or 9-hydroxynon-7-en-3,5-diynoic acid (tentative 
assignment); (G,Q) phenylalanine (tentative assignment); (H,R) 2-octenedioic acid (tentative assignment); (I,S) 
(iso)butyrylcarnitine (tentative assignment); (J,T) 2’-deoxy-guanosine 5’-phosphate (tentative assignment). 
A B C D E 
F G H I J 
K L M N O 
P Q R S T 
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On the other hand, only difference between C33AP and E6 cells exposed to lopinavir in terms 
of the level changes of metabolites is that concentrations of proline, indoline and methionine 
decrease in C33AE6 but increase in C33AP cells as lopinavir concentration increases. 
 
Generally, since methionine is known as the major methyl group donor of various 
intermediates in vivo such as methyl groups of DNA and RNA intermediates (Sirlin et al. 
1963), the decrease in the level of this compound in lopinavir challenged C33AE6 cells could 
be connected to the drop in total cellular nucleotides and carbohydrates, as observed in our 
previous work (Kim et al. 2010b). A decrease in carbohydrates for instance could also be 
potentially significant, a previous investigation reported that insulin resistance in vitro (Noor 
et al. 2006) can be induced by lopinavir, which inhibits glucose and 2-deoxyglucose uptake 
into primary rat adipocytes in vitro (Yan and Hruz 2005). Thus a decrease in the levels of 
carbohydrates and carbohydrate based nucleotides could be related to the documented effect 
of lopinavir on carbohydrate metabolism. 
 
3.5. Conclusion 
Investigation of intracellular changes of metabolites caused by indinavir and lopinavir in the 
presence and absence of HPV16 E6 against an isogenic background (C33A cervical cancer 
cells), could help towards providing a means of defining the mode of action of these 
compounds against HPV, which is not the designed target for these HIV protease inhibitors. 
The objective of the study was to identify key metabolites involved in the anti-viral response 
and to provide information related to the pathway relationships between these components.  
 
LC-MS-based metabolic profiling in combination with a variety of univariate and 
multivariate analyses such as 	-way ANOVA, PCA, PC-CVA and Bayesian networking is a 
very useful method for the determination of specific and common metabolic effects of 
indinavir and lopinavir on the cells. Rather than identifying all peaks that are seen in LC-MS 
we first selected significantly altered metabolites from univariate and multivariate statistical 
methods to be subsequently identified employing LC-MS/MS. This is valuable since 
unequivocal identification of low molecular weight metabolites is considered to be a 
challenging step in the application of metabolomics. In addition, we also confirm that the 
change in the levels of phenylalanine, 2-octenedioic acid, (iso)butrylcarnitine and 2’-deoxy-
guanosine 5’-phosphate in drug challenged C33AP and E6 cells could be thought of as 
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general drug effects on both cell lines whereas a reduction of the levels of proline, indoline 
and methionine in only lopinavir exposed C33AE6 cells represents E6 oncoprotein specified 
effects of the drug. These compounds can potentially be used for the specific biomarkers in 
order to understand the mechanism of the anti-viral drug effect against HPV, and their role 
within the mode of action of these protease inhibitors will be an area of future work. 
Furthermore, we also report that the level of the lopinavir anti-viral drug detected in C33AE6 
cells is significantly lower than in C33AP cells treated with the same dosing concentration. 
By contrast, the level of the indinavir anti-viral drug detected in C33AE6 cells is significantly 
higher than in C33AP cells treated with the same concentration. Although this is currently 
difficult to fully explain, several hypotheses have been generated for future research based 
upon the leads presented by this metabolomics investigation and our previous observation 
that indinavir is found at concentrations eight-fold higher in the nucleus compared to the 
cytoplasm. 
 
In conclusion we have demonstrated that a combination of LC-MS based profiling with 
appropriate chemometric analysis is a valuable approach for studying cellular responses to 
anti-viral drugs. In addition, we have quantified different intracellular drug levels in C33AP 
and E6 cells which suggest, certainly in the case of lopinavir, that increased activity of 
membrane transporters may contribute to the drug sensitivity of HPV infected cells, no 
previous work has been carried out in this area. In future studies, the application of several 
metabolomics platforms (i.e., LC-MS, GC-MS, and potential LC-SPE-NMR for aiding in 
identification) (Glauser et al. 2008, Moco et al. 2007, Tatsis et al. 2007), following the same 
regime as presented for LC-MS here, and / or the use of radiolabled anti-viral compounds for 
flux analyses (Harrigan et al. 2006), could potentially uncover a large area of effected 
metabolism leading to in-depth insights as to the anti-viral modes of action.  
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CHAPTER 4 
 
 
4. Investigation of Anti-viral Drug Effects on HPV16 E6 
Expressing Cervical Carcinoma Cells with GC-TOF/MS-based 
Metabolic Profiling 
 
GC-MS is a hyphenated combination of analytical techniques, where gas chromatography 
which provides high separation efficiency and can resolve highly complex metabolite 
mixtures present in biological samples, is linked with mass spectrometry that offers accurate 
measures of m/z which can be directly related to the molecular weight of each separated 
compound and which along with unique fragmentation patterns can be used for identification. 
This technique is a powerful tool for metabolic profiling of cells due to its high 
reproducibility, sensitivity and selectivity resulting from the chromatographic separation and 
a sensitive detector (Section 1.4.3.6). In comparison to LC-MS, GC-MS benefits greatly due 
to the availability of metabolite libraries such as the NIST library and Golm Metabolome 
Database (Kopka et al. 2005), as well as the ability to produce laboratory-specific libraries 
for unequivocal identification. GC-MS also offers the advantage that it covers a large range 
of metabolites from across central metabolism including many TCA cycle intermediates that 
may not be readily detected or identified by LC-MS. As shown in the previous chapter LC-
MS is also limited with respect to metabolite identification, demanding that authentic 
reference standards of high purity be available for confirmatory LC-MS/MS analyses, it was 
felt that GC-MS with its widely available commercial and open access metabolite databases 
may aid our clinical understanding of the anti-viral modes of action. In addition, GC-MS 
would also allow central metabolism to be probed which may be important for drugs that 
affect the cell cycle. Due to the time demanding effort of producing bulked samples for MS-
based analyses, it was decided that the GC-MS profiling would focus upon investigating the 
mode of action of indinavir and lopinavir in the C33AE6 cervical cancer cell line only and 
with a smaller number of dose intervals.  
 
 
 
 
 
- 115 - 
 
4.1. Materials and Methods 
 
4.1.1. Sample Preparation and GC-MS Analyses 
The initial sample preparation for GC-MS, followed the same methods as applied for LC-MS 
sample generation (Section 3.3.3) as shown in Figure 4.1, with the addition of derivatisation 
prior to analysis.  However, in order to reduce the total number of cultures, the study focused 
upon a smaller number of levels of anti-viral challenge. 1 × 106 C33AE6 cells were seeded to 
each of 90 flasks (to provide three concentration levels for each drug and five biological 
replicates) and allowed to adhere and reach 80 - 90% confluence at 37 oC, 5% CO2. 
Treatments included 0, 0.2 and 1 mM of indinavir and 0, 15 and 30 µM of lopinavir, with 
additional control water and DMSO and cells were incubated for 24h at 37 oC, 5% CO2. 
Three flasks were pooled for each drug concentration in order to obtain enough biomass to be 
detected by GC-MS.  Harvesting of the cells, metabolic quenching and extraction of 
metabolites was performed as described for LC-MS (Section 3.3.3). To each GC-MS extract, 
100 µl of internal standard solution (0.19 mg ml-1 succinic-d4 acid, 0.27 mg ml
-1 malonic-d2 
acid, 0.22 mg ml-1 glycine-d5 in HPLC-grade water) was added and the extract lyophilised at 
room temperature by speed vacuum concentration and stored at -80 oC before analysis.   
 
The dried GC-MS extracts were derivatised as follows; 50 µl of 20 mg/ml O-
methylhydroxylamine in pyridine was added and heated at 40 oC for 90 min followed by 
addition of 50 µl of N-acetyl-N-(trimethylsilyl)trifluoroacetamide and heating at 40 oC for 90 
min. The simple schematic diagram of the sample preparation for metabolic profiling of drug 
treated C33AE6 cells using GC-MS is shown in Figure 4.1. The derivatised samples were 
then analysed by GC-TOF/MS as described in (O'Hagan et al. 2005) following the optimised 
method for analysis of yeast cells. All experiments were run on a GC-TOF/MS instrument 
(Agilent 6890N gas chromatograph and LECO Pegasus III TOF mass spectrometer) using the 
manufacturer’s software (ChromaTof version 2.12). A DB-50 GC column (Supelco, 
Gillingham, U.K.; 30 m × 0.25 mm × 0.25 µm film thickness) was used. The gas 
chromatograph was operated in split mode using helium as a carrier gas in constant flow 
mode of 1 ml/min, with an initial GC temperature of 70 oC. Temperature program: 70 oC was 
held for 4 min and the temperature increased up to 300 oC (20 oC/min), 4 min hold. A 1 µl 
injection of each sample was made with a 4:1 split mode. The transfer line and source 
temperatures used were 240 and 220 oC, respectively, acquiring m/z 45-600 at 20 Hz. A 
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detector voltage was 1700 V. In the ChromaTOF software, the S/N threshold was set to 10, 
baseline offset to 1.0, data points for averaging to 5, and peak width to 3. The TOF/MS can 
collect spectra at up to 500 Hz and uses sophisticated but proprietary deconvolution software 
to discriminate overlapping peaks on the basis of their mass spectra. Each sample was 
deconvolved within ChromaTOF and the metabolites identified by library matching with high 
confidence against an in-house library, the NIST 2002 library and GMD (The Golm 
Metabolome Database). The deconvoluted profiles for each sample were next aligned thus 
forming an X and Y matrix for statistical analyses.  
 
 
 
 
Figure 4.1. The sample preparation procedure for metabolic profiling based on GC-TOF/MS 
 
4.1.2. Data Analysis 
Matlab version 7 was used to perform multi-block consensus PCA (CPCA) on the GC-MS 
data sets. PCA is widely used to reduce the dimensionality of multivariate data sets whilst 
preserving the majority of variance. PCA is typically applied to all of the metabolite variables 
and reduces them to a small number of new variables (PCs) which explain the greatest 
sources of variance, however conventional PCA does not always detect common trends 
between different sample classes. Recently, CPCA has been introduced in which each sample 
Split to 90 T75 flasks
Each 3 drug conditions ×3 
& 5 biological replicates Freeze-thaw extraction
liquid <2 for 1min & 
thawed at 4°C × 4
×90
Indinavir (0, 0.2, 1.0 mM)
Lopinavir (0, 15, 30 µM) Scraped
×90 ×30
×30
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×30
Cell extracts
evaporation
Derivatisation
GC-TOF/MS
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Block 1 T1
P1 ×
Block 2 T2
P2 ×
… Block k Tk
Pk ×
w1 w2 wk
Tsup
class or anti-viral drug that the cells have been challenged with can be divided into several 
blocks, the CPCA then looks to fit the data within the different blocks to discover common 
trends between them which may aid greatly in the production of more interpretable models 
(Figure 4.2). This multi-block method has been used in cases where the number of variables 
is large and additional information is available for blocking the variables into conceptually 
meaningful blocks (Smilde et al. 2003, Westerhuis et al. 1998). Since multi-block PCA can 
offer the potential to extend the scope of conventional PCA and to identify common trends 
between different blocks (e.g., E6 + indinavir vs E6 + lopinavir), CPCA was applied to the 
GC-MS data sets, after samples were rearranged into two separated blocks, each one for each 
type of drug and their treated concentrations as shown in Figure 4.2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2. In CPCA, the data set is divided into several blocks each containing the same number of samples and 
correlated by underlying connections (e.g., same analytical method applied on different types of samples, 
different anti-virals applied to the same sample types, etc.). Each block has its own block scores (T1, T2,…, Tk) 
and block loadings (P1, P2,…, Pk) and thus the common trend of all the blocks is presented by a super scores 
matrix (Tsup), along with a weight vector known as the block weights (w = { w1, w2,…, wk}). Block weights 
represent the contribution of each block to the super scores. For each PCA, if weights from different blocks are 
similar to each other, those blocks contain the same trend in the PCA while if there are large differences between 
weights, the super scores of the PCA may be dominated by the block with the largest block weight.  
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4.2. Results  
The C33AE6 cells were grown in the presence of indinavir at concentrations of 0, 0.2 and 
1mM, and lopinavir at concentrations of 0, 15, and 30 µM for 24 h at 37 oC, 5% CO2, giving 
a total of each three conditions and five biological replicates including the controls. The cells 
were quenched and extracted using 100% MeOH (-48 oC ) and then measured using GC-MS 
as detailed in Section 4.1. All the peak areas were normalised to that of the succinic-d4 acid 
internal standard effectively producing a semi-quantitative output. The deconvoluted and 
library matched GC-MS profiling data set from each condition was exported as a Microsoft 
excel sheet and analysed using Matlab version 7. Multi-block CPCA was then carried out to 
investigate the common effect of the two anti-viral drugs on C33AE6 cells (Figure 4.3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3. GC-MS data set is divided into two blocks according to which anti-viral the cells were exposed to 
(i.e. same cell line exposed to different types of anti-viral). 
 
The plots of super scores and each block scores from CPCA are shown in Figure 4.4. The 
common trend of the two blocks is represented by the super scores space, along with block 
weights which represent the contribution of each block to the super scores. As can be seen in 
Figure 4.4A, the super scores of C33AE6 cells exposed to low concentrations of indinavir 
and lopinavir are observed in the bottom right hand corner, as the concentration of the anti-
viral drug increases, the cluster spreads from right to left. The two drugs could not be 
detected by GC-MS due to their large molecular weights, thus the clustering of sample 
E6 + Indinavir E6 + Lopinavir 
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groups is dependent on cellular metabolism and not drug-associated peaks. In successive 
analyses, each of the block scores was plotted with the variables within the corresponding 
block. Again, each block scores from indinavir or lopinavir treated C33AE6 cells show 
similar patterns to the super score plot, indicating that these two anti-viral drugs have a 
similar effect on the cells. It is therefore valuable in the sense that these trends are directly 
associated with the concentrations of indinavir and lopinavir. This result clearly reveals that 
the metabolic profiling data from C33A HPV16 E6 expressing cervical carcinoma cells using 
GC-MS contain valuable information for studying the phenotypic effect of the anti-viral drug 
in terms of level changes of intracellular metabolites. 
 
 
 
Figure 4.4. The plots of the super scores (A) and each block scores (indinavir, B; lopinavir, C) from CPCA. 
Arrows are drawn as a visual guide indicating the relationship between the spectra and the concentrations of 
indinavir and lopinavir. 
 
To investigate which specific metabolites are associated with the anti-viral drug effects, the 
loadings vectors were calculated for each individual block and plotted (Figure 4.5). As can be 
seen in this figure, several significant variables marked by red were identified and confirmed 
as significant by the Friedman test (non-parametric 2-way ANOVA). From these loadings 
plots, 16 significant metabolite variables were determined, each variable index number and 
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identification are presented in Table 4.1 (see Appendix E for details of relaive information of 
mass ions including m/z – intensity pairs). Further metabolite variables that were identified 
and deemed as significant are also presented in Table 4.1. Of these 16 variables, although 
only three metabolites were identified through GC-MS libraries as reduced glutathione, 
aspartic acid and sugar phosphate, respectively, they show significant quantitative differences 
that correlate to the different drug doses. As can be seen in Figure 4.6, the levels of these 
metabolites are reduced as the concentration of the anti-virals increases. In addition, other 
than significant variables from the loadings plots, which show the common effect between 
two anti-viral drugs, some of the metabolites such as octadecenoic acid and lactose reveal the 
significant concentration change associated with increasing indinavir doses whereas no clear 
level changes of these metabolites are shown against increasing lopinavir concentrations 
(Figure 4.7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5. Block loadings plots of E6 cells exposed to indinavir (A) and lopinavir (B) with significant variables 
marked by red. Significant variables were identified by Friedman test. 
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Figure 4.6. Box plots of identified metabolites (A, Glutathione; B, Aspartic acid; C, Sugar phosphate) deemed as 
significant common trends by CPCA resulting from exposure of C33A E6-transfected cells to indinavir (left) 
and lopinavir (right) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7. Box plots of metabolites (Octadecenoic acid, A; Lactose, B) against the concentrations of indinavir 
(left hand side) and lopinavir (right hand side) 
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4.3. Conclusion 
This small GC-MS investigation presents efficient strategies including metabolite quenching, 
extraction, sample preparation, and data processing for high-throughput analysis of 
metabolomic data generated from human cervical cancer cell lines and which is comparable 
to the data generated by LC-MS profiling. Unfortunately, as with the LC-MS metabolic 
profiling, the number of key statistically significant metabolites that can be identified is 
limited, indicating that current GC-MS libraries also need to be improved substantially for 
this cervical cell culture based target matrix, however as with LC-MS this is greatly limited 
by the availability of high purity reference standards allowing unambiguous identification 
(Sumner et al. 2007). Despite of this limitation, GC-MS analyses have resulted in the 
detection of several statistically significant and potentially clinically interesting metabolites 
such as the stress related compound Glutathione in a reduced form. A reduction in levels of 
the sugar lactose and also a concurrent reduction in sugar-phosphate and the unknown sugars 
(index numbers 98 and 100) were seen as anti-viral dosing levels increased. This may be 
related to a reduction in energy metabolism or the arrest more specifically of glycolysis and 
potentially enhanced mitochondrial energy metabolism. Malic acid was also seen to be 
reduced as anti-viral dosing increased potentially indicating that the anti-virals were also 
having a direct influence upon the TCA cycle. Reductions of the amino acid, aspartic acid, 
also indicate that the anti-virals are impacting greatly upon central metabolism. Unfortunately 
further amino acids and organic acid intermediates of the TCA cycle were not detected and / 
or identified by GC-MS, although the amino acids proline and methionine were shown to be 
reduced in C33AE6 cells and phenylalanine increased in C33AE6 cells with increased anti-
viral dosing by LC-MS profiling.  The lack of other amino and organic acids detected by GC-
MS profiling indicates the need for further sample bulking in order to produce highly 
metabolite rich extracts in future experimentation. Octadecenoic acid levels were also seen to 
decrease with increasing levels of anti-viral exposure which could potentially also be related 
to the cellular stresses induced by the anti-viral modes of action. Despite the limitations on 
identification of metabolites, LC-MS and GC-MS have both been shown to be valuable 
metabolic profiling tools for the study of anti-viral modes of action in cell cultures. With the 
availability of high purity authentic reference standards improving and the combination of 
high sensitivity chromatography-MS based metabolic profiling with techniques such as LC-
SPE-NMR/MS (Glauser et al. 2008, Moco et al. 2007, Tatsis et al. 2007) which permit 
metabolite structural elucidation, a huge depth of clinically significant information could 
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potentially be gained from further metabolomic investigations in the future. 
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CHAPTER 5 
 
5. Raman Chemical Mapping Reveals Site of Action of HIV 
Protease Inhibitors in HPV16 E6 Expressing Cervical Carcinoma 
Cells 
 
This chapter has been published as follows: 
Kim, D.-H., Jarvis, R. M., Allwood, J. W., Batman, G., Moore, R. E., Marsden-Edwards, E., 
Hampson, L., Hampson, I. N. & Goodacre, R. (2010). Raman chemical mapping reveals site 
of action of HIV protease inhibitors in HPV16 E6 expressing cervical carcinoma cells. 
Analytical and Bioanalytical Chemistry, 398, 3051-3061. 
 
5.1. Abstract 
 
It has been shown that the HIV protease inhibitors indinavir and lopinavir may have activity 
against the human papilloma virus type 16 (HPV16) inhibiting HPV E6-mediated 
proteasomal degradation of p53 in cultured cervical carcinoma cells. However, their mode 
and site of action is unknown. HPV negative C33A cervical carcinoma cells and the same 
cells stably transfected with E6 were exposed to indinavir and lopinavir at concentrations of 1 
mM and 30 µM, respectively. The intracellular distribution of metabolites and metabolic 
changes induced by these treatments were investigated by Raman microspectroscopic 
imaging combined with the analysis of cell fractionation products by liquid chromatography-
mass spectrometry (LC-MS). A uniform cellular distribution of proteins was found in drug-
treated cells irrespective of cell type. Indinavir was observed to co-localise with nucleic acid 
in the nucleus but only in E6 expressing cells. Principal component analysis (PCA) scores 
maps generated on the full Raman hypercube, and the corresponding PCA loadings plots, 
revealed that the majority of metabolic variations influenced by the drug exposure within the 
cells were associated with changes in nucleic acids. Analysis of cell fractionation extracts by 
LC-MS confirmed the level of indinavir in nuclear extracts was approximately eight-fold 
greater than in the cytoplasm. These data demonstrate that indinavir undergoes enhanced 
nuclear accumulation in E6 expressing cells which suggests that this is the most likely site of 
action for this compound against HPV. 
 
 
 
 
- 126 - 
 
5.2. Introduction 
 
Usually, fluorescence spectroscopy, autoradiography or electron microscopies such as 
scanning electron microscopy (SEM) and transmission electron microscopy (TEM) are used 
widely to investigate morphology and biochemical information on cells or tissues (Brewer et 
al. 2002, Chapman and Eagles 2008, Langager et al. 1982, Thiberge et al. 2004). However, a 
variety of complex preparations are required and cell conditions under measurement are very 
different from in vivo (Krafft et al. 2003). In addition, fluorescence spectroscopy or 
autoradiography requires appropriate molecules to be present in biological samples, which 
are either fluoresce or radioactive. By contrast, Raman spectroscopy overcomes many of 
these limitations as this technique is rapid, non-invasive, and requires minimal sample 
preparation without the use of any dyes, labels or derivatives (Verrier et al. 2004). This 
method can also provide information about concentration, structure, and interaction of 
biological molecules within intact cells and tissues in their specific cellular location without 
homogenisation and extraction.  
 
The chemical mapping approach of Raman microspectroscopy, which involves coupling an 
optical microscope with a Raman spectrometer, is a powerful tool for analysing the chemical 
distribution of metabolites present at any point and the response of metabolic and physical 
stresses in cells or tissues (Clark and Sasic 2006). Subtle changes in chemical composition 
and distribution on cells or tissues can be monitored using this technique. This chemical 
mapping approach not only enables visualisation of spatially resolved chemical information 
but can also be used to detect small chemical changes in order to understand abiotic 
perturbations to biological systems. 
 
Thus, Raman spectroscopy has emerged as a promising diagnostic tool for disease detection 
in the biomedical field. Various diseases have been detected by comparing the differences of 
Raman spectra between normal and diseased cells or tissues, because disease progression 
results in changes of the composition and abundance of metabolites (Buschman et al. 2001, 
Hawi et al. 1996, Shafer-Peltier et al. 2002). The biomedical application of vibrational 
spectroscopy for cancer detection and disease diagnosis has been thoroughly reviewed (Ellis 
and Goodacre 2006, Ellis et al. 2007b, Hedegaard et al. 2010, Mahadevan-Jansen and 
Richards-Kortum 1997). Finally, in order to develop effective chemotherapeutic agents and 
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assess combinations of various drugs against serious diseases, the response to chemotherapy 
and the distribution of drugs inside cells or tissues has also been investigated (Beljebbar et al. 
1999, Kang et al. 2006). 
 
An estimated 493,000 women are diagnosed as cervical cancer resulting in 273,500 deaths 
each year (National Cervical Cancer Coalition. www.nccc-online.org). Indeed cervical cancer 
is a major gynaecological cancer in many low resource countries causing most of women’s 
cancer-related mortality. 
 
Human papilloma virus (HPV) is the major cause of cervical cancer (zur Hausen 1996), and 
there are over 100 different types of HPV associated with a variety of clinical lesions with 
approximately 20 of these being associated with anogenital tract lesions (de Villiers 1989). In 
particular the high-risk types are more often found in association with pre-malignant cervical 
lesions and invasive cancers (Scheffner et al. 1990, zur Hausen 1996). Although there are 16 
high risk types documented, HPV16 and 18 are the most prevalent high-risk types associated 
with cervical cancer and account for >60% of cases (Hampson et al. 2006, Harper et al. 2004, 
Munoz et al. 2003). 
 
Although many countries are implementing anti-HPV vaccination programmes, these only 
cover types 16 and 18 which mean that there is still a significant proportion of high risk HPV 
related cervical disease that will not be protected by this strategy. Coupled with the facts that 
many women are already persistently infected with high risk types of HPV and that cervical 
cancer can take from 10-20 years to develop, alternative therapies are needed for many years 
to come. Whilst surgery is still the preferred treatment of choice for HPV related pre-
cancerous cervical intraepithelial neoplasia (CIN) (Harper et al. 2004, Villa et al. 2005), it 
does carry an increased risk of infertility and thus there is a need for a simple, preferably self-
administered non-surgical therapy which would provide several advantages such as better 
preservation of obstetric function which would enable the treatment to be offered for low 
grade disease (Kyrgiou et al. 2006). 
 
Expression of high risk types of the E6 and E7 viral oncoproteins are largely responsible for 
the oncogenic properties of HPV (zur Hausen 2000). One of the most intensively studied 
properties of the E6 protein is its ability to compromise the function of the p53 tumour 
suppressor protein (Huibregtse et al. 1991), as detailed in Figure 1.5. In association with the 
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cellular E3 ubiquitin ligase (E6AP), E6 binds to the p53 protein. E6 mediated activation of 
E6AP then catalyses the ubiquitination and subsequent proteasomal degradation of p53 
(Huibregtse et al. 1993). Indeed this strategy of inappropriate activation of the proteasome is 
used by many other viruses to subvert the function of a variety of cellular protein that would 
prove detrimental to viral persistence (Banks et al. 2003, Thomas et al. 1999, zur Hausen 
1996). This implies that selective inhibition of proteasomal function could prove to be an 
effective strategy for the treatment of HPV infections. 
 
We have recently reported that the anti-viral drugs, indinavir and lopinavir, which are 
currently used as a human immunodeficiency virus (HIV) protease inhibitors, also inhibit E6-
mediated proteasomal degradation of p53 and selectively kill E6-dependant cervical 
carcinoma cells in vitro (Hampson et al. 2006) and that these drugs alter the phenotype of 
these carcinoma cells (Kim et al. 2010b). However, the mode and site of action of these drugs 
with respect to HPV is largely unknown. Therefore in this study in order to understand the 
mechanism of this drug against HPV on human cervical cancer cell lines we investigate the 
changes of the intracellular distribution of analytes and the location of the drugs within 
control cervical carcinoma cells and HPV16 E6 expressing cells exposed to indinavir and 
lopinavir at physiologically relevant concentrations. 
 
5.3. Materials and Methods 
 
5.3.1. Cell Line and Culture Medium 
HPV-negative human C33A cervical carcinoma cells were maintained in RPMI 1640 
(Invitrogen, Paisley, UK) supplemented with 10% fetal bovine serum (FBS) and 2mM L-
glutamine (Sigma-Aldrich Company Ltd, Dorset, UK) (complete medium) at 37 °C, 5% CO2. 
C33A cells stably transfected with HPV16 E6 (termed "C33AE6 cells") and the pcDNA3.1 
control vector (termed "C33AV cells") were derived and cultured as previously described 
(Hampson et al. 2001). 
 
5.3.2. Protease Inhibitor 
Indinavir was obtained through the NIH AIDS Research and Reference Reagent Program 
(Division of AIDS, NIAID, NIH): indinavir sulphate (8145). Lopinavir was provided as a 
generous gift from Abbott Laboratories, Park Road, Abbott Park, IL 60064-6187, USA. 
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Indinavir and lopinavir were dissolved in sterile distilled water and DMSO (Sigma-Aldrich 
Company Ltd, UK), respectively, at a working stock concentration of 20mM. 
 
5.3.3. Raman Sample Preparation 
Each 1 × 106 of C33AV and E6 cells was seeded in T75 culture flasks with 20 ml of the 
complete medium and then incubated at 37 °C, 5% CO2. Before cells reached confluence, the 
complete medium was removed and 800 µL of trypsin (0.25%, 2.5 g/l) was added in order to 
detach the adherent cells from the flask. Cells were then incubated for 3 min at 37 °C, 5% 
CO2. After this incubation period, cells were resuspended in 10 ml of the complete medium 
and were counted. Next, 2 × 104 cells were seeded on to a single CaF2 disc (Crystran Plc, 
Dorset, UK, 20 mm diameter × 2 mm thickness) in 3 ml of  the complete medium in a 6-well 
culture dish and allowed to adhere overnight at 37 °C, 5% CO2. Previous work (Hampson et 
al. 2006) reported dose-dependent experiments on the HIV protease inhibitors indinavir and 
lopinavir to inhibit the degradation of p53 promoted by E6.  Based on this study cells were 
then treated with either 1 mM of indinavir, 30 µM of lopinavir, water or DMSO (as controls) 
and incubated for 24 h at 37 °C, 5% CO2. The cells were subsequently fixed in ice cold 
methanol for 4 min at -20 °C then washed and stored in PBS at 4 °C until use; cells were 
analysed within approximately 2 - 5 days. 
 
5.3.4. Raman Microspectroscopy and Data Analysis 
Raman point spectra for the chemical maps were obtained on a Renishaw System 2000 
Raman microscope (Renishaw Plc., Old Town, Wotton-under-Edge, Gloucestershire, UK). 
Raman spectra were recorded directly from a well isolated single cell on a CaF2 disc. All cells 
on the discs were covered with PBS and then cover slips during the measurement to avoid 
desiccation. An 830 nm NIR diode laser was used for excitation, with a laser power of ~5 
mW at the sample using a x 50 microscope objective, with 0.95 numerical aperture (NA) this 
resulted in ~ 0.75 µm lateral spatial resolution. At each location (or pixel) a Raman spectrum 
was acquired over the region from 400 to 2000 cm-1 and the stage was then moved at 1 µm 
steps before another spectrum was collected. This process generated a 3D hypercube over the 
single cell of dimensions X vs. Y vs. Raman spectra (see Figure 5.1). Spectral acquisition was 
performed in GRAMS WiRE software (Galactic Industries Corp., Salem, NH) and data 
processing was carried out using Matlab version 7 (The MathWorks, Inc., Natick, MA., USA). 
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The visual inspection through the microscope was performed in order to check any of 
mophological changes of the cells being studied, caused by laser-induced damage after the 
spectra were collected.   
 
 
 
 
 
 
 
 
 
 
Figure 5.1. The microscope offers focussing and data collecting optics for both spectral and white light images 
from the cell. After the Raman spectrum is collected from the first point, the incident light is moved in a raster 
pattern across the grid in a diffraction-limited spot size (1 µm × 1 µm) then another spectrum is taken. This 
process is continued until the area of the cell assigned by the operator has been covered. 
 
Chemical image maps were generated against a variety of univariate metrics including peak 
area and S/N ratios. The full process of generating chemical image maps is detailed in Figure 
5.2. Matlab was also used to perform principal components analysis (PCA) on the Raman 
spectral hypercubes using the NIPALS (nonlinear iterative partial least squares) algorithm 
(Wold 1966). PCA is a widely used multivariate technique for reducing the dimensionality of 
spectroscopic data from hundreds of wavenumber assignments to a few principal components 
(PCs), which retain the majority of the variance within the data (Jolliffe 1986, Sumner et al. 
2003), and image maps can be constructed from plotting the PC scores as a function of X and 
Y. 
 
5.3.5. Subcellular Fractionation of C33AE6 Cells 
1 x 106 C33AE6 cells were seeded into each of six T75 culture flasks to give six biological 
replicates and then incubated at 37 °C, 5% CO2 as described in Section 2.3. Before cells 
reached confluence, 0.3 mM of indinavir were added to the flasks and cells were incubated 
for 24 h at 37 °C, 5% CO2. After this incubation period, the complete medium was removed 
and 800 µL of trypsin (0.25%, 2.5 g/l) was added in order to detach the adherent cells from 
the flask. Cells were then incubated for 3 min at 37 °C, 5% CO2. Cells were resuspended in 
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10 ml of the complete medium and centrifuged at 500 × g for 5 min, following this the 
supernatant was removed. Next, cells were resuspended and washed with PBS twice and 
pelleted by centrifugation at 500 × g for 3 min. For sub-fractionation into cytoplasmic and 
nuclear extracts, cells were lysed in NE-PER nuclear and cytoplasmic extraction reagents 
(Pierce, USA) with a protease inhibitor cocktail set (III) (Calbiochem, USA) according to the 
manufacturer’s protocols.  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2. The data analysis process for the generation of chemical image maps, A: The average spectrum is 
plotted by the mapping function so that peaks can be selected interactively, B: Taking the total area under the 
spectrum and plotting as a 2D image map allows identification of the cell against the substrate background, C: A 
simple threshold is then applied to select pixels/spectra from the map that represent the cell position, D: The 
data are reanalyzed minus the background substrate spectra, E: This can be performed through integration of 
peak areas, PCA mapping or alternative algorithms, F: The resultant image can be further smoothed by applying 
a 2D moving filter window 
 
5.3.6. Western Immunoblotting of Sub-fractionated Samples 
This was carried out as described in (Hampson et al. 1997, Laemmli 1986). 25 µg of each 
sub-fraction was loaded per track onto a 15% PAGE mini gel (Biometra, UK) and separated 
at 20 mA for 2 h. Following this proteins were transferred to Hybond C Extra (GE Healthcare 
Lifesciences, Buckinghamshire, UK) using a semi-dry blotter (Biometra). Membranes were 
blocked with 3% skimmed milk (Tesco UK Ltd., own brand) in PBS for 2 h. Primary 
antibodies in PBS were added as follows HDAC 1 : 800 and GAPDH 1 : 1000 and incubated 
overnight. Membranes were washed with three changes of PBS, incubated with 1 : 2000 HRP 
conjugated secondary antibody in 3% skimmed milk for 2 h, washed again with PBS and 
visualised with ECL and Hyperfilm (GE Healthcare Lifesciences). 
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5.3.7. LC-MS Analysis of Cell Sub-fractions 
The resulting samples from the fractionations yielded 1055 µl of cytoplasmic fraction and the 
nuclear fraction was 500 µl; which is a reflection of the nucleus-cytoplasmic ratio for these 
cervical cell lines based on volume. Aliquots (25 µl) of the above cell nuclear and 
cytoplasmic sub-fractions were treated with five volumes of cold acetone for 1 h at -20 °C to 
precipitate out proteins. The samples were then centrifuged at 14,500 x g for 15 min and the 
supernatant recovered. The supernatants were dried by speed vacuum concentration for 
approximately 1 h at 45 °C to reduce the samples to their original volume of ~ 25 µl. 
 
A 10 min LC methodology using 10 mM ammonium formate, pH 9 as mobile phase A and 
acetonitrile as mobile phase B, was performed with an Acquity UPLCTM (Waters Ltd., 
Manchester, UK). A 2 µl sample injection was made onto a 2.1 x 100 mm HSS T3 (C18) 
Acquity column held at 45 °C, the mobile phase flow rate was 0.6 ml/min.  The following 
gradient elution was employed (time (min), %B): (0,2), (8,98), (8.6,100), (9.1,2). 
 
The MS instrument employed was a XevoTM QTof (Waters Ltd., UK) operated in ESI 
positive ionisation mode. Prior to sample analysis the instrument was calibrated with sodium-
formate following the instrument setup wizards. Sample data were acquired in MSE mode 
(Bateman et al. 2007, Wrona et al. 2005) with a 0.05 s scan time, the lockspray standard 
applied was leucine enkephalin (Leu Enk), 2 points were employed for lockmass; m/z 
556.2771 and a fragment ion from Leu Enk m/z 120.0813. ESI was operated in the positive 
ion mode employing an extraction cone voltage of +3 V and sampling cone voltage of +45 V. 
The capillary voltage was set at +3 kV. The source and desolvation temperatures were 120 
and 400 °C, respectively, and the cone and desolvation gas flow rates were 20 L h-1 and 800 L 
h-1, respectively. Data were acquired over the m/z range 50-1,000. For each of the six 
biological replicates the measurements from the nuclear and cytoplasmic fractions were 
performed in triplicate, to account for analytical variability. 
 
5.4. Results and Discussion 
 
5.4.1. Raman Analysis of C33AV Control Cells 
In order to see if there were any changes in cell phenotype when exposed to physiologically 
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relevant levels of anti-viral drugs C33AV cells were treated with 1 mM of indinavir and 30 
µM of lopinavir for 24 h at 37 oC, 5% CO2. Representative cells were then measured using 
Raman microspectroscopy as detailed above. The average Raman spectra for C33AV and 
drug exposed C33AV cells are shown in Figure 5.3 including peak assignments. All the 
internal components such as proteins, lipids, nucleic acids and carbohydrates contribute to the 
Raman spectra of a single C33AV cell as shown in Table 5.1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3. Mean normalised Raman spectra from vector control cell (A), C33AV cells exposed to indinavir (B) 
and lopinavir (C) 
 
As can be seen in Figure 5.1A-C, the differences between the spectra of drug treated and 
control untreated C33AV cells are very subtle apart from a large 1047 cm-1 carbohydrate 
signal (see Table 5.1) which was reduced after incubation with either of the compounds. 
Although C33AV cells treated with lopinavir do not proliferate (Hampson et al. 2006), the 
spectral differences from the level changes in intra-cellular components such as lipid, protein, 
DNA and RNA caused by proliferation are very subtle (Short et al. 2005). Therefore the 
spectral changes between drug challenged and non-drug challenged control C33AV cells were 
not observed by visual analysis of vibrational bands in the Raman spectra.  
 
Chemical maps of control C33AV and the drug exposed C33AV cells were employed to 
analyse and visualise the biochemical distribution of internal components such as proteins, 
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nucleic acids and lipids inside the cell. The white light images, which are referenced to 
provide information on the cell shape and chemical maps of each cell are shown in Figure 5.4. 
CaF2 substrate background removal was carried out before the image maps were generated 
(as illustrated in the schematic in Figure 5.2).  
 
Table 5.1. The tentative Raman band assignments for the C33A cell  
Wavenumber 
(cm
-1
) 
Assignment Raman Vibrational Modes 
642 Tyr (643) C-C twist 
670 T, G (669)  
680 G  
712 unidentified  
746 T   
780 C, U, T (782)  
792 C, T  n: (O-P-O) backbone 
825   n: (O-P-O) backbone(828) 
836  n: RP (834) 
850  p: (C-CH) aromatic def.(852) 
890  n: (O-P-O) backbone (898) 
p: (C-C) skeletal modes (898) 
934  p: (C-C) backbone str. (937)  
948 Deoxyribose (950)  
1003-4 Phe (C-C) aromatic ring str. 
1032 Phe  protein: (C-N) str. 
1047 Carbohydrate (1049) (C-O) str. 
1063  p: (C-N) str.; l: chain (C-C) str.  
1086  n: (O-P-O) backbone (1088); p: (C-C) 
skeletal modes (1086) 
1109  nucleotide: (O-P-O) backbone(1106) 
1128, 1133  p: (C-N) str.; l: chain (C-C) str. (1129)  
 
1156  p: (C-C/C-N) str. (1158) 
1172,1174 Tyr, Phe (1175) (C-C) str. (1172) 
1206 Phe, Tyr, Amide III (1209)  
1256 Amide III(1254); C, A (1255)  
1297  (CH2) def. 
1341 A, G (1342) p: (CH) def. (1342) 
   
Tyr, tyrosine; Phe, phenylalanine; A, adenine; T, thymine; G, guanine; C, cytosine; U, uracil; RP, reverse primer; 
str., stretching; def., deformation; p, protein; l, lipid; n, nucleotide; parenthesised numbers, original Raman shifts 
from (Faolain et al. 2005, Notingher et al. 2003, Uzunbajakava et al. 2003) 
 
This process is significant since the original Raman signal is often hindered by background 
fluorescence induced by laser irradiation in the acquisition of Raman spectra from biological 
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material, even with excitation in the near IR. Thus, background removal ensured that the 
spectra of the cells acquired for Raman chemical maps only consisted of relevant biological 
information. These chemical maps were generated with a spatial resolution of 1 µm from the 
peak area to baseline of each band within the Raman spectra acquired from the cell and 
surrounding area. The intense red regions indicate a higher concentration of a chemical 
constituent(s) relative to the low intensity signal recorded from the CaF2 disc substrate, which 
is represented by blue coloured pixels. It is well known that biological molecules are not 
homogeneously distributed inside cells and the localised and specific activities of 
components are related to the distribution of molecules (Uzunbajakava et al. 2003). The 
chemical maps obtained from the average spectra of the C33AV and the drug exposed C33AV 
cells show that the concentrations of different molecules show variation. Single cell image 
maps of proteins at 850 cm-1, 1004 cm-1 and 1032 cm-1 show a uniform distribution 
throughout the whole cell. By contrast, as one high expect, those from nucleic acids at 746 
cm-1 reveal more concentrated localisations, indicating potential compartmentalisation. In 
addition, in these control cells exposed to indinavir or lopinavir no Raman spectral bands that 
could be attribute to the drugs were observed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4. White light images of C33A vector control cell (A), vector cell exposed indinavir (B) and vector cell 
exposed to lopinavir (C); Scale bar, 10 µm. Raman chemical mean filtered maps of each of these cells are also 
shown, based on the results from each band of a mean row normalised spectrum with a spatial resolution of 1µm: 
(1) 746 cm-1 (thymine); (2) 850 cm-1 (protein); (3) 1004 cm-1 (phenylalanine); (4) 1032 cm-1 (protein). The 
rainbow maps indicate the concentration of each cellular component inside the cell, red showing high and blue 
showing low concentration of molecules.  
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5.4.2. Raman Analysis of C33AE6 Cells 
Next we wanted to observe if there was any effect when the cervical carcinoma cells were 
expressing the HPV16 E6 oncogene. Therefore the spectra of C33AE6 cells and drug 
challenged C33AE6 cells were taken by Raman microspectroscopy with the same 
instrumental conditions as those applied to C33AV cells. Since the expression of the 
oncoproteins induces improper activity of the 26S proteasome to degrade the p53 tumour 
suppressor and other cellular proteins (Banks et al. 2003, Mantovani and Banks 1999b, 
Scheffner et al. 1990, zur Hausen 1996), it is expected that the composition and concentration 
of intracellular compounds of these cells will be different from those of the C33AV cells. The 
average spectra of C33AE6 and drug exposed C33AE6 cells are shown in Figure 5.5A-C. As 
expected, an average spectrum obtained from the C33AE6 cell shows significant variations 
relating to several increased and decreased peak intensities when compared to the C33AV cell. 
The comparison of the spectrum from the C33AE6 cell with that from the C33AV is shown in 
Figure 5.5D. It is well known that E6, in association with E6AP, can facilitate the 
proteasomal destruction of numerous proteins, such as p53, that are detrimental to viral 
persistence (Banks et al. 2003). Yet it is also known that the levels of other cellular proteins 
are increased by indirect effects of E6 and other viral proteins in HPV infected cells (Martin 
et al. 2009, Wan et al. 2008). What is clear is that infection with high-risk HPV produces 
multifactorial effects generally aimed at targeting and perturbing the function of a variety of 
cellular “hub” proteins. Thus the spectral comparison of C33AE6 and C33AV cells shown in 
Figure 5.5D represents snapshot of some of these effects and it is noteworthy that we have 
previously shown the biological properties of these two cell types to be very different. For 
example, xenografted experimental tumours derived from C33AE6 cells are highly resistant 
to radiotherapy when compared to tumours derived from C33AV cells (Hampson et al. 2001) 
and more recently we have used the complementary vibrational spectroscopic technique of 
FT-IR spectroscopy to elucidate gross phenotypic differences between host C33A cells and 
those expressing E6 (Kim et al. 2010b). 
 
In Figure 5.5A-C, several large changes between the spectra of indinavir challenged (E6I), 
lopinavir challenged (E6L), and non-treated control C33AE6 cell were observed. No peaks 
were seen at 670, 680, 746, 780 and 825 cm-1 in the spectrum of the C33AE6 cell whereas the 
resulting spectra of these cells following the treatment of both drugs revealed marked bands 
at these wavenumber shifts. Interestingly, all bands at 670, 780 and 825 cm-1 for E6I, and 680, 
746 and 825 cm-1 for E6L, which are observed after the exposure of the drugs, correspond to 
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peaks ascribed to nucleic acids (Table 5.1). With regard to the function of E6 protein, it could 
be hypothesised that these drugs might increase the level of specific types of nucleic acids in 
cells. By contrast, no clear bands are observed at 1063, 1132 and 1172 cm-1 in the spectra of 
drug exposed to C33AE6 cells, which are very prominent in the C33AE6 unexposed cells and 
this also suggests an additional phenotypic effect as these can be attributed to reduction in 
proteins, lipids, and aromatic amino acids (Table 5.1).   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5. Mean normalised spectra from C33A E6-transfected cells (A), C33AE6 cell exposed to indinavir (B) 
and lopinavir (C). Comparison of average Raman spectrum from C33AE6 cell with that from C33A vector 
control cell (D). Comparison of average Raman spectra from indinavir exposed C33AE6 cells with that from 
indinavir itself (E). 
 
As we know a priori that E6 mediates proteasomal degradation of mutant p53 in C33A cells, 
the inhibition of this activity by indinavir and lopinavir might be reflected in these large 
spectral differences. This effect will be studied in more detail elsewhere using metabolic 
profiling (Goodacre et al. 2004).  In addition, a very interesting feature of the E6I spectra is 
the band at 880 cm-1 which was deduced to be a peak originating from indinavir itself, by 
comparing the spectrum of E6I to that of the drug itself (Figure 5.5E). No discernible band 
associated with lopinavir within the cells was detected (Appendix F). 
 
The chemical image maps of C33AE6 cells, both with and without either indinavir or 
lopinavir, were generated as described above; white light images and chemical maps are 
shown in Figure 5.6. As can be seen in 5.6A, the map from the band at 890 cm-1 (5.6A1) 
- 138 - 
 
µm
µ
m
890 cm-1
 
 
 5 10 15 20 25
 5
10
15
20
25 1.5
2
2.5
3
3.5
µm
µ
m
1003 cm-1
 
 
 5 10 15 20 25
 5
10
15
20
25
1.8
2
2.2
2.4
2.6
2.8
3
3.2
µm
µ
m
1063 cm-1
 
 
 5 10 15 20 25
 5
10
15
20
25 2
2.5
3
3.5
4
4.5
5
5.5
µm
µ
m
1088 cm-1
 
 
 5 10 15 20 25
 5
10
15
20
25
2
2.5
3
3.5
4
4.5
5
µm
µ
m
1133 cm-1
 
 
 5 10 15 20 25
 5
10
15
20
25
2
2.5
3
3.5
4
4.5
5
5.5
6
µm
µ
m
642 cm
-1
 
 
 5 10 15 20
 5
10
15
20
25
0.5
1
1.5
2
2.5
3
3.5
4
4.5
µm
µ
m
880 cm
-1
 
 
 5 10 15 20
 5
10
15
20
25
2
3
4
5
6
7
8
9
10
µm
µ
m
1003 cm
-1
 
 
 5 10 15 20
 5
10
15
20
25
2
2.5
3
3.5
4
µm
µ
m
1088 cm
-1
 
 
 5 10 15 20
 5
10
15
20
25
1.2
1.4
1.6
1.8
2
2.2
2.4
2.6
2.8
3
µm
µ
m
642 cm-1
 
 
 5 10 15 20 25 30 35
 5
10
15
20
25
0
0.5
1
1.5
2
2.5
3
µm
µ
m
850 cm-1
 
 
 5 10 15 20 25 30 35
 5
10
15
20
25
0.5
1
1.5
2
2.5
3
3.5
µm
µ
m
747 cm-1
 
 
 5 10 15 20 25 30 35
 5
10
15
20
25
0
1
2
3
4
5
6
µm
µ
m
1003 cm-1
 
 
 5 10 15 20 25 30 35
 5
10
15
20
25
0.5
1
1.5
2
2.5
3
µm
µ
m
1088 cm-1
 
 
 5 10 15 20 25 30 35
 5
10
15
20
25
1
2
3
4
5
6
µm
µ
m
780 cm
-1
 
 
 5 10 15 20
 5
10
15
20
25
2.5
3
3.5
4
4.5
5
5.5
2 3 4 51
C
B
A
which arises from both nucleic acids and proteins shows a general distribution throughout the 
cell, as does the phenylalanine ring vibration at 1003 cm-1 (5.6A2). Bands at 1063 and 1133 
cm-1 which originate from proteins and lipids and 1086 cm-1 from O-P-O backbone 
composition of the nucleic acids, reveal more localisation (5.6A3-5).  
 
As shown previously vibrations arising from proteins are uniformly distributed throughout 
both E6I (642 cm-1, 5.6B1; 1003 cm-1, 5.6B4; 1088 cm-1, 5.6B5) and E6L (642 cm-1, 5.6C1; 
1003 cm-1, 5.6C4; 850 cm-1, 5.6B3). The chemical image maps of the drug exposed C33AE6 
cells show very interesting features in terms of the spatial distribution of nucleic acids. 
Unlike C33AV (Fig. 5.4) and non-challenged C33AE6 cells (Fig. 5.6A), there are clear 
localisations from 780 cm-1 for E6I and 747 cm-1 for E6L as shown in Figure 5.6B2 and 5.6C2, 
respectively. Also, the maps from 670 and 825 cm-1 for E6I, and 680 cm-1 for E6L show the 
same distinct localisations as 780 cm-1 and 747 cm-1, respectively (Appendix G). Interestingly, 
all these wavenumbers which have distinct distributions are assigned to nucleic acids (Table 
5.1). Based upon the comparison of the spatial distribution of nucleic acids with that of the 
band at 880 cm-1, which we think arises from indinavir, it may be that the activity of this drug 
against the activity of E6 occurs in the nucleus.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6. White images of C33A E6-transfected cell (A), C33AE6 cell exposed indinavir (B), C33AE6 cell 
exposed to lopinavir (C); Scale bar, 10 µm. Raman chemical mean filtered maps of each of these cells are also 
shown, based on the results from each band of a mean row normalised spectrum with a spatial resolution of 1µm. 
A: (1) 890 cm-1 (nucleotide); (2) 1003 cm-1 (phenylalanine); (3) 1063 cm-1 (protein); (4) 1086 cm-1 (nucleotide; 
protein), (5) 1133 cm-1 (protein; lipid), B: (1) 642 cm-1 (tyrosine); (2) 780 cm-1 (nucleotide); (3) 880 cm-1; (4) 
1003 cm-1, (5) 1088 cm-1, C: (1) 642 cm-1; (2) 747 cm-1 (nucleotide); (3) 850 cm-1 (protein); (4) 1003 cm-1, (5) 
1086 cm-1. The rainbow maps indicate the concentration of each cellular component inside the cell, red showing 
high and blue showing low concentration of molecules.  
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In order to investigate this hypothesis further PCA of drug exposed (C33E6I) cells was 
conducted.  PCA provides the most compact representation of all the variations within the 
multivariate data sets by visualising and mining information from an XY data matrix 
containing the large number of Raman detected variables (in the Z axis in this spectral 
hypercube). Thus, in order to investigate which spatial region is the most variable and which 
spectral band is related to the area, PCA was carried out as described above. PCA chemical 
maps and their loadings plots are shown in Figure 5.7.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.7. PCA chemical maps constructed from PC scores with the corresponding loadings plots. E6-
transfected cell exposed to indinavir showing (A) PC1 (78.5%) and (B) PC2 (14.4%) and E6-transfected cell 
exposed to lopinavir showing (C) PC1 (85.6%) and (D) PC2 (6.5%). 
 
The maps and loadings plots from the PCA allow for the selection of significant variables 
associated with the drug activities from the spectrum of each cell. On the basis of chemical 
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image maps and loadings plots from PC1 and PC2, which represent the largest and second 
largest variations, respectively, many of the important variations occurring in E6I cells are 
found to be associated with peaks at 670, 780 and 836 cm-1 corresponding to nucleic acids 
(Figure 5.7A-B).   
 
Furthermore, the large variation of the band at 880 cm-1 indicates that the drug location is 
related to the changes in levels of nucleic acids and may occur in the nucleus. Similar to E6I, 
for E6L it was found that the largest variations (PC1) are derived from nucleic acids, although 
a large contribution is also made by proteins, the second largest variations (PC2) mostly 
occur at the position corresponding to peaks arising from the following nucleic acids; 680, 
747 and 1432 cm-1 (Figure 5.7C-D). 
 
5.4.3. LC-MS Analysis of Subcellular Localisation of Drug 
In order to support the hypothesis that indinavir localises to the nucleus, LC-MS was 
performed on subcellular fractionations from indinavir treated C33AE6 cells. As shown by 
western blotting of nuclear and cytoplasmic extracts with antibodies to these specific 
compartments (Figure 5.8), sub-fractionation of drug treated C33AE6 cells was carried out 
successfully with only minimal cross contamination. This process resulted in six biological 
replicates for both the nucleus and cytoplasm and each of these were analysed in triplicate by 
LC-MS. Cellular fractions were treated with ice cold acetone in order to precipitate out 
proteins and then analysed by LC-MS with UPLC linked to a Xevo Q-Tof (Waters Ltd., UK). 
Different volumes of the extracts were generated and so this dilution factor needed to be 
considered. In addition, in order to adjust for the cytoplasmic to nucleus ratio visible 
microscopy was conducted on C33AE6 cells treated with indinavir and was calculated as 
11.6. 
 
 
 
 
 
 
Figure 5.8. Western blot of sub-fractionated samples from C33A E6-transfected cells exposed to indinavir and 
immunoprobed with a HDAC1 (nuclear marker) and GAPDH loading control antibodies. Sub-fractionation of 
drug treated C33AE6 cells was carried out successfully with only minimal cross contamination. C: cytoplasm, N: 
nuclear, 1-6: biological replicates. 
- 141 - 
 
After taking these factors into account UPLC-MS indicated that the abundance of indinavir 
was approximately eight fold greater in the nuclear than cytoplasmic fractions (Table 5.2). 
This orthogonal analytical technique definitively confirms the findings from Raman chemical 
mapping that indinavir is being localised to the nucleus, and this is presumably where the 
mode of action is occurring for this anti-viral drug.  
 
Table 5.2. Indinavir concentration in cytoplasm and nucleus of C33A E6-transfected cells 
 
Fraction# Cytoplasm abundance* Nucleus abundance Nucleus:Cytoplasm 
1 19.2 149.9 7.8 
2 19.7 204.6 10.4 
3 20.8 191.8 9.2 
4 18.4 156.8 8.5 
5 24.7 126.6 5.1 
6 27.0 171.7 6.3 
  Mean 7.9 
 
#Each fraction was analysed in triplicate (2 µl injected into LC-MS) and means are shown.  
*Abundance is the extracted ion chromatogram (XIC) for the identified indinavir peak following scaling factors 
due to extraction volume differences and cytoplasm-to-nuclues volume.  
 
5.5. Conclusion 
This study has revealed that Raman microspectroscopy coupled to a chemical mapping 
technique is a promising method for investigating the action site of drugs within a single cell 
and the changes of intracellular distribution of chemical species (viz. proteins, nucleic acids, 
lipids) caused by drug exposure. We show clearly the distribution of intra-cellular 
components within human C33A cervical cancer cells by generating chemical image maps 
where significant variations between the spectra of vector control and E6-transfected cells 
were observed. This indicates that the expression of the E6 HPV oncogene causes gross 
phenotypic changes as seen previously by us using FT-IR spectroscopy (Kim et al. 2010b).  
 
An unexpected finding during this study was that Raman microspectroscopy was able to 
detect indinavir localised to the nucleus of C33A cervical cancer cells, but only those cells 
expressing E6. This finding was corroborated using PCA imaging and confirmed using LC-
MS from fractions isolated from the nucleus and compared with those from the cytoplasm. 
 
Visualising the distribution of the drugs applied to cells and other intracellular components is 
an exciting prospect for Raman spectroscopy.  Raman spectroscopy is a label free method and 
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we believe this approach will be very valuable for understanding the mechanism of the anti-
viral drugs on human cervical cancer cells.   
 
In conclusion, we have unequivocal evidence that the HIV anti-viral drug indinavir is 
targeted to the nucleus of HPV16 E6 expressing cervical carcinoma cells.  This novel finding 
will now allow for targeted analysis of the mode of action of this drug. 
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CHAPTER 6 
 
6. Final discussion 
 
Cervical cancer is the major gynaecological cancer in women worldwide and over 2700 
women are diagnosed with the cancer which leads to approximately 1000 deaths per annum 
in the UK (Section 1.3). It is known that the human papillomavirus (HPV) is the major cause 
of cervical cancer and high risk types of HPV (e.g., HPV16 and 18) have been shown to be 
associated with over 99% of cervical carcinomas (Section 1.3.). However, there is no 
treatment other than surgery for HPV-related pre-malignant lesions of the cervix and so the 
treatment of these viruses has become a major issue in gynaecology. It is particularly 
important to develop simple, preferably self-administered non-surgical therapies for several 
advantages and especially for better preservation of obstetric function (Section 2.2).  
 
Expression of the high risk types of the E6 and E7 viral oncoproteins are largely responsible 
for the oncogenic properties of HPV. Especially, E6 binds to the p53 tumour suppressor 
protein and E6-mediated activation of E6-associated protein (AP) then catalyses the 
ubiquitination and subsequent proteasomal degradation of p53 (Section 2.2). Thus, this 
implies that selective inhibition of proteasomal function could prove to be an effective 
strategy for the treatment of HPV infections.  
 
Hampson et al. (2006) have recently reported that the anti-viral drugs, indinavir and lopinavir, 
which are currently used as HIV protease inhibitors, could also inhibit E6-mediated 
proteasomal degradation of p53 and selectively kill E6-dependant cervical carcinoma cells in 
vitro (Section 1.3). Therefore, the aim of this thesis was to understand the modes and site of 
action of these anti-viral drugs on HPV16 E6 expressing cervical carcinoma cells using 
advanced metabolomics methods. Using finger- and foot-printing, metabolite profiling and 
chemical mapping of the cells, the biochemical and phenotypic differences caused by the 
drugs were observed. Analytical methods studied and reported in this thesis were based on 
Fourier transform-infrared (FT-IR) spectroscopy, Raman microspectroscopy, liquid 
chromatography-mass spectrometry (LC-MS) and gas chromatography-mass spectrometry 
(GC-MS).  
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In the first result chapter (Chapter 2), FT-IR finger- and foot-print analyses were applied in a 
screening mode in order to investigate the overall biochemical changes in the intra- and extra-
cellular components in order to understand the phenotypic response of cervical cancer cell 
lines exposed to the HIV protease inhibitors, indinavir and lopinavir. FT-IR spectroscopy has 
widely demonstrated enough versatility to be used for the investigation of metabolic changes 
in biological processes as well as to identify the components of biological systems in the field 
of metabolomics (Section 1.4.3.1). This technique is also a powerful tool for global, sensitive, 
rapid and highly reproducible biochemical analysis with minimal sample preparation 
requirements and so it has been used widely for disease diagnosis as well as the investigation 
of the response of patients to chemotherapeutic drugs (Section 1.4.3.2). Metabolic 
fingerprinting is a high-throughput analytical technique for investigating intracellular 
metabolites and is used commonly for the classification of biological samples based upon 
their origin or biological relevance. Therefore, this technique is often employed for screening 
purposes in functional genomics experiments, for identification of major alterations in 
biochemical pathways as well as for diagnostic usage in industrial or clinical applications 
(Section 1.4.1 and 2.2). However, measuring intra-cellular metabolites does pose several 
challenges. In particular, the rapid metabolite turnover leads to technical difficulties requiring 
robust methods for the rapid quenching of metabolism, and reproducible and robust 
extraction of metabolites from cells. Therefore, these difficulties can be overcome by 
measuring extracellular metabolites which are excreted from cells into their growth media. 
This strategy is called metabolic footprinting (Section 1.4.1 and 2.2). Thus in Chapter 2 this 
study provided the detection of the overall biochemical changes in intra- and extra-cellular 
components of C33A control parent (C33AP) and E6-transfected (C33AE6) cervical 
carcinoma cells caused by exposure to a series of lopinavir concentrations using FT-IR 
spectroscopy. For data analysis, the standard statistical method of data reduction using 
principal components analysis (PCA), followed by discriminant analysis using PC-canonical 
variates analysis (CVA) was employed. PCA was sufficient to reveal inherent differences 
between C33AP and E6 cells and PCA loadings vectors showed proteins, nucleotides and 
carbohydrates contributed to the separation. Furthermore, from box plots, a drop in the levels 
of total cellular proteins, nucleotides and carbohydrates was also detected. Individual PC-
CVA was adequate to show the trends according to the increasing drug doses and that 
metabolic relationships between drug concentrations and FT-IR spectra are more significant 
for the C33AE6 cells and less so for the C33AP indicating that the C33AE6 cells have a 
stronger drug response. Finally, partial least squares regression (PLSR) showed good 
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predictions for the concentration of the drugs from the metabolic finger- and foot-prints 
suggesting a dose-related phenotypic response.  
 
Although FT-IR spectroscopic analysis has enough resolution to detect clear metabolic 
changes caused by the anti-viral drug, there is a limitation to the identification of specific 
chemical structures contributing to anti-viral drug effect. Thus, in order to measure 
metabolites, in the second and third result chapters (Chapter 3, 4) the next step was to 
investigate the level of and compositional changes in intracellular components of C33AP and 
E6 cells upon exposure to a series of indinavir and lopinavir concentrations with MS-based 
metabolic profiling. In addition, the quantification of levels of the drugs inside the cells was 
achieved by LC-MS and in combination this provided an understanding of the mechanism of 
these drugs against HPV on human cervical cell lines. LC-MS is a powerful analytical tool to 
quantify metabolites as well as to identify known compounds in biological samples. Unlike 
GC-MS, LC-MS is more suitable to analyse both primary and secondary metabolites, and is 
fully automated, generally requires no derivatisation, and thus is particularly suited to high-
throughput metabolomics analysis. Therefore, this technique is used widely for biomarker 
discovery in order to diagnose diseases, for drug discovery and development as well as for 
the investigation of drug metabolism and uptake (Section 1.4.3.7 and 3.2). Non-targeted 
metabolic profiling aims to detect as comprehensive a metabolite profile as is possible in 
order to allow non-biased selection of significant metabolites within a system, provided well 
established non-targeted sample preparation procedures are applied (1.4.1). Therefore, this 
strategy is very suitable for the detection of cellular metabolite alterations caused by the anti-
viral drugs on human cervical cancer cells. LC-MS based metabolic profiling (Chapter 3) in 
this thesis provided confirmation that this technique could detect the level and compositional 
changes in intracellular components of C33AP and E6 cells upon exposure to a series of 
indinavir and lopinavir concentrations. Similar to FT-IR work (Chapter 2), the statistical 
method using PCA, followed by PC-CVA showed clear separation between C33AP and E6 
cells as well as very good trends according to the increasing doses of the drugs (individual 
PC-CVA of each C33AP and E6 cells) indicating common metabolic effect of indinavir and 
lopinavir on the cells. To determine chemically which variables (mass ions) contributed to the 
separations and trends indicating anti-viral drug effects, significantly altered metabolites were 
selected from 	-way ANOVA and multivariate analysis such as 2-way PCA, and these peaks 
were subsequently identified by LC-MS/MS. Proline and indoline were confirmed 
unambiguously by performing comparative LC-MS/MS analysis on both the profiling sample 
- 146 - 
 
and to authenticated reference standards. The other several metabolites, 2,3-dihydrothiophene, 
2,5-dihydrothiophene, but-3-yne-1-thol, cyclopenta[b]pyran, methionine, 6-acetyl-2-hydroxy-
cyclohepta-2,4,6-trien-1-one, 9-hydroxynon-7-en-3,5-diynoic acid, phenylalanine, 2-
octenedioic acid, (iso)butyrylcarnitine and 2'-deoxy-guanosine 5'-phosphate were putatively 
identified by comparing most likely bond cleavages and elemental composition of detected 
fragments with structure of tentatively assigned metabolites using MassFragment software 
(Table 1 in Section 3.4). It is valuable in the sense that identification of low molecular weight 
metabolites is known as a very challenging step in metabolomics approaches (Fiehn et al. 
2007a). In addition, we also confirmed general drug effects with the level changes of 
phenylalanine, 2-octenedioic acid, (iso)butrylcarnitine and 2’-deoxy-guanosine 5’-phosphate 
on both cell lines as well as drug specified effects with a reduction in the levels of proline, 
indoline and methionine in only lopinavir exposed C33AE6 cells. In successive analysis, a 
partial correlation network was generated.  This was based on a genetic algorithm for variable 
selection prior to a Bayesian network and provided potential biochemical significance by 
showing that 24 key metabolites selected by univariate and multivariate analyses, and the 
Bayesian network were significantly correlated to many others (Figure 3.6 in Section 3.4). 
Finally, upon investigating the quantification of the drugs, lopinavir inside cells using LC-MS 
showed that the drug level in C33AE6 cells is significantly lower than in C33AP cells. This 
suggests that lopinavir is actively excreted by membrane efflux pumps related to multidrug 
resistance (MDR), which is a major function of cancer cells (Section 3.4). Future studies will 
therefore focus on confirming whether multidrug resistance properties are up-regulated in 
C33AE6 cells using western blotting against MDR gene expression. By contrast, the levels of 
indinavir were greater in C33AE6 than C33AP cells. This could be explained with the fact 
that indinavir is found at concentrations eight-fold higher in the nucleus compared to the 
cytoplasm in indinavir challenged C33AE6 cells (Chapter 5). 
 
With respect to the further work on metabolite identification of important peaks/analytes, a 
variety of several metabolomics platforms will have to be applied in order to aid unequivocal 
identification as well as to potentially uncover a large area of affected metabolism leading to 
in-depth insights of the modes of action of these protease inhibitors. Since NMR 
spectroscopy is one of the most selective analytical instruments giving valuable structural  
information about a compound, this technique can be used to identify chemical structures and 
to obtain specific evidence for the elucidation of a compound (Moco et al. 2007). 
Furthermore, 1H-NMR spectroscopy has also been employed to identify significant host-
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microbiome metabolic interactions affecting human drug metabolism (Clayton et al. 2009) 
and more recently high resolution (HR)-magic angle spinning (MAS) NMR has been used for 
determining the labelling of metabolites in brain tissue as changes of the concentration of key 
metabolites indicative of metabolic degradation are detected (Griffin and Corcoran 2005). In 
addition, LC-SPE-NMR became recently available, allowing for a specific metabolite to be  
separated by LC and trapped in the same SPE cartridge several times and concentrated, and 
then each compound is subsequently subjected to NMR for identification (Moco et al. 2007, 
Tatsis et al. 2007). This technique has been used successfully employed for the separation 
and identification of flavonoids and phenolic compounds (Christophoridou et al. 2005, 
Exarchou et al. 2003, Tatsis et al. 2007). Therefore, these techniques can be used to enhance 
metabolomics investigations for metabolite identification and biomarker discovery in order to 
understand the drug modes of action further. 
 
Due to its high reproducibility, sensitivity and selectivity resulting from the chromatographic 
separation and a sensitive detector, GC-MS is widely employed for metabolic profiling of 
biological samples. GC-MS also benefits greatly due to the availability of metabolite libraries 
such as the NIST library and Golm Metabolome Database (Section 4). As already mentioned 
above since unambiguous metabolite identification is one of the most challenging steps in 
LC-MS-based metabolomic study due to the limited availability of authentic reference 
standards of high purity for LC-MS/MS analyses, GC-MS with widely available commercial 
and open access metabolite databases can provide our clinical understanding of the anti-viral 
modes of action by allowing the identification of a greater number of metabolites. As a small 
experiment, GC-MS based profiling (Chapter 4) was performed to investigate the mode of 
action of indinvair and lopinavir in C33AE6 cells. What this chapter provided was to 
determine whether or not GC-MS based profiling could detect the level changes in primary 
metabolites such as lipids and amino acids of C33AE6 cells exposed to a series of indinavir 
and lopinavir concentrations. Like LC-MS based profiling work (Chapter 3), the multivariate 
analysis using CPCA revealed strong trends associated with the increasing doses of the drugs 
indicating the common trend between different classes of samples (i.e., indinavir challenged 
C33AE6 vs. lopinavir challenged C33AE6). To investigate which metabolites contributed to 
the trends, loadings vectors based upon the CPCA model were calculated and 16 significant 
variables were finally selected by the calculated loadings vectors. Of these 16 variables, three 
metabolites were identified as reduced glutathione, aspartic acid and sugar phosphate and 
showing significant level changes associated with different drug doses. This could be due to a 
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reduction in energy metabolism or the arrest more specifically of glycolysis and potentially 
enhanced mitochondrial energy metabolism. In addition, a drop in the levels of octadecenoic 
acid and lactose associated with increasing doses of indinavir was detected in indinavir 
challenged C33AE6 but not in the lopinavir challenged cells showing the drug specified 
effects. Other than significant variables, reductions of malic acid and aspartic acid were also 
determined indicating that the anti-viral drugs have a great impact upon central metabolism. 
However, due to the lack of other amino and organic acids, future work will have to use 
highly metabolite rich extracts by bulking more biomass to reach the low detection levels 
needed.  
 
In the final research chapter (Chapter 5), Raman microscopic chemical mapping was applied 
for investigating the intracellular distribution of the HIV protease inhibitors, indinavir and 
lopinavir, and other cellular components within a single cervical carcinoma cell. It was hoped 
that this would allow for the determination of the site of action of these drugs within the cells 
as well as distribution phenotypic changes caused by the drugs. Unlike FT-IR, water is not a 
significant factor in Raman spectroscopy and so it has been used widely to analyse 
biochemical molecules in intact tissue and cells on both the macroscopic and microscopic 
scale. This rapid and non-invasive technique requires minimal sample preparation and also 
provides information about relative concentration, structure, and interaction of biological 
molecules within intact cells and tissues in their specific cellular location without 
homogenisation and extraction (Section 1.4.3.3 and 5.2). Therefore, this technique has been 
employed widely for cancer detection, disease diagnosis, and development of effective 
chemotherapeutic agents as well as investigation of the distribution of the drugs inside cells 
or tissues (Section 1.4.3.4). Our study in Chapter 5 clearly illustrates that it is possible to 
measure the intracellular distribution of proteins, carbohydrates and nucleic acids in a single 
cervical carcinoma cell. From this experiment, a uniform cellular distribution of proteins was 
found in drug challenged cells irrespective of cell type (Fingure 5.5 and 5.7 in Section 5.4.2.). 
However, PCA scores maps generated on the full Raman hypercube and the corresponding 
PCA loadings plots showed that the majority of metabolic variations influenced by the drug 
exposure within the cells were associated with changes in nucleic acids (Figure 5.8 in Section 
5.4.2). Interestingly, indinavir was observe to co-localise with nucleic acid in the nucleus but 
only in E6 expressing cells and analysis of cell fractionation products by LC-MS confirmed 
the level of indinavir in nuclear extracts was approximately eight-fold greater than in the 
cytoplasm (Table 5.2 in Sectoin 5.4.3). Therefore, these data from Chapter 5 demonstrated 
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that indinavir undergoes enhanced nuclear translocation in E6 expressing cells which 
suggests that this is the most likely site of action for this compound against HPV. In the future 
for identifying where these drugs are located in tissues alternative vibrational spectroscopies 
could be explored. These include coherent anti-stokes Raman scattering (CARS) microscopy 
for real-time tissue imaging (Evans et al. 2005) and transmission Raman spectroscopy for the 
detection of endogenous components within mammalian tissue (Stone and Matousek 2008).  
Provided the Raman cross section for these drugs is large and characteristic bands can be 
detected these, can be used to determine whether the anti-viral drugs penetrate the cervix 
tissue and where the site of action of the anti-virals is.  This may help to understand the 
mechanism of these drugs against HPV in vivo and develop effective and self-administered 
therapies for HPV related cervical carcinomas. 
 
In conclusion, the combination of metabolic fingerprinting, footprinting using FT-IR 
spectroscopy and MS-based metabolite profiling with appropriate chemometric analyses is a 
promising and valuable approach for investigating cellular responses to anti-viral drugs. In 
addition, different drug levels in C33AP and E6 expressing cells were verified by LC-MS 
suggesting a potential key for the treatment of HPV infection. Raman chemical image 
mapping has been shown to be complementary to FT-IR spectroscopy, and LC and GC-MS 
for studying the distribution of intracellular components within single human C33A cervical 
cancer cells and the same cells expressing the HPV16 E6 oncoprotein. Interestingly, it has 
been shown for the first time that the HIV anti-viral drug indinavir is specifically targeted to 
the nucleus of HPV 16 E6 expressing cervical carcinoma cells suggesting that the nucleus is 
the most likely site of action for this compound against HPV.  
 
Overall, although the two drugs, indinvir and lopinavir, have ultimately the same anti-viral 
effect against C33A E6 expressing cells resulting in the stabilisation of the level of p53 
tumour suppressor protein (Hampson et al. 2006), they showed slightly different metabolic 
changes such as a reduction in the levels of proline, indoline and methionine in only lopinavir 
exposed C33AE6 cells (Chapter 3). However, the effects of the E6 protein are exptremely 
pleiomorphic and there is much that in unknown concerning the metabolic effects of this 
highly multifunctional viral protein. As has been discussed (Chapter 1) one of its primary 
effects is to facilitate inapporiate activation of the proteasome in order to promote viral 
replication and the drugs lopinavir and indinavir are known to inhibit this ability. However, 
this is not a simple effect as it has been shown that HIV protease inhibitors can actually up-
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regulate expression of the proteasome (Waring et al. 2010). Clearly the interaction of E6 
expressing cells with HIV protease inhibitors is not a simple relationship. Thes the specific 
effects of lopinavir on proline, indoline and methionine in C33AE6 cells, are signifincant but 
at this time it is impossible to speculate on the mechanism underling this effect which will 
form the basis of continued investigations. 
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Appendix B     A supporting information figure of Bayesian network representing the lung 
cancer problem: L=low, H=high, T=true, F=false, Pos=positive and Neg=negative
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Appendix C     Additional PCA scores plot from C33A parent and E6-transfected cells 
exposed to indinavir, PC1 vs PC2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix D     Additional PCA scores plots from 2-way comparisons 
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Peak ID Mass RT (Sec) RI Metabolite Name Definitive / Putative Mass (m/z) Intensity pairs
Internal standard 
succinic d4 acid
251 505.566 1433.4 Succinic d4 acid Definitive  30  19; 31   7;  32   9; 33   1; 42   5; 43  45; 44  33; 45 150; 46  46; 47  11; 48  65; 49   3; 50   1; 51   5; 52   6; 53   5; 54   1; 
55   6; 56  26; 57  49; 58 192; 59  52; 60  20; 61  15; 62  34; 63   6; 64   2; 66  25; 67   2; 70   4; 71   5; 72  30; 73 641; 74  
88; 75  43; 76 280; 77  25; 78  11; 79   2; 84   3; 85   1; 86   1; 87   6; 88   8; 89   4; 90  18; 91   3; 99   3; 100   3; 101   2; 
102   3; 103  12; 104   2; 105   8; 106   1; 113   1; 114   1; 115   8; 116   7; 117  14; 118  35; 119  10; 120   2; 130   2; 131  
22; 132  53; 133  41; 134  16; 135   6; 136   2; 146   4; 147 999; 148 207; 149 121; 150  30; 151  10; 152   2; 160   2; 162   
1; 164   1; 171   8; 172   1; 173   2; 174   3; 175  23; 176  33; 177  32; 178   5; 179   4; 189  12; 190   2; 206   2; 221   1; 222   
Hyun_May08 21 86 446.266 1271.6 Leucine Definitive 30 751;  31   6; 39   4;  41  44;  42  29;  43  78;  44 338;  45  79;  46   1;  47  28; 51   5;  52   1; 57  17; 60   5;  61  24; 63   1;  
70   1; 74  57;  75 169;  76   7; 80   2; 84   4;  85   6;  86 999;  87  60;  89   1; 96   1; 100   4; 102   2; 103  32; 104  10; 105   
2; 117  14; 127   1; 128   2; 129  15;  130  28; 131   5; 142   7; 146  39; 148   5; 159   6; 168   8;  170  33; 171  17; 188  40; 
Hyun_May08 23 86 458.266 1304.4 Isoleucine Definitive 30 280;  31   4; 39   6; 41  63;  42   2;  43  18;  44 108;  45  83;  46   5;  47  43;  48   2;  51   5;  52   8;  54   2;  56  35;  57  71;  
58  27;  59  24;   60  12;  61  30;  66  33;  67   1;  68   2;  69 157;  70  17;  71   3;  73  18;  74  75;  75 195;  76  14;  77   5;  84   
9;  85   2;  86 999;  87  93;  88   4;  91   7;  92   1;  96   4;  98   4;  99   3;  100   3; 101   0; 102  21; 103  38; 104   3; 105  11;  
112   1;  115   2; 116   1; 118   1;  124   1;  130  56; 131  31; 132   4;  141   2; 142  19; 143   3;  146  78; 147 268; 148  41; 
149  22;  158  51; 159   7;  160   2;  165   3;  170  34; 171  10; 186   1; 188  32; 189   2;  232   1;   260   1;  277   1;   290   1;  
302   1;   310   1;   318   1;  329   1;  334   1;   340   1;  344   1; 346   1;  354   1;  358   1;  366   1;   380   1;  383   1; 385   1;  
401   1; 402   1; 403   1; 404   1; 405   1;  408   1;  412   1;  417   1;  420   1;  423   1;  425   1;  430   1;  434   1;  439   1;  440   Hyun_May08 12 102 407.166 1179.5 Glycine Definitive 30  13;  31  15; 40   1; 42   5;  43  57;  44  37;  45 174;  46   9;  47  21; 49   1;  50   6;  51   7;  52  21;  53   5;  54   1;  55   6;  
56   6;  57  12;  58  83;  59  80; 61   8; 66  87;  67   4; 69   4; 70   5;  71   2;  72  27;  73 803;  74  69;  75  85;  76   3;  77   1;  
78   7;  79   8;  81  14; 84   1; 86  26;  87  19;  88   4;  89   2; 95   4; 100   6; 101  10; 102 999; 103 154; 105   1; 114   1; 115   
7; 117  25; 118   3; 119   4; 127   3;  130   3; 131  84; 132  17; 133  30; 134   3; 147 409; 148  65; 149  29; 150   2; 158   2; 
174   1; 176  50; 177   9; 178   1; 190   3; 204  71; 205  17; 206   4; 233   1
Hyun_May08 14 102 409.366 1183.0 Glycine Definitive 30  34; 32   4;  33   5; 35   4;  36   1;  37   4; 41  10; 43 263;  44  22;  45 292;  46  44;  47 121; 49  28; 50   1;  51  98;  52  37;  
53   5; 56   4;  57  39;  58 204;  59  89; 60  21;  61  45;  62   3; 64   4; 66  74;  67  17; 69   9; 72  20;  73 819;  74 118;  75 
174;  76  38; 78  28;  79 170; 81  22;  82   9; 85   3;  86   4;  87  19;  88  17;  89   9; 95  47; 101  14; 102 999; 103 210; 111   
1; 114   3; 115  29; 116   5; 117  10; 118  25; 120   8; 126  23; 127  25; 130   9; 131  84; 132  25; 133  26; 134  17; 135  13; 
138   4; 145   4; 146   8; 147 220; 149  27; 150   9; 156   3; 157   1; 159  12; 161   8; 163   4; 169   4;  170   3; 173   6; 174   Hyun_May08 40 103 514.866 1458.7 2,4-dihydroxybutanoic acid Putative 32  17;  33   1;  39   1; 40   4;  41  38;  42  15;  43  56;  44  41;  46  17;  47   7; 51   9;  52   7;  55  65;  57  64;  58  41;  61  21;   
63   1; 70  14;  71  81;  72   2;  75  43; 83   4;  84   5;  85  17; 103 999; 104  85; 105  22; 113   2; 120   4; 121   5; 126   1; 
128   3; 129 121; 137   1;  140   2; 141   1; 145   3;  150   4; 156   1; 157   1; 159   2; 171   5; 177  16; 178   2; 186   1; 189   
8; 192   2; 203  28; 204   4; 206   2; 211   3; 212   1; 214   1; 219 191; 220  54; 221  23; 227   2; 264   1; 266   1; 269   2; 274   
Hyun_May08 32 112 487.264 1383.4 Phosphate Definitive 30  10;  31   5;  32  78;  34   2;  35   8;  36   2;  37   2;  38  13;  39  45;  41  86;  42   5;  43  39;  44 182;  45 551;  46  15;    48  
32;  50 108;  51  85;  54  13;  55   8;  56  31;  59  47;  61   4;  64   1;  67   4;  68  21;  69 430;  70  86;  71   4;  72  16;  73 999;  
74  90;  78 156;  82  14;  83  25;  84   7;  85   5;  86  28;  87   3;  89   1;  93  29;  94   5;  95  10;  96   1;  97  19;  99   1;  100  
53; 103  13; 104   4; 105  17; 107  11;  109   1;  110  63; 112 417; 113  23; 115  50; 116  32; 117   3; 119  46;  120   3; 121  
34; 122   2; 123  12; 126   6; 127  48; 128   8;   130  16; 131  57; 133 370; 134  42; 135 116; 136  12; 137  38; 138   5; 139   
3;  140 385; 141  12; 142  10; 143   5; 144  20; 145   3; 146   4; 147  52; 148   8; 149   6;  150   1; 151  57; 153   5; 156   6; 
157   4; 158  75; 159   7;  161   3; 163  10; 164   2; 165  18; 166   3; 167  12; 168   2;  171   6; 172  27; 173   7; 175   1; 176   
5; 177  20; 178   7; 179  20;  180   5; 181  34; 182   6; 183   8; 187  49; 189  34;  190   7; 191 133; 192  30; 193 169; 194  
32; 195  36; 196   5; 197   7; 198   1; 199   1;  200   1; 201   1; 202   1; 203   1; 205  33; 206   7; 207 194; 208  42; 209  32;  
Hyun_May08 09 116 389.766 1151.6 Alanine Definitive 31   4; 42   5;  43  28;  44  41;  45  99;  46   6;  47   1; 55   3; 57   4; 59  56; 60   8;  61  12; 66   1; 68   1; 70   2;  71   1;  72   9;  
73 600;  74  55;  75  40;  76   1; 82   1;  83   1;  84   2; 86  13;  87   2;  88   2; 94  18; 98   1; 100  44; 101   9; 102   7; 103  49; 
104   4; 105   2; 114   8; 115   8; 116 999; 117  87; 118  35; 119   4; 128  15; 129   1; 130   2; 131  51; 132  10; 133  18; 143   
8; 144   2; 145   1; 147 125; 148  21; 149  10; 158   1; 173   2; 174   2; 190  30; 191   3; 192   1; 218  13; 233   2
Hyun_May08 35 117 501.266 1421.6 Threonine Definitive 45  26; 56  16;  57 353;  59  17; 61   1; 73 999;  74  20;  75  61; 84   9;  86  17; 98   5; 100 108; 101 277; 102  35; 103  14; 
112   4; 114  24; 115   2; 117 359; 118  38; 119  15; 128  97; 129 117; 130  29; 131  26; 132  27; 133  27; 134   3; 142   3; 
144   6; 145   1; 158   7; 159  11; 160  10; 161   2; 163   3; 176   1; 177   2; 186   2; 188   2; 202  34; 203  38; 204   3; 216   
1; 217   1; 218 271; 219 292;  220  72; 221  31; 222   5; 223   1; 30   8; 231  11; 232   3; 246   1; 248   1; 291  57; 292  38; 
293  15; 294   5; 299   4; 301   1; 320  10; 321   2; 322   1
Appendix E     Details of GC-MS mass ions 
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Peak ID Mass RT (Sec) RI Metabolite Name Definitive / Putative Mass (m/z) Intensity pairs
Hyun_May08 93 133 633.866 1917.8 Tetradecanoic acid Definitive 39  22; 41 151;  42  38;  43 161;  44   9;  47  33;  48   1; 53   7;  54   5;  55 252;  58  11; 60   6;  61  53;  62   3;  67  29;  69  
48; 72  11;  73 253;  74  32;  75 640;  76  50;  77  28;  79   7; 81  41;  83  17;  84   5;  89   4; 91   2;  93   7;  95  44;  96   2;  
97  27;  98  26; 101   1; 105  26; 106   1; 107   4; 111   3; 116  46; 117 999; 118  98; 119  41; 120   1; 121   2; 123   2; 129 
396; 130  42; 131 149; 132 471; 133  55; 134  19; 143  27; 145 208; 146  25; 154   2; 159  22; 167   2; 171  14; 181   1; 
185  24; 186   1; 187  17; 188   2; 199   6; 201  43; 202   5; 213   2; 215   7; 241  13; 242   2; 243   4; 255   1; 257  12; 285 
Hyun_May08 47 140 547.966 1571.9 4-hydroxyproline Definitive 31   5;  32   3;  39   3;  40   1;  41  28;  42   7;  43  27;  44  22;  45 157;  46  10;  47  27;  48   1;  49   1; 52   2;  53   2;  54   2;  
55  16;  56   1;  57   8;  58  12;  59  60; 60   7;  61  14;  62   1;  66   4;  67   4;  68  54;  69   8; 71   4;  72  20;  73 999;  74  82;  
75 130;  76   9;  77   5; 80   1;  82   1;  83   8;  84   5;  85   7;  86   3;  87   4;  88   1;  89   4; 94   1;  95   1;  96   3;  97   2;  98   
5;  99   7;  100  20; 101  15; 102   4; 103  10; 104   1; 105   3;  110   1; 111   3; 112   5; 113   7; 114   4; 115   8; 116   9; 117  
12; 118   2; 119   6; 124  11; 125   1; 126   3; 128   3; 129  15; 130   9; 131  18; 132   4; 133  37; 134   5; 135   3; 138   2; 
139   3; 140 441; 141  63; 142  43; 143   7; 144   2; 145   1; 146   1; 147  92; 148  14; 149  14; 150   1; 152   1; 156   5; 157   
2; 158  15; 159   3;  160  12; 161   1; 166   1; 168   1;  170   7; 171   1; 172   4; 173   1; 175   4; 177   1; 182   1; 187   3; 188  
11; 189   5;  190   2; 191   2; 198   1; 200   1; 202   1; 203   1; 214  14; 215   3; 216   3; 217   1; 228   5; 229   2; 230 501; 
231 113; 232  46; 233   9; 234   2; 240   1; 245   2; 258   1; 259   1; 260   1; 304  14; 305   4; 306   2; 332   9; 333   3; 334   1
Hyun_May08 33 142 491.866 1396 Phosphate Definitive 31   5;  32   3; 43  28;  44  29;  45 275;  46  14;  47  13; 52   1;  55   2;  57   8;  59  48; 60   3;  61  18;  62   1;  63   1;  69   1; 
71   5;  72  15;  73 999;  74  86;  75  42;  76   1;  77  18;  79   2; 84   1;  85   5;  86   1;  87   8;  88   1;  89   8; 90   1;  91   5; 
101   1; 102   2; 103  32; 104   6; 105  20; 106   2; 107  10; 109   2; 113   1; 115  40; 116   2; 117  19; 118   3; 119  31; 120   
4; 121  23; 122   2; 123   9; 127   1; 131  34; 132   3; 133 189; 134  26; 135  68; 136   8; 137  29; 138   3; 139   2; 142  13; 
143   2; 145   3; 147  54; 148   8; 149   8; 150   2; 151  41; 152   4; 153   5; 161   2; 163   8; 164   1; 165  16; 166   3; 167  
11; 168   1; 169   1; 174   2; 175   2; 176   3; 177  12; 178   4; 179  13; 180   3; 181  30; 182   4; 183   9; 184   1; 189  22; 
190   5; 191  81; 192  17; 193  99; 194  18; 195  21; 196   3; 197   5; 198   1; 203   1; 205  17; 206   4; 207  98; 208  21; 209  
17; 210   4; 211  95; 212  14; 213   8; 221  11; 222   2; 223   2; 225  61; 226  10; 227  18; 228   2; 229   1; 239   1; 253   5; 
254   1; 255   4; 256   1; 267   4; 268   1; 269   8; 270   2; 271   1; 283  38; 284  11; 285   5; 286   1; 298   8; 299 354; 300 
Hyun_May08 109 144 687.365 2164.8 Spermidine Putative 31   3; 41   4;  42   5;  43  27;  44   6;  45  86;  46   6;  47   4; 53   1;  55  23;  56   6;  57  13;  58  18;  59 137; 60  11;  61   2;  
64   1;  67   1;  68   5;  69  33; 70  14;  71  16;  72  25;  73 999;  74 100;  75  42; 81   3;  82   9;  83  19;  84  54;  85  26;  86 
227;  87  22;  88  15; 94   1;  95   1;  96   8;  97   9;  98  12;  99  32; 100 131; 101  27; 102  39; 103   8; 104   8; 109   2; 110   
9; 111  16; 112  18; 113   7; 114  31; 115  59; 116 329; 117  43; 118  15; 119   2; 123   1; 124   1; 125   7; 126  23; 127   5; 
128  42; 129  24; 130  54; 131  17; 132   9; 137   1; 138   2; 139   2; 140  14; 141   4; 142  72; 143  12; 144 414; 145  56; 
146  47; 147  21; 148   2; 150   1; 151   1; 152   2; 153   3; 154  34; 155   5; 156 178; 157  75; 158  20; 159   3; 160 142; 
161  24; 162  13; 163   1; 164   2; 165   8; 166   2; 168   4; 170  69; 171  14; 172 119; 173  21; 174 267; 175  46; 176  23; 
177   3; 178   1; 179   1; 180   2; 182   1; 183  10; 184   4; 185   2; 186  25; 187   7; 188   8; 192  22; 193   4; 194   1; 195   1; 
196   1; 198   2; 199   1; 200  27; 201  46; 202   8; 203   3; 206   3; 207   4; 209   1; 214  19; 215   6; 216   3; 221   7; 222   2; 
228   1; 229   2; 230   1; 237   3; 238   1; 239   1; 241   1; 248   1; 251   1; 257   2; 263   1; 264 104; 265  25; 266  10; 267   
Hyun_May08 19 144 441.466 1258.5 Valine Definitive 30  21;  31  22;  32 115; 36   2;  37   1; 39  57; 40  25;  41 115;  42  42;  43 256;  44  85;  45 287;  46  18;  47  36; 49   5; 54  
21;  55  95;  56  84;  57 186;  58 245;  59 128; 60  20; 62   8;  63   6;  64   5; 66  20;  67  13;  68  10;  70  98;  71 243;  72  
31;  73 999;  74  30; 76   4;  77   9; 80   1; 82   7; 84  41;  85  69;  86  28; 88  14; 92   1; 98  10;  99  24;  100 145; 101  12; 
102  14; 103  32; 104  22; 110   7; 111   2; 112  23; 113  18; 114  29; 126   2; 128  20; 130  15; 132   3; 133  25; 142   5; 
143   6; 144 792; 145 108; 146  31; 147  54; 155   2; 156   7; 157   1; 158   2; 161   8; 170   5; 171   1; 172   1; 185   2; 186   
1; 188   2; 192   5; 203   5; 218 137; 219  28; 237   3; 246  11; 283   1; 285   1; 338   1; 354   1; 355   3; 356   1; 380   1; 407   
1; 449   1; 458   1; 486   1; 502   1; 527   1; 540   2; 554   2; 556   1; 582   1
Hyun_May08 92 156 633.466 1916.0 Glutamine Definitive 31   9;  32  61;  34   1;  45 179;  46  18;  47   8; 52   7;  59 104; 60  12;  64   1;  66  10; 73 825;  74 101; 87   8;  88  25; 90   6;  
94   3; 100  89; 101  13; 102  27; 103 106; 104  11; 114  46; 115  49; 128 125; 137   1; 139  34; 142  15; 144   5; 147 255; 
148  48; 149  40; 150   5; 151   5; 155 191; 156 999; 157 135; 158  56; 160   7; 161   3; 162   3; 163   4; 164   1; 165   2; 
166   3; 172  12; 173  25; 174 173; 175  35; 176  15; 177   2; 179   1; 184   9; 186   4; 188  11; 189  10; 190   4; 191  11; 
192   1; 193   3;  200  18; 202   1; 203  61; 204  22; 205  15; 206   2; 207   3; 208   1; 212   1; 213   1; 214   9; 216  16; 217  
50; 218  32; 219  12; 220   4; 221  11; 222   2; 223   2; 227   7; 228  15; 229  31; 230  53; 231  14; 232  13; 233   2; 240   1; 
244   4; 245  87; 246  19; 247   8; 248   2; 249   1; 253   5; 254   1; 258   3; 259   1; 260   1; 267   1; 272   6; 273  15; 277   3; 
278   1; 279   1; 281   3; 282   1; 283   3; 288   3; 289   1; 291   1; 292   1; 299   9; 301   3; 302   1; 303   1; 304   2; 305   1;  
307   4; 308   1; 309   1; 311   1; 312   1; 313   1; 314   2; 315   1; 317  30; 318  10; 319   4; 320   1; 327   1; 329   4; 330   2; 
331   1; 333   1; 341   1; 342   1; 343   1; 344   1; 347  14; 348   5; 349   3; 350   1; 355   4; 356   1; 357   1; 362   5; 363   2; 
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Peak ID Mass RT (Sec) RI Metabolite Name Definitive / Putative Mass (m/z) Intensity pairs
Hyun_May08 26 158 473.166 1345.0 Isoleucine Definitive  30  23;  31  17;  32  39;  33   4;  34   2;  36   2;  37   6;  38   4;  39  36;   40  11;  41 139;  42  26;  43 176;  44  47;  45 169;  
46   8;  47   9;  48   5;  49   3;  50   5;  51  27;  52  44;  53   7;  54  11;  55  88;  56  23;  57 114;  58  48;  59  83;  60   4;  63   4;  
65  10;  66  79;  67  16;  68  23;  69 265;  70 273;  71  65;  72  39;  73 864;  74  85;  75 104;  76   3;  78  37;  79  11;  80   3;  
81   4;  82  12;  83  93;  84  58;  85  51;  86  41;  87  16;  88   5;  90   3;  91  34;  93  26;  94   3;  95   2;  96   3;  97  28;  98  
15;  99  19;   100 149; 101  14; 102  44; 103  34; 104   6; 105  13; 108   5; 109  12;  110   4; 111  38; 112  16; 114  17; 115  
20; 116  11; 117  23; 119   1;  120   6; 124   1; 125  13; 126  10; 127   7; 128  17; 129  11;   130  22; 131  34; 132  19; 133   
4; 139   3;  140   1; 142  18; 143  22; 145   1; 146  11; 147 493; 148  73; 149  41;   150   3; 151   3; 153   4; 154   4; 155   1; 
156   8; 157   4; 158 999; 159 147;  160  44; 161   6; 162   2; 163  10; 164   1; 165   2; 167   2; 169   1;  170  25; 171   6; 172   
5; 177   1;  183   3; 184   3; 185   1; 186   2; 188   1; 189   1;   190   2; 192   2; 197   2;  201   6; 203   4; 204   4; 205   2;  210   
2; 211  25; 212   5; 213   2; 215   1; 216   3; 217   3; 218 201; 219  41;  220  14; 221   4; 222   1; 225   2; 227  10; 229   3;   
230   1; 232  33; 233  35; 234  10; 237   2; 238   2; 239   2;  240   1; 241   7; 242   1; 243   2; 244   2; 245   1; 246   2; 248   
2;  253   5; 254   1; 257   1;  260  10; 261   2;  273   2;  284   1; 285   2; 286   3; 287   2; 288   1; 289   2;  290   2;  298   2; 
299   1;  300   1; 301   1; 302   3; 303   2; 304   2; 305   1; 307   1; 308   2; 309   1;  310   1; 311   1; 312   1; 313   2; 315   2; 
Hyun_May08 77 159 613.066 1832.3 Asparagine Definitive 30   7;  31   5;  32  30; 40   8;  42  50;  43  85;  44 999;  45 185;  46  17;  47  67;  48   3;  49   1; 50   1;  51   1;  52   2;  54   2;  
55   8;  56   4;  58  16;  59  27; 60  18;  61  44;  62   3;  63   1;  64   1;  66   2;  67   1;  68   1;  69  13;  70  20;  72  33;  73 377;  
74  95;  75 365;  76  34;  77  16;  78   1; 84  21;  85   3;  86  10;  87   5;  88   3;  89   4; 90   8;  91   5;  92   1;  98   1; 100  51; 
101   5; 102   7; 103  18; 104   1; 105   1; 114  17; 115  12; 116 203; 117  33; 118  31; 119   3; 120   4; 123   2; 125   2; 128  
39; 129  18; 130  83; 131  54; 132  35; 133  10; 134   8; 136   2; 141  14; 143  26; 144  16; 145  11; 146   8; 147  33; 148   
4; 149   9; 150   1; 154   2; 157   1; 158   9; 159 315; 160  38; 161  18; 162   1; 169   3; 171   4; 172   1; 179   5; 184   1; 186  
13; 187   4; 188   3; 190   6; 202  10; 215   7; 216   2;  220   2; 231   2; 233   5; 234   1; 241   4; 242   1; 243   2; 244  11; 245   
Hyun_May08 46 160 547.665 1570.7 Aspartic acid Definitive 30  12;  31  11;  32  86;  33   3;  37   3;  38   3;  39  32; 40  11;  41  26;  42  35;  43 127;  44  77;  45 305;  46  16;  47  99;  48   
5;  49   2; 50   8;  51   9;  52  18;  58  33;  59  42;  60  39;  61  37;  62   8;  66  17;  68  25; 70  21;  71   6;  72  24;  73 999;  74 
111;  75 318;  76  37;  77   2;  79   3; 83   2;  84   9;  85  13;  86  15;  88  75;  89   5; 90   3;  91   1;  92   3;  94   1;  97   2;  98   
7;  99  12; 100  97; 101  45; 102  15; 103  19; 104   1; 105   7; 106   2; 112   8; 113   4; 115  10; 116 162; 117 238; 118  28; 
119  14; 124  19; 125   5; 126   4; 127   1; 128  10; 129   9; 130 255; 131  62; 132  24; 133  83; 134  34; 135  12; 136   4; 
138   5; 139   9; 140 154; 141  13; 142  31; 144  28; 145   4; 146  22; 147 378; 148  70; 149  32;  150   7; 151   1; 156   5; 
157   2; 158  17; 159  18; 160 392; 161  51; 162  18;  170   1; 171   2; 172   5; 175   6; 176  39; 177   6; 178   1; 179   1; 187   
4; 188   6; 189   1; 190   1; 191   4; 202  16; 203   2; 206   2; 214   8; 215   1; 216   2; 218  15; 220 121; 221  21; 222  10; 
228   6; 229   1; 230 220; 231  24; 232  26; 233   7; 234  25; 235   5; 236   1; 241   2; 243   1; 244   6; 245  33; 246   2; 247   
3; 248   2;  250  11; 251   5; 262   6; 278   1; 283  10; 294  22; 295   6; 296   3; 299   9; 305   1; 320   3; 321   0; 322  36; 323  
Hyun_May08 02 163 292.366 995.79 Glutathione reduced Definitive 31  15; 39   1; 41   3; 42   3; 43  11; 44   8; 45 204; 46  11; 47  13; 52  27; 53   0; 54   0; 55   1; 57   8; 59  71; 60   6; 61  10; 
72   2; 73 999; 74  89; 75 111; 76   6; 77   9; 89   6; 90  11; 91  18; 92   2; 93  12; 106   5; 117   2; 119   4; 130   1; 131  12; 
132   2; 133   7; 146   9; 147  35; 148   5; 149   4; 163 495; 164  82; 165  60; 166   8; 167   2; 171  25; 172   2; 173   1; 178  
70; 179  12; 180   8; 181   1Hyun_May08 16 174 417.766 1196.4 Pyruvic acid Definitive 30  11;  31  25;  32  28;  33   4; 38   1;  39   1; 40  11;  41  38;  42  47;  43 126;  44  36;  45 240;  46  22;  47  43;  48   1;  49   
1; 50   7;  51   3;  52  31;  53   5;  54   6;  55   9;  56  16;  57  46;  58 105;  59 229;  60  23;  61  24;  62   1;  63   1; 68   5;  69   
2;  70  19;  71  18; 73 999;  74 242;  75 146;  76  18; 79  17; 83   1;  84  17;  85   1;  86   9;  87   3;  88   1;  89 231;  90  20;  
91   7;  98   3;  99  69; 100 143; 101  29; 103   5; 113   1; 114  16; 115 102; 116  17; 117 102; 118  13; 119  11; 120   4; 127   
2; 131  11; 132   2; 133   8; 143   5; 144   4; 145   1; 147  29; 148  11; 149   4; 158  27; 159   7; 160   5; 174 351; 175  39; 
176  14; 177   1; 188   4; 189   9; 190   7; 191   7; 192   1;  232  26; 233   6; 234   2; 248  15; 249   2;  250   1; 263   1
Hyun_May08 28 174 477.866 1357.8 Glycine Definitive 31  12;  41   2;  43  34;  44  22;  46  12;  47   9;   50   2;  51   2;  52   6;  53   1;  54   1;  55   3;  56   6;  57  11;  58  17;  59 146;  
60  34;  61   8;  69   1;  70  23;  71   6;  72  20;  73 999;  74  78;  75  38;  76   3;  78   2;  79   4;  82   1;  83   2;  84   6;  85   6;  
86 383;  87  47;  89   9;   90   1;  91   1;  95   1;  98   1;  99   3;  100 196; 101  54; 102  19; 103  14; 104   3; 105   3;  113   7; 
114   6; 115   8; 116  13; 117  38; 118   9; 119  11;   120   3; 127   1; 128   1; 129   3;  130  39; 131  42; 132  11; 133 101; 
134  30; 135   9; 136   1;  144   7; 145   2; 146   5; 147 334; 148  52; 149  23;  150   2; 158  14; 159   4;  160   8; 161   2; 162   
2;  172   8; 173   4; 174 760; 175 170; 176 253; 177  44; 178  16; 179   3;  187   1; 188  10; 189   4;  190   4; 191   1;  200   
1; 202   3; 203   1; 204   4;  216   1;  246  10; 247   3; 248 110; 249  31;  250  34; 251   7; 252   1;  276  33; 277   9; 278   6
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
- 174 - 
 
Peak ID Mass RT (Sec) RI Metabolite Name Definitive / Putative Mass (m/z) Intensity pairs
Hyun_May08 90 175 632.765 1912.8 Lysine Definitive 30   2;  31  10;  32  43; 44   3;  45 134;  46   9; 52   6;  59 192; 60  20;  64   1;  66   7;  68   6; 73 999;  74 110; 78   2; 80   1;  
82   5;  86 185;  87  23;  88  99; 90   7;  94   6; 100 182; 101  20; 102  59; 103  62; 104   8; 112  27; 114  40; 115  44; 124   
1; 126   4; 128 232; 130  53; 138   3; 140  26; 142  14; 144   5; 146  28; 147 183; 148  33; 149  13; 150   3; 151   9; 152   1; 
154  37; 156 556; 158  22; 161   1; 163   1; 164   2; 165   1; 166  10; 167   2; 170   5; 172  21; 173  15; 174 647; 175 120; 
176  56; 177   7; 178   1; 179   1; 184   4; 186  17; 188   3; 189  11; 190   4; 191  19; 192   3; 193   2; 200  60; 202  19; 204   
5; 205  14; 206   3; 207   4; 211   1; 212   4; 213   4; 214  21; 215   6; 216   7; 217  23; 218  29; 219  12; 220   7; 221   9; 222   
2; 223   1; 226   1; 228  42; 229   2; 230 144; 231  30; 232  11; 233   1; 235   1; 239   1; 240   4; 244   1; 249   1; 251   1; 253   
1; 254   1; 255   3; 258   3; 260   2; 261   1; 262   1; 263   1; 264   2; 265   1; 267   2; 272   4; 273   6; 275   1; 277   1; 281   7; 
282   2; 283   2; 299   2; 315   1; 317 114; 318  37; 319   4; 327   1; 329  13; 330   5; 331   2; 341   1; 353   1; 355   9; 356   
3; 357   2; 361   1; 391   2; 392   1; 419   3; 420   1; 429   1; 434  11; 435   5; 436   2; 501   1; 502   1; 503   1; 543   1; 558   
Hyun_May08 37 186 503.764 1428.4 Urea Putative 31  24;  35   1;  39   1; 40   2;  41  29;  42 335;  43  81;  44  83;  45  22;  47  57; 51  10;  52  73;  54   8;  55   6;  59  38; 60  
16;  61   7;  64  55;  65  26;  66 278;  67  19;  68   2;  69 126; 70  72;  71  91;  72  48;  74   5;  75  27;  78  30;  79 169; 80  
12;  83   5;  84  11;  85  48;  86  37;  87 185;  88   9;  91   4;  94   1;  96   2;  97   5;  98   7;  99 233; 100 153; 101  51; 102  
24; 106   1; 107  22; 108   1; 109   2;  110  89; 111  14; 113  26; 114  29; 115  19; 116  11; 125   2; 128   6; 129   6; 130 
154; 131  66; 139   3; 140   4; 141   8; 142  10; 143   6; 144   1; 146 152; 155  13; 156  15; 157  37; 158   1; 159   3; 171 
472; 172  80; 173 163; 174  13; 181   1; 186 181; 187  14; 188  10; 189 999; 190 179; 191  75; 192   6; 193   1; 195   5; 
204  36; 205   3; 207   4; 211   3; 218   7; 219   7; 224   7; 225   1; 228   1; 238   5; 240   2; 245   6; 246   1; 291   2; 292   1; 
Hyun_May08 68 186 597.766 1771.1 2-oxoglutaric acid Definitive 30  25;  31  24;  33  12; 47 256; 54 112;  55 557;  59 240; 60  23;  61 115;  62  13;  68  62; 72  43;  74 201;  75 822; 82  68;  
89 530; 90  19;  91  30; 102  14; 109  13; 112 256; 126 154; 128  56; 136   8; 138  10; 147  66; 150   3; 152   3; 153   1; 154 
124; 155   8; 159  44; 160   8; 162   2; 163  15; 166   2; 170 320; 171  28; 172  71; 173  34; 174   7; 176   4; 181  17; 182  
11; 184  89; 185   8; 186 337; 187  37; 188  26; 195   2; 196   4; 197   1; 198 999; 199 119; 200  36; 201  23; 202 205; 206  
26; 207  20; 212  14; 213   5; 224   1; 229 200; 235   6; 238   1; 239   5; 240   9; 244  40; 245  10; 246   3; 249   7; 256   3; 
272  11; 273   0; 274  38; 275   8; 276   3; 281   2; 283   4; 285   2; 288 220; 289  52; 290  23; 292  57; 295   4; 300   3; 304 
160; 305  29; 311   1; 316   1; 320  13; 323  11; 325   1; 332   6; 343   1; 355   2; 359   7; 360   5; 368   5; 381   3; 382   1; 
390   1; 394   3; 395   3; 397   1; 406   3; 411   2; 414   2; 415   1; 442   3; 443   6; 464   1; 476   1; 524   1; 565   1; 569   2; 
Hyun_May08 100 189 645.166 1970 Sugar Putative 31   2;  39   1; 42   5;  43  41;  44  12;  45  98;  46   6;  47  11;  52   1;  53   4;  54   6;  55  35;  56  25;  58   6;  59  47; 60   4;  
61  11;  65   1;  66   7;  67   3;  68   5;  69  16; 70   3;  72  14;  73 999;  74  80;  75 102;  76   6;  77   6; 80   2;  81   4;  82   4;  
83  13;  84  82;  85   9;  86   3;  87   7;  88   2;  89  31; 90   2;  91   1;  94   1;  96   9;  97   1;  98   2;  99   8; 100  14; 101  26; 
102   7; 103  88; 104   9; 105   6; 108   4; 109   2; 110   1; 111   7; 112   3; 113  21; 114   9; 115  18; 116  26; 117 118; 118  
13; 119  13; 120   1; 121   1; 122   2; 124   1; 125   1; 126   1; 127   3; 128  15; 129  71; 130  14; 131  39; 132   8; 133  72; 
134  10; 135   8; 136   4; 138   1; 140   1; 141   2; 142   5; 143  21; 144   8; 145   5; 146   1; 147 266; 148  43; 149  46; 150   
8; 151   3; 152   1; 153   1; 154   2; 155   2; 156  36; 157  20; 158   8; 159  24; 160  13; 161   5; 162   2; 163  17; 164   2; 165   
1; 168   8; 169   6; 170  21; 171   3; 172   1; 173  23; 174   7; 175   7; 176   1; 177   9; 178   1; 179   1; 180   1; 181   1; 182   
8; 183   3; 184   9; 185   3; 186   2; 187   1; 188   1; 189  42; 190  10; 191  98; 192  17; 193   8; 194   1; 196   5; 197   3; 198  
Hyun_May08 73 192 602.166 1788.7 Phenylalanine Definitive 31  11;  36   2; 45 149;  46  13;  47   7;  49   1; 51   4;  52   6;  58   3;  59  48; 60   7;  63   4;  65  21; 72   2;  73 999;  74  88;  
75  42;  76   2;  77  15; 86  20;  87   8;  88   3;  89  19; 90   8;  91  56;  92  14; 100 243; 101  30; 102  17; 103  40; 104   4; 
105   9; 107   1; 115   3; 117  91; 118   6; 119   4; 120   9; 121   2; 122   2; 128   4; 129   8;  130  45; 131  29; 132  28; 133   
9; 134   1; 135   5; 138   1; 142   1; 143   4; 144   1; 145  12; 146  18; 147 127; 148  11; 149  17; 155  57; 156  21; 157   2; 
160  20; 161   3; 162   5; 163  12; 164   2; 165   1; 174   1; 175   2; 176  11; 177  10; 178   2; 179   2; 185  29; 186   8; 188   
1; 189   3; 190   4; 192 333; 193  60; 194  16; 197   1; 201   2; 202   1; 203   8; 204   7; 205   4; 206   4; 207   4;  210   2; 211   
3; 212   1; 213   2; 215   3; 217  61; 218 512; 219 118; 220  47; 221   9; 222   2; 229   6; 230  12; 231   2; 246   2; 256   1; 
258   6; 260   4; 264   1; 266  23; 267  10; 268   4; 273   5; 281   1; 282   2; 284   1; 285   1; 288   1; 291   1; 292   1; 293   1; 
294   7; 295   2; 303   1; 311   1; 321   2; 342   1; 344   2; 347   5; 348   1; 355   1; 385   1; 387   1;  390   2; 408   1; 426   1; 
428   1; 437  11; 438   3; 439   1; 449   2; 462   1; 463   1; 466   1;  470   1; 506   1; 507   1; 508   1; 522   1; 524   1; 527   1; 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
- 175 - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Peak ID Mass RT (Sec) RI Metabolite Name Definitive / Putative Mass (m/z) Intensity pairs
Hyun_May08 84 202 625.97 1883.9 N-acetylaspartic acid Definitive 32   1;  33   1;  35   2;  37   2;  38   3; 40  12;  42 110;  43 607;  44  19;  46   7;  47 174;  48  10;  49   9; 50   3;  51   4;  55  62;  
56  15;  57   7; 60  26;  61 106;  62  13;  63   5;  65   4;  68 212; 70 140;  71  12; 75 867;  76  51;  77  72;  78   4;  79   5; 84  
36;  85  13;  86   1; 93   1;  98  17; 100  66; 109   3; 112 114; 116 425; 122   1; 136   1; 142 149; 144 304; 145   4; 146  52; 
155  10; 156  21; 158 999; 159 107; 167   2; 171   1; 172  50; 174   1; 184  34; 186  98; 187  11; 192   6; 193  13; 194   1; 
195   7; 202 397; 203  56; 204  53; 214 123; 245 150; 246  17; 252   1;  275   1; 276  30; 281   1; 283   1; 298   2; 304 170; 
311   1; 327   1; 354   1; 361   1; 393   1; 395   1; 396   1; 397   1; 400   1; 405   1; 412   1; 415   2; 416   1; 417   1; 418   1; 
419   1; 425   1; 426   1; 427   1; 435   2; 436   2; 444   1; 446   1; 453   2; 456   1; 458   1; 460   1; 461   1; 472   2; 475   1; 
477   1; 481   1; 483   1; 488   1; 491   1; 492   1; 494   1; 498   1; 499   1;  509   1; 514   2; 516   1; 517   1; 518   1; 519   1; 
530   1; 532   1; 537   1; 540   1; 547   1; 550   2; 551   1; 553   1; 557   1; 561   1; 564   1; 576   1; 578   1;  580   1; 583   1; 
Hyun_May08 135 204 771.065 2551.1 Lactose Definitive 30   1;  31   3;  32   3; 41   5;  42   1;  43  13;  44   6;  45  48;  46   2;  47   6; 51   1;  52   2;  53   4;  54   2;  55  15;  56   2;  57   
3;  58   4;  59  21; 60   1;  61   2;  66   4;  67   4;  69  32; 71   3;  72   8;  73 999;  74  86;  75  66;  76   4;  77   3;  79   1; 81  13;  
82   2;  83   4;  85   4;  86   1;  87   4;  88   3;  89  44; 90   3;  91   1;  97  11;  98   1;  99   4; 100  11; 101  14; 102   7; 103 153; 
104  15; 105  16; 106   2; 109   5; 111   4; 113   7; 114   4; 115   7; 116   7; 117  98; 118  10; 119   8; 126   1; 127   5; 128   
2; 129 131; 130  20; 131  26; 132   4; 133  52; 134   7; 135   4; 139   2; 140   1; 141   4; 142   4; 143  35; 144   4; 145   8; 
146   1; 147 271; 148  44; 149  31; 150   3; 151   2; 153   3; 154   1; 155  21; 156   4; 157  26; 158   4; 159   5; 160  39; 161   
9; 162   2; 163  11; 164   1; 165   1; 167   1; 168   2; 169 104; 170  15; 171   8; 172   3; 173   5; 174   1; 175   4; 177   4; 178   
2; 180   1; 181   1; 183   3; 185   2; 186   2; 187   2; 188   1; 189  27; 190   6; 191  49; 192   9; 193   4; 195   1; 196   1; 198   Hyun_May08 34 204 496.166 1407.7 Phosphate Definitive 30   1;  31   4;  32  26;  38   1;  39   4;   40   6;  41   4;  42   6;  43  25;  44   6;  45 119;  46  10;  47  14;  49   1; 50   8;  51   9;  
52  19;  55   5;  56   5;  57  15;  58  31;  59  55; 60   8;  61  12;  62   1;  66   4;  67   1;  68   2;  69  24; 70  12;  71   5;  72  19;  
73 999;  74  89;  75 102;  76   7;  77  13;  78  11;  79  22; 80   1;  81   1;  82   1;  84   5;  85   4;  86  16;  87   9;  88  13;  89  
11;  90   1;  91   3;  93   5;  95   2;  98   2;  99   2; 100 163; 101  25; 102  11; 103  33; 104   4; 105   9; 106   1; 107   3; 112   
3; 113   1; 114  21; 115  26; 116  47; 117  36; 118   7; 119  13; 120   2; 121   7; 123   3; 127   8; 128   1; 129   2;  130  17; 
131  28; 132  20; 133  77; 134  14; 135  20; 136   1; 137  10; 144   7; 145   2; 146   6; 147 120; 148  21; 149  13;  150   1; 
151  11; 152   1; 153   1; 158   5; 159   2; 160   1; 163   8; 164   1; 165   5; 167   3; 172   4; 174  16; 175   5; 176  10; 177   3; 
178   1; 179   2; 181  10; 182   1; 183   6; 188  56; 189  25; 190   9; 191  20; 192   3; 193  20; 194   3; 195   4; 197   1; 202   
1; 203   4; 204 277; 205  57; 206  25; 207  16; 208   3; 209   2; 211  21; 212   2; 213   1; 216  11; 217   2; 218 184; 219  37; 
Hyun_May08 22 205 451.766 1286.6 Glycerol Definitive 30   5;  31   8;  32  15; 37   1;  39   6;  40   3;  41  27;  42   2;  43  32;  44  28;  45 155;  46  10;  47  31;  48   1;  49   1;    50   4;  
51   5;  52   5;  53   1;  55  17;  56  14;  57   8;  58  36;  59  84;  60   7;  61  16;  62   1;  65   1;  69  10;  71   1;  72  22;  73 999;  
74  89;  75 107;  76   7;  77   1;  78   1;  79   2;  85   5;  87   6;  88   5;  89  40;  90   3;  95   4;  99   3;  101  50; 102   5; 103 
283; 104  27;  111   2;  113   5;  115  17; 116  22; 117 348; 118  34; 119  29;  120   1; 121   1;  128   1; 129  60;  130   8; 131  
76; 132   9; 133 160; 134  20; 135  14;  145   2;  147 500; 148  80; 149  63;  150   6; 151   3;  159   3;  161   1; 162   1; 163  
11; 164   1; 165   3;  174   2; 175  21; 176   3; 177  25; 178   4; 179   2;  180   1;  185   4;  189   7;  190   1; 191  29; 192   5; 
193   1;  203  28; 204  36; 205 231; 206  46; 207  21; 208   3;  217  13; 218  87; 219  19;  220   7; 221   3; 222   1;  293   5; 
Hyun_May08 42 217 520.666 1474.5 Threitol and/or erythritol Putative 32   1;  39   1; 41  17;  42   4;  43  34;  44  14;  45 103;  46   5;  47   6; 51   1;  52   2;  53   1;  54   1;  55   9;  56   1;  57  28;  
58   7;  59  49; 60   3;  61   6;  66   9;  67   1;  69  85; 70   7;  71  27;  72  20;  73 999;  74  79;  75  63; 83   1;  84   1;  85  14;  
86   3;  87   6;  88   7;  89  33; 90   1;  99   7; 101  49; 102   4; 103 283; 104  26; 105  13; 111   2; 113   7; 115  19; 116  74; 
117 231; 118  23; 119  17;  120   1; 129  80; 130  13; 131  41; 132   4; 133  98; 134  12; 135   7; 141   3; 143  11; 145   3; 
147 456; 148  72; 149  45; 150   4; 151   1; 155   1; 159   1; 161   2; 163   5; 174   5; 175   5; 177   3; 189 101; 190  19; 191  
76; 192  12; 193   5; 203   6; 204  87; 205 154; 206  33; 207  16; 208   2; 215   7; 216   1; 217 309; 218  64; 219  28; 220   
3; 221  14; 222   3; 223   1; 230   1; 231   9; 232   2; 233   1; 248   5; 277   7; 278   2; 279   1; 291   1; 293  16; 294   4; 295   
2; 305   4; 306   1; 307  25; 308   7; 309   3;  320   8; 321   2; 322   1Hyun_May08 69 217 599.77 1779.1 Fructose Definitive 41  75;  43 133; 53   9;  55 124;  56  22;  57 150; 67  21;  68  34;  69 251; 70  99;  71  96;  72  37;  73 999;  74 104; 76   5;  
79   2; 81  28;  82  26;  83 137;  84  34;  85  63;  88   7;  89  52; 90   2;  95   5;  96   5;  97  51;  98  24;  99  20; 101  14; 102   
6; 103 156; 104  17; 105  11; 109  21; 110  22; 111  87; 112  47; 113  31; 114   9; 115  19; 116   2; 117 107; 118   6; 119   
3; 123   6; 125  41; 126  14; 127  19; 128   9; 129 156; 130 128; 131 100; 132   5; 133  81; 134   6; 137   2; 139  20; 140   5; 
141  42; 142  17; 143  72; 144   9; 145  15; 146  11; 147 244; 148  29; 149  56;  150   7; 151   6; 152   2; 153  23; 154  14; 
155 136; 156  96; 157  47; 158   1; 161   4; 162   2; 163   3; 164   1; 165   3; 167   7; 168   5; 169  50; 170  18; 171  10; 172   
4; 173   3; 175   7; 176   1; 177   9; 179   2; 181   1; 182   1; 183   8; 185  10; 186   1; 187   1; 188   4; 189  47; 190  16; 191 
130; 197   3; 201  11; 202  31; 203  39; 205  45; 206   5; 207  15; 208   1; 209   2; 213   1; 214   3; 215  47; 216  11; 217 
943; 219  64; 220   6; 221  24; 222   4; 223   6; 224   1; 228   2; 229  23; 230  56; 231  19; 232  21; 233   9; 234   2; 238   5; 
239   1; 240  17; 241   5; 242  26; 243  17; 244   6; 245   6; 246   9; 247   4; 248   1; 250   1; 254  19; 255  13; 256  11; 257 
122; 258  34; 259  12; 260   1; 261   1; 262   1; 264   1; 268   2; 270   1; 271   8; 272   5; 273   4; 274  18; 275  17; 276   3; 
277   7; 278   5; 287   1; 289   2; 291  18; 292   3; 293   6; 295   1; 303  21; 304   9; 305  12; 306  13; 307   3; 308   1; 313   
- 176 - 
 
Peak ID Mass RT (Sec) RI Metabolite Name Definitive / Putative Mass (m/z) Intensity pairs
Hyun_May08 49 218 549.966 1579.9 Aminomalonic acid Putative 30   4;  31   9;  32  15;  39   6; 40   4;  41  16;  42  15;  43  54;  44  32;  45 176;  46  10;  47  27; 50   1;  51   4;  52   6;  53   2;  
55  15;  56  31;  57  34;  58  20;  59 108; 60   3;  61  12;  66  10;  67   0;  68  16;  69  27; 70  13;  71  17;  72  37;  73 999;  74  
67;  75 114;  76   3;  77   2; 83  10;  84   6;  85  11;  86 216;  87  27; 95   1;  97   2;  98   2;  99   5; 100 104; 101  17; 102   8; 
103  26; 104   3; 105   3; 106   1; 110   1; 111   5; 112   2; 113   2; 114   5; 115   9; 116  11; 117  44; 118   4; 119   8; 124   1; 
125   1; 126   1; 128   3; 129   6; 130  43; 131  58; 132  14; 133 107; 134   7; 135   6; 142  12; 143  10; 144   6; 145   2; 146   
5; 147 479; 148  74; 149  34; 150   3; 156   1; 157   2; 158  10; 159   3; 160  51; 161   6; 162   1; 172   7; 173   2; 174 261; 
175  47; 176  10; 188   5; 190  10; 191   1;  202   2; 203   1; 204   5; 205   2; 216  10; 217   2; 218 277; 219  62; 245   2; 246   
5; 247   1; 248  28; 249   8; 276   5; 277   1; 292  46; 293  17; 294   3; 299   1; 304  21; 305   4; 306   2; 320  86; 321  25
Hyun_May08 71 218 600.965 1783.9 Phenylalanine Definitive 31  14;    37   3;  43  15;  44  23;  46  15;  47   4; 51  16;  52   5;  53   8;  55   3;  56   5;  58  21;  59  54;  60   3;  61  13;  62   4;  
63   5;  65  17; 70   4;  72  19;  73 999;  74 107;  75  79;  76   9;  77  17;  78   2;  79   1; 84   1;  86  19;  87   6;  88   5;  89  12; 
90   9;  91  45;  92  11;  93   4;  98   3;  99   3; 100 159; 101  25; 102  34; 103  70; 104  26; 105  18; 106   2; 107   5; 109   1; 
110   2; 113   6; 114   7; 115 104; 116  26; 117  27; 118  19; 119  12; 120   7; 121   9; 122   1; 123   1; 126   2; 128   8; 129  
21;  130 613; 131 217; 132  62; 133  40; 134   6; 135  10; 136   1; 137   1; 138   1; 140   1; 143   3; 144   2; 145  11; 146 
101; 147 424; 148  55; 149  16;  150   3; 157   1; 158   5; 159   2; 160  19; 161  14; 162  26; 163   8; 164   3; 168   1; 172   
6; 173   3; 174  10; 175   2; 176  32; 177  15; 178   8; 179   1;  180   1; 183   1; 186  11; 187   1; 188  30; 189   9; 190  26; 
192 181; 193  32; 194   7;  200   1; 201   2; 202 126; 203 114; 204  86; 205  24; 206   5; 208   1; 216   3; 218 282; 219  54;  
220  90; 221   9; 222   5; 232   1; 235   1; 242   2; 243   3; 245   1; 246   1; 250   1; 262   4; 263   1; 266  12; 267   3; 268   3; 
Hyun_May08 07 219 374.066 1126.5 Lactic Acid Definitive 30   1;  31  11; 41   2;  42   8;  43 106;  44  44;  45 268;  46  17;  47  50;  48   2;  49   1; 51   7;  52  19;  53   5;  54   1;  55  38;  
56   6;  57  13;  58  21;  59  87; 60  12;  61  27;  62   1; 70   5;  71   9;  72  28;  73 999;  74  94;  75 141;  76   8;  77   4; 85   3;  
86   2;  87  20;  88  65;  89   9; 94   3; 99   2; 101  26; 102  21; 103  15; 104   2; 105   7; 115  12; 116   6; 117 649; 118  78; 
119  35; 120   2; 129  14; 130   1; 131  38; 132   6; 133  70; 134   9; 135   5; 147 597; 148 113; 149  64; 150   7; 151   1; 
175   6; 176   1; 190 100; 191 131; 192  31; 193  11; 194   1; 203   6; 204   1; 219  51; 220  10; 221   4
Hyun_May08 48 220 549.466 1577.9 4-aminobutanoic acid Putative 31   6; 42   4;  43  27;  44  27;  45 159;  46  17;  47  21;  48   6;  49   1; 52   1;  53   1;  55   5;  57   2;  58  31;  59  58;  60  49;  
61  18;  62   5;  66   7;  67   2;  68  10;  69   5; 70  17;  72  32;  73 999;  74 107;  75 115;  76  37;  77   6; 83   4;  84   6; 86  
56;  87  17;  88 118;  89  14; 90   6;  91   1;  97   1;  98   1;  99   1; 100  56; 101  41; 102  14; 103  18; 104   5; 105  17; 106   
1; 111   2; 112   3; 113   2; 114   4; 115   9; 116  45; 117  80; 118  17; 119   9;  120   4; 128   4; 129   1; 130  76; 131  57; 
132  25; 133  68; 134  50; 135  11; 136   4; 142  11; 143  11; 144  10; 145   3; 146   9; 147 459; 148  89; 149  48; 150   7; 
151   1; 156   4; 157   1; 158   7; 159   5; 160 108; 161  16; 162   9; 163   1; 172   6; 173   2; 174 161; 175  35; 176  84; 177  
15; 178   6; 179   1; 187   1; 188   3; 189   3; 190   5; 191   5; 192   2; 193   1; 204   1; 206   5; 207   1;  214   3; 216   9; 217   
1; 218   3; 219   8; 220 201; 221  42; 222  18; 223   3; 230  22; 231   1; 233   1; 234   9; 235   2; 236   1; 244   1; 245   9; 246   
6; 247   3; 248   1; 249   1; 250  20; 251   5; 252   2; 278   3; 279   1; 293   1; 294  34; 295  12; 296   6; 297   1; 299   1; 304  
Hyun_May08 55 220 567.265 1649.1 Cysteine Definitive 30  10;  31   5;  32  29;  33   1;  39   7; 40   7;  41  16;  42  36;  43  80;  44  42;  45 176;  46  12;  47  25;  48   4; 50   3;  51   4;  
52  10;  53   4;  54   3;  55  18;  56  28;  57  23;  58  70;  59  59; 60   6;  61  29;  62   2;  64   1;  66   1;  67   2;  68   1; 70  24;  
71  66;  72  87;  73 999;  74  56;  75  80;  76   3;  77   5; 81   1;  83   1;  84   6;  85   1;  86   9;  87   4;  88   1;  89   5; 90   2;  
91  11;  94   1;  97   1;  98   2;  99   4; 100 127; 101  20; 102  13; 103  10; 104  11; 105   7; 106   2; 110   2; 113   5; 114   9; 
115  22; 116  35; 117  10; 118   4; 119   5; 120   1; 121   2; 123   2; 124   2; 128   3; 129   9; 130  12; 131  15; 132  45; 133  
33; 134   6; 135   6; 137   3; 141   1; 143   1; 144   1; 145   1; 146  13; 147  58; 148  30; 149  12; 150   1; 151   2; 153   1; 
155   9; 158   3; 160   7; 161   2; 163   6; 165   3; 172   4; 173   1; 174   1; 177   2; 178   1; 180   2; 181   9; 182   2; 183   1; 
184   1; 190   2; 193   2; 203   1; 204  11; 205   5; 206   2; 207   1; 209   2; 211   1; 217   6; 218 175; 219  33;  220 195; 221  
40; 222  22; 223   3; 232   7; 243   2; 244   1; 294   5; 296   2; 322   1Hyun_May08 98 226 640.966 1950.6 Sugar Putative 30   2;  31   2;  32  47;  38   1;  39  26; 40   4;  41 134;  42  37;  43 278;  44  19;  45  91;  46   6;  47  14; 52   4;  53  11;  54  
17;  55 126;  56  79;  57 277;  58  23;  59  49; 60   6;  61  19;  65   1;  66   8;  67  17;  68  19;  69  83; 70  40;  71 212;  72  
34;  73 999;  74  66;  75 209;  76  13;  77   8;  79   3; 80   7;  81  18;  82  13;  83  62;  84 191;  85 133;  86  12;  87   9;  88   4;  
89  38; 90   8;  94   2;  95   6;  96  22;  97  23;  98  21;  99  52; 100  37; 101  32; 102   6; 103 115; 104   9; 105   9; 106   1; 
108   9; 109   4; 110   5; 111  18; 112  11; 113  47; 114  13; 115  25; 116  47; 117 187; 118  22; 119  15; 120   1; 122   7; 
124   3; 125   3; 126   8; 127  15; 128  22; 129  90; 130  18; 131  60; 132  35; 133  85; 134  10; 135   8; 136  13; 138   5; 
139   2; 140   7; 141  11; 142   6; 143  12; 144  12; 145  18; 146   3; 147 290; 148  44; 149  49; 150  14; 151   2; 152   2; 
154   7; 155  17; 156  78; 157  27; 158  14; 159  41; 160  17; 161   4; 162   1; 163  17; 164   2; 165   1; 168  24; 169   8; 170  
39; 171   5; 172   5; 173  31; 175   5; 176   1; 177   6; 182  17; 183   8; 184  23; 185   5; 186   6; 187   1; 188   5; 189  65; 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
- 177 - 
 
Peak ID Mass RT (Sec) RI Metabolite Name Definitive / Putative Mass (m/z) Intensity pairs
Hyun_May08 50 232 554.166 1596.7 Aspartic acid Definitive 30   1;  31   5;  32   1; 41   1;  42   6;  43  52;  44  27;  45 144;  46  11;  47  24;  48   1; 52   2;  53   1;  54   2;  55  10;  56   2;  
57   7;  58  12;  59  48; 60   9;  61  15;  62   1;  66   5; 70  46;  71   4;  72  24;  73 999;  74  99;  75 132;  76   9;  77   5; 82   1;  
83   1;  84   5;  85   3;  86   9;  87   3;  88   2;  89   2; 98   9;  99   6; 100 287; 101  33; 102  14; 103  14; 104   1; 105   2; 113   
1; 114   4; 115  14; 116   9; 117  73; 118   8; 119  12; 120   1; 128   7; 129   4; 130  30; 131  21; 132  17; 133  48; 134   8; 
135   5; 140   1; 142  15; 143   6; 144   6; 145   2; 146   4; 147 142; 148  24; 149  23; 150   3; 151   1; 158   2; 159   2; 160  
16; 161   3; 162   1; 163  19; 164   3; 165   1; 171   2; 172   9; 173   3; 174  15; 175   2; 176   2; 177   3; 184   1; 188  45; 189  
10; 190   6; 191   3; 200   1; 202  53; 203  10; 204  12; 205   3; 206   1; 215   1; 216  18; 217   4; 218  80; 219  16; 220   7; 
221   3; 230   2; 231   1; 232 391; 233  84; 234  39; 235   6; 236   1; 244   5; 245   5; 246   2; 262   1; 292   5; 293   1; 306   
Hyun_May08 25 233 468.966 1333.5 Malonic acid Definitive 31   5;  42  11;  43  57;  44  30;  45 153;  46  11;  47  55;  48   2;  49   1;  51   2;  52   9;  53   2;  55   5;  56   1;  57   7;  58  15;  
59  40;  60   8;  61  25;  62   1;  66 140;  67  11;  69  11;  70   4;  71   4;  72  44;  73 578;  74  52;  75 166;  76  12;  77   7;  87  
14;  88   5;  89   3;  91   1;  99  26;  100   2; 101  13; 102   2; 103   7; 104   1; 105   5;  109  14;  110   1;  113   1;  115  12; 
116   6; 117  14; 118   2; 119   3;  131  29; 132   4; 133  40; 134   5; 135   3;  143  18; 144   1; 145   1; 147 999; 148 161; 
149  94;  150  10; 151   2;  158   2; 159   1;  162   1;  173   3;  189   5;   190   1; 191   1;  204   1;  217   5; 218   1;  233  53; 
Hyun_May08 63 243 582.065 1708.3 Glutamine Definitive 30  12;  31   9;  32  14;  38   1;  39   8; 40   5;  41  71;  42  32;  43  98;  44  53;  45 195;  46  19;  47  87;  48   6;  49   4; 50   7;  
51  14;  52   2;  53   7;  54  11;  55  40;  56 242;  57  45;  58  38;  59  67; 60  20;  61  47;  62   4;  63   3;  64   2;  65   2;  66   1;  
67   4;  68   7;  69   6; 70  20;  71  11;  72  48;  73 874;  74  86;  75 445;  76  38;  77  24;  78  24;  79   5; 80   4;  81   2;  82   
6;  83  21;  84 999;  85  55;  86  15;  87  10;  88   7;  89  18; 90   2;  91   5;  92   0;  93   3;  94   1;  95   3;  96   2;  97   2;  98   
8;  99   9; 100 105; 101  35; 102  11; 103  27; 104   2; 105   3; 106  23; 107   2; 110   1; 111   2; 112  10; 113   7; 114  16; 
115  81; 116  53; 117  24; 118   5; 119   3; 121   1; 124   3; 125   1; 126   2; 127   3; 128  93; 129  35; 130  31; 131  18; 132  
12; 133  30; 134   4; 135   3; 136   1; 139   2; 140  37; 141   6; 142  11; 143  19; 144  11; 145   7; 146  12; 149  11; 150   1; 
152   1; 153   7; 154   3; 155   4; 156 113; 157  27; 158 127; 159  19; 160   7; 161   1; 163   1; 168   1; 169   1; 170   2; 171   
5; 172   3; 173  12; 174 196; 175  26; 176   8; 177   1; 184   5; 185   3; 186  50; 187   7; 188   3; 189   2;  190   1; 198   1; 
201  12; 202   4; 203   2; 204   6; 214   3; 215   2; 216   2; 217   3; 218   7; 219   2; 220   1; 221   2; 222   1; 227   1; 228   2; 
229   1; 230  65; 231  13; 232   5; 237   1; 241   1; 242   1; 243  24; 244   6; 245   6; 246 189; 247  24; 248  13; 249   1; 250   
Hyun_May08 74 243 608.166 1812.7 Ornithine Definitive 31   4; 43  15;  44  13;  45  85;  46   3;  47   9; 50   7;  51  16;  52   1;  55  10;  57  12;  58  15;  59  69; 60   8;  61   9;  67   4;  
68  11;  69  25;   70  10;  71  11;  72  12;  73 999;  74  94;  75 218;  76  13;  77   3;  78  18;  79   6;  82   7;  83  53;  85  15;  
86  75;  87   6;  88   4;  89   8;  90   5;  91   9;  93   1;  94   1;  95   4;  97   1;  98   7;  99   5; 100  81; 101  19; 102  39; 103  18; 
104   6; 105  16; 109   2; 110   6; 111  10; 112  13; 114  16; 115  22; 116 118; 117  27; 118   2; 119   8; 120  75; 121   4; 
124   2; 125   6; 126  12; 127   6; 128  41; 129  19;  130  47; 131  38; 132  71; 133  43; 134   3; 135   1; 136  39; 137   4; 
138   1; 139   6; 140   7; 141  46; 142 535; 143  73; 144  34; 145   2; 146  42; 147 111; 148  23; 149   6; 151   3; 152   3; 
153   5; 154   5; 155 105; 159  24; 160   5; 161   5; 162   2; 163   1; 164   2; 167   3; 168   1; 169   7; 170   2; 171  15; 172  
27; 173   5; 174 188; 175  36; 176  20; 177   4; 178   1; 179 100; 180  13; 181   3; 183   1; 184   0; 185   1; 186   8; 187   7; 
188  44; 189  15; 190   6; 191  10; 192   3; 193   3; 194   3; 195   2; 196   3; 197   1; 198   1; 199   2; 200  39; 201  11; 202  
Hyun_May08 36 245 502.266 1424.4 Urea Putative 30  10;  31   5;  32  12; 42   4;  43  34;  44  30;  45  47;  46  28;  47  15;  48  15;  49   1; 51   6;  52  28;  53  22;  54  10; 56   8;  
57  43;  58  35;  59  35; 60  23;  61   9;  62   8;  63   2;  64  20;  65   7;  66 132;  67   9;  68   3;  69  16;  70  15;  71  18;  72  
36;  73  76;  74   4;  75  69;  76  66;  77   5;  78  20;  79  57; 80   2;  82   3;  83  39;  84  24;  85  14;  86  12;  87  72;  88  11;  
90   6;  93   4;  98   5;  99  71; 100  62; 101  52; 102  10; 111   2; 113  13; 114  11; 115  17; 116   8; 117   3; 118   4; 127   5; 
128  16; 129  11; 130  61; 131  35; 132  44; 133   6; 135   1; 141   3; 142  12; 143  69; 144   9; 145   2; 146  57; 147 999; 
148 174; 149 101; 150  10; 151   4; 155  25; 157  24; 158   1; 159   5; 170   3; 171 207; 172  31; 173  66; 174   8; 175   6; 
176  13; 177   8; 178   1; 183   1; 186   9; 189 404; 190  73; 191  10; 201   2; 202   4; 203   3; 204   8; 211   1; 217  10; 218  
37; 219  31; 220   3; 222   1; 230   1; 245 274; 246  54; 247  25; 248   3; 251  25; 252   5; 253   2; 266   1; 272   3; 300   1; 
Hyun_May08 45 245 545.466 1561.9 Malic acid Definitive 31   3;  32   5; 42   2;  43  21;  44  20;  45 125;  46   8;  47  25;  48   1; 51   1;  52   4;  53   4;  54   1;  55 113;  56   4;  57   5;  
58  10;  59  47; 60   5;  61  12;  66   8; 71   1;  72  23;  73 999;  74  78;  75 108;  76   6;  77   3; 85   2;  87   3;  89   1; 99   3; 
101  66; 102   6; 103   8; 105   3; 115   8; 116   8; 117  44; 118   4; 119   8; 129   7; 131  28; 132   3; 133 105; 134  14; 135  
10; 143  17; 144   2; 145   3; 147 400; 148  64; 149  44; 150   4; 151   6; 157   1; 163   1; 171  22; 172   2; 173   3; 175  43; 
176   7; 177  11; 178   1; 185   1; 189  48; 190  41; 191  36; 192   7; 193   2; 203   4; 204   2; 205   2; 207   1; 217  19; 218   
3; 219   2; 221   9; 222   2; 223   1; 233  85; 234  17; 235   7; 236   1; 245  55; 246  10; 247   7; 248   1;  260   1; 263  11; 
264   3; 265  14; 266   3; 267   1; 305   1; 306   3; 307  13; 308   5; 309   2; 319   4; 320   1; 335  13; 336   4; 337   2
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
- 178 - 
 
Peak ID Mass RT (Sec) RI Metabolite Name Definitive / Putative Mass (m/z) Intensity pairs
Hyun_May08 66 246 591.966 1747.9 Pyroglutamic acid and/or glutamic acid Definitive 44   9;  45 311;  46   5;  47   1; 57   1;  58  16;  59  43; 60   3;  61   4;  66  18;  67  11; 70   4;  72  29;  73 999;  74  91;  75  73;  
76   2; 80   1;  81   4;  85   5;  86  14;  87   5;  89   7; 94   3;  95   2;  97   1;  98   5;  99   7;  100  15; 101   7; 102   3; 103  90; 
104   7; 105   7; 108   1; 112  14; 113   7; 114   7; 115   7; 116   1; 117  56; 118   7; 119   7; 122   6; 126   2; 127   2; 128  15; 
129  14; 131  28; 132   4; 133  66; 134   7; 135   4; 139   4; 140  17; 141  13; 142   2; 145   1; 147 190; 148   7; 149   4; 153   
1; 156 137; 157  94; 158  36; 159   4; 169   1; 170   2; 172   1; 173   1; 174   2; 175   1; 181   1; 183   2; 189   3; 190   3; 191   
5; 198   1; 204   8; 205  19; 206   4; 207   3; 211   1; 213   1; 214  16; 215   8; 216   2; 217  30; 218   6; 219   1; 221   4; 228   
4; 229   7; 230 115; 231  35; 232  13; 233   2; 242   1; 243   1; 246  33; 247   7; 248   2; 255   1; 257   2; 258 134; 259  28; 
260  14; 261   1; 273   6; 274   0; 275   0; 276   0; 277   1; 291   1; 299   1; 303   6; 304   2; 305   1; 306   0; 307   6; 308   1; 
Hyun_May08 39 247 506.766 1436.6 Succinic acid Definitive 40   1;  42   2;  43  31;  44  20;  45  77;  46  13;  47  39;  48  23;  49   1; 51   2;  52   2;  54   1;  55  59;  56  62;  57  31;  58  25;  
59  24;  60  12;  61  22;  62  15;  63   5;  65   1;  66  18;  67   2; 70   3;  71   4;  72  25;  73 491;  74  45;  75 133;  76  38;  77  
12; 84   3;  85   3;  86   3;  87   1;  88   3; 90   1;  91   2;  99   4; 101   3; 103   4; 105   6; 113   7; 115  11; 116  14; 118   8; 
119   2; 127   2; 129  28; 130   4; 131  15; 132  16; 133  24; 134   5; 135  10; 136   1; 143   1; 145   1; 146   5; 147 999; 148 
148; 149  92; 150  12; 151   4; 157   1; 171   6; 172  27; 173  11; 174   4; 175   7; 176   8; 177   6; 179   3; 189   9; 203   1; 
207   1; 240   1; 247  48; 248   8; 249   6; 250   3; 251  10; 252   3; 253   1; 255   4; 262   1; 281   1; 300   1; 301   2
Hyun_May08 41 248 517.066 1464.7 Alanine Definitive 31  12; 42   4;  43  35;  44  27;  45 225;  46  15;  47  20; 52   4;  54  30;  55  15;  58  18;  59 222; 60  20;  61  16;  66  11; 70   
8;  72  29;  73 999;  74  85;  75  85; 83   1;  84   1;  85   2;  86 436;  87  47;  88  18;  89   1; 95   6;  98   2;  99  38; 100 296; 
101  40; 102  30; 104   2; 105   2; 113   9; 114  13; 115  14; 116  16; 117  36; 118   4; 119  13; 120   1; 128   2; 130 107; 
131  62; 132  19; 133 178; 134  24; 135  11; 136   1; 138   1; 140   1; 142  16; 143   3; 144   5; 145   2; 146  27; 147 405; 
148  68; 149  33; 150   3; 157   1; 158   7; 159   2; 160  40; 161   8; 162   3; 163   3; 170   1; 172  16; 173  11; 174 654; 175 
120; 176  56; 177   3; 178   1; 187   2; 188  13; 189   2;  190   7; 200   2; 202   5; 204   8; 205   1; 206   1; 214   1; 216   5; 
218   1; 232  32; 233   6; 234   2; 248 459; 249 118; 250  59; 251   8; 252   1; 274   1; 288   7; 289   2; 290 102; 291  26; 
Hyun_May08 59 271 574.266 1677.1 Gluconic acid Putative 40   6;  41   3;  43  10;  45  81;  46   9; 53   2;  55  13;  57   1;  59  17;  60   2;  65   1;  66  27;  67   3; 73 999;  74  87;  75  96;  
76   4;  78   1; 80   2;  81   8;  82   2;  83  12;  84   9;  85  13;  87   2; 89  10; 90   1;  97   8; 99  13; 100   2; 101  24; 103 159; 
104  12; 109  24; 110   2; 111   4; 113   8; 115  32; 116  16; 117 142; 118  13; 119   8; 122   1; 126   2; 129  26; 131  32; 
132   1; 133  74; 134  12; 141   4; 143  24; 144   2; 145   4; 147 307; 148  46; 149  29; 150   3; 151   2; 152   1; 153   2; 154   
8; 157   5; 158   2; 159   3; 167   2; 170   3; 172  27; 173   6; 175   4; 177   3; 183  56; 184   7; 185   2; 186   4; 187   1; 189  
56; 190  11; 191  15; 192   2; 193   1; 196   2; 198   5; 199  24; 200   5; 201  73; 202  13; 203  13; 204 243; 205  94; 206  
29; 207  10; 208   1; 214   6; 215   5; 217  78; 218  16; 219   6; 229   3; 230   6; 231  21; 232   2; 233   4; 239   2; 240   3; 
242   2; 243   1; 245   3; 246   3; 247  18; 248   3; 249   2; 255  11; 256  12; 257  17; 258   4; 259   1; 261   1; 271  54; 272  
14; 273  17; 274   3; 275   1; 277   4; 278   2; 288   6; 289   2; 291  16; 292   4; 293   2; 299   4; 302   5; 303   1; 304   1; 305   
1; 306   2; 307   9; 308   2; 330   5; 331   2; 332   1; 333   1; 344   1; 345  52; 346  17; 347   8; 348   1; 359  12; 360  28; 361  
Hyun_May08 91 274 632.766 1912.8 2-methylascorbic acid Putative 31   3;  32 155;  33   1;  34   1; 45  86;  46   3; 52   7; 64   2; 73 999;  74  20;  78   3; 103  63; 104   6; 133  21; 135   3; 137   
1; 140 200; 142  27; 147 288; 148  44; 149  48; 150   3; 158   7; 159  46; 160  16; 163   3; 165   4; 184  34; 189  12; 190   4; 
191  11; 193   2; 194   2; 195   1; 204  21; 205  60; 206  11; 207  10; 208   1; 214  13; 216   5; 217  52; 230 120; 231  26; 
232  50; 233  10; 234   2; 244   2; 247   1; 253   1; 258   3;  260   1; 263   1; 271   1; 272   1; 273  13; 274 243; 275  53; 276  
33; 277   9; 278   4; 291   1; 292  15; 293   5; 294   2; 297   1; 298   5; 299  22; 304  22; 305  13; 306   5; 307   4; 311   1; 
313   1; 314   2; 315   2; 319  19; 320   2; 321   2; 332   6; 333  17; 334   6; 335   3; 348  12; 349   3; 350   2; 354   2; 359   3; 
360   1; 361   1; 365   1; 367   1; 375   1; 376  27; 377   9; 378  12; 379   4; 380   2; 382   1; 423   2; 433   1; 450   2; 451   1
Hyun_May08 05 285 341.666 1074.7 2,5-Furandicarboxylic acid Putative 30   1; 42   3; 43  16; 45 296; 46  15; 47  74; 48   1; 49  38; 53  35; 55   1; 58  10; 59   3; 60   2; 61  27; 63  12; 66   5; 67   1; 
69 522; 70   4; 71   1; 72  35; 73 999; 74  76; 75 165; 76   5; 77 235; 78   5; 79  25; 81  27; 90   1; 91   1; 99  76; 100   2; 
101   3; 103   5; 110   1; 115   6; 116   1; 117   9; 118   1; 119   1; 120   1; 131  28; 132   1; 133  23; 134  16; 135   8; 137   4; 
143 108; 144  10; 145   7; 147 970; 148 150; 149  78; 150   5; 151  37; 152   4; 153   4; 157   9; 159   4; 163  17; 164   3; 
165  57; 166   1; 169   2; 193  41; 194   2; 211   1; 213  13; 214   1; 231  55; 232   9; 233   2; 285 335; 286  66; 287  29; 288   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
- 179 - 
 
Peak ID Mass RT (Sec) RI Metabolite Name Definitive / Putative Mass (m/z) Intensity pairs
Hyun_May08 106 291 675.766 2111.2 Pantothenic acid Definitive 30   6;  31   2;  32   9;  39   7; 40   2;  41  33;  42  23;  43  42;  44  18;  45  80;  46   5;  47  28;  48   1;  49   1; 53   5;  54   2;  
55  77;  56  13;  57   1;  58  22;  59  33; 60   6;  61  22;  66   2;  67  19;  68   3;  69  33; 70  18;  71  48;  72  58;  73 999;  74  
82;  75 485;  76  40;  77  26;  79   4; 81  11;  82   8;  83  31;  84  10;  85  22;  86  11;  87  37;  88   8;  89  13; 90   1; 93   4;  
94   1;  95  13;  96   2;  97   9;  98  31;  99  16; 100  19; 101  17; 102  25; 103 316; 104  30; 105  20; 106   1; 107   3; 108   1; 
109   6; 110   1; 111   9; 112   7; 113   5; 115  22; 116  34; 117 535; 118  72; 119  38; 120   2; 121   2; 123   1; 124  12; 125   
3; 127   1; 128   8; 129 121; 130  44; 131  71; 132   4; 133  49; 134   9; 135   5; 136   1; 141   4; 142   1; 143  36; 144  34; 
145  35; 146  16; 147  41; 148  10; 149  16; 150   2; 154   1; 155   1; 156  10; 157 145; 158  25; 159  89; 160  12; 161   4; 
162   1; 163   6; 166   3; 168   1; 169   1; 170   2; 171   3; 172   6; 173   3; 174   5; 175   2; 176   4; 177   2; 181   2; 182   1; 
184   2; 185   3; 186   3; 188   5; 191   4; 195   1; 198   1; 199   1; 200   1; 201 128; 202  19; 203  13; 204   6; 211   1; 212   
1; 217   6; 218   7; 219   2; 228   1; 231   1; 240   2; 244   1; 246   8; 247  47; 248  10; 249   4; 261  17; 262   5; 263   1; 273   
1; 275   2; 276   1; 285   1; 291 102; 292  22; 293   9; 294   1; 299   3; 300   1; 305   3; 313  38; 314  15; 315   3; 318   1; 330   
Hyun_May08 44 292 544.266 1557.1 Erythronic and/or threonic acid Putative 45  66; 55  29;  57  11;  59   9; 69  39; 73 999;  74  89; 83  54;  85   1;  89  23; 102 180; 103 165; 104  18; 105   4; 111  17; 
112   7; 113   1; 115   6; 117 249; 118  20; 119  11; 125   3; 129  53; 130 169; 131  44; 132   6; 133  69; 134   2; 135   2; 
143  40; 145   2; 147 582; 148  92; 149  58; 150   3; 153   3; 157   6; 163   4; 167   3; 174   1; 177  25; 178   2; 189  20; 203   
6; 204  16; 205 152; 206  26; 207  19; 208   1; 217 123; 218  16; 219  10; 220 198; 221  62; 222  20; 223   4; 291  18; 292 
218; 293  61; 294  30; 295   5; 319  14; 320   2; 321   1
Hyun_May08 108 311 679.366 2127.8 Hexadecenoic acid Definitive 39  70; 40   5;  41 301;  42  61;  43 103;  45  59;  46   3;  47  44;  49   1; 53  43;  54 109;  55 461;  56  64;  59   3; 60   9;  61  
70;  62   5;  65  19;  66  11;  67 275;  68  95;  69 190; 70  26;  71  39;  72  46;  73 578;  74  79;  75 999;  76  77;  77  74;  78  
12;  79 121; 80  58;  81 239;  82 124;  83 161;  84 227;  85  53;  86  12;  87  13;  88   8;  89  23; 91  11;  92  17;  93  72;  94  
45;  95 157;  96 291;  97 152;  98 204;  99  41; 100   2; 101  12; 102   2; 103   9; 104   2; 105  31; 106   8; 107  36; 108  22; 
109  86; 110  92; 111  57; 112  37; 113   5; 115   5; 116  69; 117 652; 118  69; 119  55; 120  10; 121  35; 122  20; 123  70; 
124  41; 125  19; 126   4; 127   2; 128   4; 129 609; 130  77; 131 112; 133  35; 134  22; 135  22; 136  11; 137  46; 138  34; 
139  12; 140   2; 141  15; 142   5; 143  38; 144   4; 145 180; 146  17; 148   6; 149   3; 150   3; 151  25; 152  63; 153  10; 
154   1; 155  42; 156   7; 157  20; 158   7; 159  10; 160   3; 161   7; 162   4; 164   2; 165  12; 166  11; 167   2; 168   2; 169  
13; 170   5; 171  30; 172  12; 173  11; 175   2; 176   2; 181   3; 183  20; 184   3; 185  47; 186  12; 187   3; 188   2; 189   2; 
191   8; 192   7; 193  11; 194  36; 195   5; 197   2; 199  60; 200  13; 203   1; 205   1; 207   6; 208   3; 211   3; 213  11; 214   
2; 215   1; 217  16; 220   1; 223   1; 225   1; 227   6; 228   0; 229   3; 230   2; 236  28; 237   3; 241   1; 244   3; 255   1; 267   
Hyun_May08 107 313 676.566 2114.9 Hexadecanoic acid Definitive 30   2;  31   3;  38   1;  39  30; 40   6;  41 217;  42  45;  43 271;  44  21;  45  90;  46   6;  47  49;  48   2;  49   1; 51   1; 53  13;  
54  14;  55 247;  56  41;  57  94;  58  19;  59  29; 60  11;  61  64;  62   4;  63   2;  64   0;  65   2;  67  55;  68  10;  69  95; 70  
14;  71   9;  72  25;  73 825;  74  86;  75 877;  76  60;  77  42;  78   1;  79  18; 80   2;  81  59;  82   8;  83  60;  84  24;  85  21;  
86  10;  87   8;  88   5;  89  26; 90   3;  91   6;  93  15;  94   1;  95  49;  96   6;  97  41;  98  37;  99  20; 100   2; 101  11; 102   
2; 103   2; 105  28; 106   2; 107   7; 109  12; 110   1; 111  17; 112   8; 113   1; 115   6; 116  52; 117 999; 118  95; 119  41; 
120   1; 121   6; 123   3; 124   1; 125   4; 126   3; 127   3; 128   2; 129 417; 130  50; 131 151; 132 433; 133  79; 134  21; 
135   6; 137   1; 139   2; 140   2; 141   2; 142   1; 143  32; 144   4; 145 212; 146  28; 153   2; 154   3; 155   1; 157   8; 158   
1; 159  22; 160   3; 167   1; 168   1; 171  16; 172   2; 173   6; 174   3; 181   1; 182   1; 185  22; 186   3; 187  17; 188   5; 195   
2; 199   5; 201  38; 202   6; 203   1; 213   5; 214   1; 215   4; 216   1; 227   5; 228   1; 229   7; 230   1; 241   3; 243   7; 244   
1; 255   1; 257   4; 269   7; 270   2; 271   2; 283   1; 285   7; 286   2; 312   1; 313 107; 314  28; 315   7; 316   1; 328  13; 329   
Hyun_May08 126 315 734.466 2382.2 Myo-inositol phosphate Putative 45   3; 55   1;  56   2;  57  45; 69  19; 70   1;  71  12;  72   2;  73 999;  74  68; 83  16;  85  11;  87   2;  89   1; 95   1;  97   3;  98   
9;  99   5; 103  26; 105   1; 107   1; 109   3; 110   1; 111   3; 112   2; 115   2; 116  14; 119   1; 120   1; 121   5; 127  12; 128   
3; 129  74; 131  57; 133  90; 134  11; 135   6; 138   4; 139   1; 141   2; 142   6; 143  30; 144   7; 145   2; 147 335; 148  43; 
149  35; 150   2; 151   9; 153   6; 155   7; 156   2; 157   4; 158   1; 159   2; 161   3; 163   4; 165   1; 169   1; 175   4; 177   2; 
181   8; 183   1; 186   3; 188   2; 189   7; 190  10; 191 112; 192  13; 193  19; 195   4; 201   1; 203   3; 204   8; 205   5; 206   
1; 207  25; 208   3; 209   2; 211  39; 212   8; 213   5; 215   8; 217  78; 218  22; 219   7; 221  22; 222   6; 223   2; 225  14; 
226   3; 227  16; 228   4; 229   2; 230  15; 231   4; 236   1; 239   7; 241   1; 242   3; 243  23; 244   6; 246  24; 247   4; 248   
2; 249   1; 255  19; 256   5; 257   6; 265   6; 266   2; 269   6; 300  62; 301  26; 302   4; 303   1; 304   3; 305  10; 306   5; 311   
3; 312   1; 313  10; 314   4; 315 233; 316  57; 317  38; 318 260; 319  74; 320  36; 321  10; 322   1; 323   1; 325   1; 327   2; 
328   2; 330   2; 331   4; 332   3; 333   2; 337   1; 342   6; 343  17; 344   8; 345  12; 346   3; 347   3; 352   2; 353   1; 359   4; 
360   2; 369   2; 371   1; 372   2; 373   9; 374   4; 375   2; 379   1; 385   3; 386   9; 387  98; 388  35; 389  44; 390  14; 391   
5; 392   1; 393   1; 406   1; 417   3; 418   2; 419   6; 420   2; 421   1; 423   1; 429   7; 430   3; 431   3; 432   9; 433   9; 434   4; 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
- 180 - 
 
Peak ID Mass RT (Sec) RI Metabolite Name Definitive / Putative Mass (m/z) Intensity pairs
Hyun_May08 83 319 624.066 1876.3 Glucose Definitive 31   1; 41   4;  43   4;  44   4;  45  59;  46   3; 54   2;  55   8; 60   2;  61   2;  67   1; 72  11;  73 999;  74  85;  75  32; 82   6;  83  
14;  85   1;  86   3;  87   3;  88   4;  89  53; 90   4;  97   1; 100  11; 101  14; 102   9; 103 156; 104  15; 105  30; 106   3; 111   
1; 112   1; 114  13; 115   6; 116   5; 117 116; 118  12; 119  10; 126   1; 127   3; 128   4; 129 140; 130  25; 131  30; 132   4; 
133  78; 134  10; 135   5; 141   1; 142   6; 143  15; 144   3; 145   7; 146   1; 147 349; 148  56; 149  35; 150   4; 151   1; 157 
119; 158  25; 159   9; 160 270; 161  44; 162  12; 163  14; 164   2; 168   2; 169   2; 170   1; 172   3; 173   6; 174   2; 175   6; 
176   1; 177   7; 178   1; 180   1; 186   3; 187   1; 188   1; 189  36; 190  10; 191  23; 192   4; 193   1; 201   4; 202   3; 203   4; 
204  33; 205 213; 206  46; 207  24; 208   3; 210   4; 211   3; 212   1; 214   2; 215   3; 216  11; 217 129; 218  28; 219  13; 
220   2; 221   9; 222   2; 223   1; 228   1; 229  41; 230  11; 231  17; 232   5; 233   9; 234   6; 235   1; 240   1; 242   1; 243   2; 
244   4; 245   2; 246   4; 247   2; 248   1; 256   1; 259   1; 260   1; 262   7; 263   1; 265   1; 268   1; 269   3; 270   1; 274   7; 
275   2; 276   1; 277   7; 278   2; 279   1; 291   9; 292   2; 293   1; 305   3; 307   6; 308   1; 318   1; 319 163; 320  57; 321  
Hyun_May08 61 329 580.366 1701.5 Creatinine Definitive 30   3;  31   6;  32   2; 41  23;  42  98;  43  49;  44  30;  45 236;  46  16;  47  30;  48   1;  49   1; 50   1;  51   1;  52   5;  53   1;  
54   3;  55  15;  56 108;  57  22;  58  17;  59  88; 60  12;  61  19;  62   1;  64   2;  66  17;  67   2;  68   4;  69   3; 70  14;  71   8;  
72  38;  73 999;  74  98;  75 240;  76  17;  77   7;  78   2;  79   1; 82   2;  83  10;  84 432;  85  32;  86  31;  87  15;  88   7;  89   
3; 91   1;  97   1;  98   8;  99  35; 100 288; 101  40; 102  18; 103  14; 104   1; 105   2; 110   1; 111   4; 112   8; 113  16; 114  
63; 115 816; 116 113; 117  52; 118   6; 119   4; 125   2; 126   9; 127   4; 128  72; 129  24; 130  44; 131  43; 132  17; 133  
23; 134   4; 135   2; 139   2; 140  18; 141  10; 142  19; 143 390; 144  56; 145  21; 146  13; 147 154; 148  26; 149  21; 150   
3; 151   1; 154   1; 155   5; 156  46; 157  22; 158  75; 159  13; 160   6; 161   1; 168   1; 169   1; 170   2; 171 105; 172  29; 
173  18; 174 199; 175  32; 176  12; 177   1; 183   1; 184   2; 185   3; 186  30; 187  25; 188  11; 189   3; 190   1; 198   1; 199   
4; 200   6; 201  12; 202   4; 203   1; 204   6; 205   1; 213   2; 214   9; 215  13; 216   6; 217   2; 218   6; 219   1; 226   4; 227   
1; 228   1; 229   1; 230  36; 231   9; 232   4; 239   1; 240   2; 241   8; 242   2; 243   1; 244   1; 245   5; 246 139; 247  29; 248  
15; 249   2; 256   2; 257   1; 258   4; 259   1; 260   1; 261   2; 276  10; 277   2; 278   1; 313   1; 314  41; 315  12; 316   6; 317   
Hyun_May08 123 339 716.566 2299.5 Octadecenoic acid Definitive 39  26; 41 189;  42   1;  43  47;  47   1; 53  25;  54  78;  55 356;  56  45;  57  70; 60   4;  61  50;  62   2;  65  11;  66   4;  67 
226;  68  71;  69 148; 70  23;  71  26;  72  31;  73 999;  74  54;  75 462;  76  53;  77  44;  78   6;  79  94; 80  45;  81 191;  82 
101;  83 135;  84 203;  85  33;  86   5;  87  11;  88   4;  89  27; 90   6;  91  39;  92  11;  93  50;  94  31;  95 113;  96 237;  97 
118;  98 155;  99  30; 105  27; 106   9; 107  26; 108  20; 109  71; 110  79; 111  55; 112  22; 113   9; 116  53; 117 753; 118  
64; 119  50; 120   9; 121  29; 122  11; 123  54; 124  33; 125  17; 126   5; 127   1; 128   1; 129 488; 130  56; 131  80; 133  
30; 134  20; 135  18; 136   2; 137  36; 138  26; 139   6; 141   3; 142   3; 143  28; 144   4; 145 174; 146  21; 148   7; 149   1; 
150   8; 151  22; 152  31; 153   6; 155  26; 156   2; 157  17; 158   6; 159   9; 160   4; 161   6; 162   2; 163   2; 165  10; 166  
15; 167   7; 168   2; 169  24; 170   6; 171  23; 172   9; 173   9; 175   1; 178   2; 179   6; 180  21; 181   4; 183  23; 184   4; 
185  52; 186  11; 187   5; 188   2; 190   2; 193   5; 194   2; 197   3; 199  62; 200  11; 201   1; 204   3; 206   1; 207   3; 208   
2; 209   1; 211   9; 212   1; 213   8; 214   1; 217   1; 220   5; 221   8; 222  21; 223   4; 225   1; 227   7; 228   1; 229   1; 235   
3; 236   5; 237   1; 241   6; 246   3; 249   1; 253   1; 255   2; 256   1; 258   2; 259   1; 264  20; 265   3; 267   1; 271   1; 274   
1; 283   1; 287   1; 288   1; 295   1; 299   3; 300   4; 304   2; 305   2; 307   1; 309   1; 311   1; 314   1; 315   7; 316   1; 317   1; Hyun_May08 121 341 714.766 2291.2 Octadecanoic acid Definitive 30   1;  31   2;  39  24; 40   4;  41 209;  42  43;  43 302;  44  19;  45  72;  46   5;  47  36;  48   1;  49   1; 53  11;  54  14;  55 
251;  56  44;  57 128;  58  20;  59  28; 60   9;  61  54;  62   3;  63   1;  65   2;  67  56;  68  11;  69 104; 70  17;  71  32;  72  34;  
73 820;  74  83;  75 804;  76  56;  77  39;  78   1;  79  17; 80   2;  81  60;  82   8;  83  65;  84  23;  85  24;  86  10;  87   8;  88   
4;  89  26; 90   4;  91   7;  93  15;  94   1;  95  49;  96   5;  97  47;  98  40;  99  19; 100   7; 101  12; 102   2; 103   1; 105  25; 
106   1; 107   8; 109  14; 110   1; 111  20; 112  10; 113   2; 114   3; 115   7; 116  51; 117 999; 118  96; 119  41; 120   1; 121   
7; 123   4; 124   1; 125   5; 126   2; 127   3; 128   2; 129 426; 130  51; 131 140; 132 463; 133  96; 134  23; 135   8; 137   1; 
139   2; 140   2; 141   2; 142   1; 143  34; 144   4; 145 246; 146  33; 147   2; 149   1; 150   1; 153   1; 154   4; 155   2; 157   
7; 159  25; 160   3; 161   1; 167   1; 168   1; 171  17; 172   6; 173   6; 174   7; 175   1; 181   1; 185  26; 186   4; 187  18; 188  
11; 189   2; 199   5; 201  46; 202   8; 203   2; 210   1; 211   3; 213   4; 215   7; 216   1; 223   1; 227   8; 228   1; 229   3; 230   
1; 241   6; 242   1; 243   7; 244   2; 255   3; 257  10; 258   2; 269   1; 271   3; 283   1; 285   1; 297   6; 298   2; 299   6; 300   
Hyun_May08 80 357 617.766 1851.1 Glycerol-3-phosphate Putative 31   4;  32  23;  38   1;  39   3; 40   8;  41  18;  42   5;  43   9;  45  95;  46   4;  47   7; 50   2;  52   5;  53   1;  54   3;  55   4;  56   
6;  57   1;  58   9;  59  76; 60   6;  61  10;  62   1;  63   2;  66   9;  68  15; 71   1;  72  22;  73 999;  74  78;  75 101;  76   6;  77   
9;  78   1;  79   2; 81   3;  83   3;  84  29;  85   6;  86   1;  87  15;  88   8;  89  24; 90   1;  93   3;  95   2;  96   1;  97   1;  98   2;  
99  10; 101 140; 102   5; 103 249; 104  27; 105  13; 106   1; 107   2; 109   1; 111   2; 113  60; 114   4; 115  26; 116  26; 117  
62; 118   7; 119  12; 121   3; 122   1; 123   2; 124   1; 127   2; 129 126; 130  17; 131  83; 132   9; 133 112; 134  13; 135  26; 
136   2; 137   7; 138   1; 140   1; 143   2; 145   3; 146   3; 147 456; 148  57; 149  46; 150   6; 151  10; 153   2; 155   2; 156   
2; 157  17; 158   2; 159   6;  161   2; 163  11; 165   3; 167   2; 169   1; 170   1; 171   1; 173   3; 175   3; 177   2; 179   3; 181  
15; 182   2; 183   9; 184  12; 185   1; 189  19; 190   5; 191  24; 192   5; 193  16; 194   2; 195  11; 196   2; 197   3; 198   2; 
199   3; 201   1; 203  19; 204  10; 205  59; 206  11; 207  30; 208   7; 209   3; 210   1; 211 104; 212  18; 213   8; 217  88; 
218  54; 219  21;  220   5; 221   5; 222   1; 223   1; 224   1; 225  25; 226   9; 227  27; 228   5; 229   7;  230   2; 231   4; 233   
1; 241  29; 242   5; 243  16; 244   2; 245   4; 246   1; 253   3; 254   1; 255   4; 256  38; 257   7; 258   5; 259   1; 262   1; 263   
1; 265   1; 269   1; 270   2; 271   2; 277   3; 278   2; 279   1; 281   1; 284   1; 285  11; 286   3; 287   1; 291   1; 298   5; 299 
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Peak ID Mass RT (Sec) RI Metabolite Name Definitive / Putative Mass (m/z) Intensity pairs
Hyun_May08 88 364 628.166 1892.7 Citric acid Definitive 45  55;  46   4; 59  10; 67  64;  69   7; 72  15;  73 999;  74  92;  75  14;  76   3; 83   4;  87   2;  88   4;  89  39; 90   3;  95   4;  
96   2;  97   8;  99  10; 100   5; 101   8; 102   3; 103 141; 104  13; 105  13; 106   1; 111  12; 112   2; 115  21; 116   7; 117  
69; 118   7; 119   9; 128   1; 129 105; 130  12; 131  43; 132   7; 133 106; 134  12; 135   9; 139   6; 141   8; 142   2; 143  28; 
145   4; 146   1; 147 456; 148  85; 149  78; 150  10; 151   5; 154   1; 157  72; 158  15; 159   7; 160 110; 161  20; 162   6; 
163  14; 164   2; 165   1; 169   8; 170   1; 171   6; 172   1; 173   6; 175   4; 177   7; 178   1; 180   1; 182   1; 183  60; 184   5; 
185  16; 186   4; 187   3; 189  22; 190  10; 191   3; 192   1; 201   6; 203   3; 205 115; 206  22; 207  20; 208   3; 209   1; 210   
1; 211  72; 212  11; 213  13; 214   6; 215  12; 216   4; 217  68; 218  12; 219   7; 220   1; 221  30; 222   7; 223   3; 228   1; 
Hyun_May08 43 373 521.766 1477.5 Threitol and/or erythritol Putative 32  49;  37   2; 48   2; 50   5; 73 177; 80   1;  86   6; 95   4; 100   4; 115   3; 121  10; 123   4; 133  21; 135  40; 137   2; 153   
2; 163   3; 164   1; 165  21; 166   2; 167   2; 170   1; 174  34; 177  13; 179  11; 181  12; 189   9; 191 109; 192  23; 193 118; 
194  17; 195  41; 196   3; 197   3; 200   7; 201   4; 205  17; 207 159; 208  26; 209  19; 211  43; 212   2; 213   2; 221   2; 223   
6; 225  11; 227   1; 248  24; 249  23; 250   1; 251  13; 253   1; 255  26; 257   2; 265   2; 266   2; 267   4; 269  31; 270   4; 
271   2; 283  14; 284   3; 285 164; 286  34; 287  16; 290   2; 298   2; 299 149; 300  32; 301  16; 305   2; 314  19; 328   1; 
343  11; 357  44; 358  15; 359  10; 371   1; 372  47; 373 999; 374 308; 375 189; 376  42; 377  14; 390   1; 438   2
Hyun_May08 136 446 773.166 2560.8 Sugar phosphate Putative  30   4;  31   4;  32  16;  39   6; 40   4;  41  34;  42   9;  43  26;  44  14;  45  74;  46   4;  47  15; 51   1;  52   2;  53   6;  54   5;  
55  19;  56   3;  57  16;  58   7;  59  24; 60   3;  61   5;  65   1;  66   4;  67   6;  68  40;  69  18; 70   3;  71   8;  72  11;  73 999;  
74  71;  75  76;  76   4;  77   5; 80   5;  81   9;  82   8;  83   8;  84   7;  85   9;  86   2;  87   3;  88   2;  89  26; 90   2;  92   1;  94   
2;  95   3;  96  26;  97  15;  98  18;  99  16; 100   5; 101  14; 102   7; 103 174; 104  17; 105   9; 106   2; 107   7; 108   2; 109   
5; 110   4; 111   6; 112   4; 113  13; 114   5; 115   7; 116   5; 117  42; 118   4; 119   6; 120   1; 121   2; 122   1; 123   5; 124   
4; 125   3; 126   6; 127   5; 128   9; 129  47; 130   7; 131  15; 132   3; 133  47; 134   7; 135  11; 136   1; 137   2; 138   3; 139   
2; 140   7; 141   5; 142  21; 143  17; 144   3; 145   4; 146   1; 147 149; 148  30; 149  20; 150   2; 151   3; 152   1; 153   4; 
154   4; 155   3; 156  48; 157  14; 158   6; 159   2; 161   1; 163   3; 166   2; 167   4; 168   7; 169 139; 170  34; 171  17; 172   
5; 173  40; 174   6; 175   4; 177   3; 179   1; 180   3; 181   5; 182   4; 183  12; 184   4; 185   2; 186  17; 187   4; 189  12; 190   
Hyun_May08 79 451 616.866 1847.5 Fructsoe Definitive 30   5;  31   6;  32  36;  38   1;  39   3; 40   9;  41  10;  42  10;  43  26;  44  17;  45 134;  46   8;  47  15;  48   1; 50   2;  51   2;  
52   6;  53   3;  54   4;  55   9;  56   9;  57   8;  58  13;  59  45;  60   4;  61   4;  62   1;  63   2;  64   0;  65   1;  66   8;  67   1;  68  
12;  70  11;  71   5;  72  26;  73 999;  74  78;  75  76;  76   4;  77   7;  78   1;  79   2; 80   1;  81   3;  82   3;  83   7;  84  26;  85   
3;  86  12;  87   9;  88   6;  89  34;  90   3;  91   1;  93   2;  95   2;  96   1;  98   2;  99   5; 100  10; 101  14; 102   7; 103 294; 
104  35; 105  16; 106   1; 107   1; 112   1; 113  23; 114   5; 115  10; 116   1; 117  41; 118   5; 119   6;  121   1; 126   1; 127   
1; 128   3; 129  30;  130   6; 131  21; 132   3; 133  48; 134   5; 135   9; 136   1; 137   1; 140   1; 142   6; 143   4; 144   2; 145   
2; 146   4; 147 185; 148  25; 149  17; 150   2; 151   2; 154   1; 155   3; 156   4; 159   2; 161   1; 163   5; 165   2; 170   1; 171   
1; 172   9; 173  12; 174  28; 175   8; 176   2; 177   2; 181   3; 182   1; 183   1; 184   8; 185   1; 186   9; 187   1; 188   1; 189  
20; 190   4; 191  12; 192   2; 193   7; 195   2; 196   1; 198   1; 199   2; 201   5; 202   3; 203   3; 204   6; 205  11; 206   1; 207   
6; 208   1; 211   4; 212   1; 216   3; 217 148; 218  35; 219  14; 220   2; 221   3; 225   1; 227   1; 228   1;  230   1; 231   3; 235   
Hyun_May08 134 480 767.165 2533.1 Lactose Definitive 30   1;  31   2; 43   3;  44   1;  45  26;  46   1; 53   2;  54   2;  55   9;  58   2;  59  17; 60   1;  61   2;  67   1;  69  25; 2   8;  73 
999;  74  81;  75  36;  76   1; 81  13;  82   2;  83   1;  85   3;  86   2;  87   3;  88   3;  89  42; 90   3;  97  11;  98   1;  99   3; 100   
9; 101  15; 102   9; 103 149; 104  14; 105  23; 106   2; 109   5; 110   1; 111   3; 113   8; 114   8; 115   8; 116   8; 117 118; 
118  12; 119   9; 126   1; 127   6; 128   4; 129 155; 130  23; 131  29; 132   4; 133  68; 134   8; 135   5; 138   1; 139   2; 140   
1; 141   5; 142   6; 143  40; 144   5; 145  11; 146   1; 147 345; 148  52; 149  39; 150   4; 151   2; 152   1; 153   4; 154   1; 
155  28; 156   5; 157  35; 158   7; 159   6; 160  65; 161  13; 162   4; 163  14; 164   2; 165   1; 167   2; 168   3; 169 136; 170  
20; 171  10; 172   3; 173   8; 174   3; 175   5; 176   1; 177   5; 178   1; 180   1; 181   2; 182   1; 183   3; 184   1; 185   2; 186   
3; 187   2; 188   1; 189  34; 190   8; 191  66; 192  11; 193   5; 195   1; 196   1; 198   1; 199   2; 200   1; 201   2; 203  10; 204 
320; 205 134; 206  43; 207  13; 208   2; 210   9; 211   1; 212   1; 214   1; 215   7; 216   8; 217 217; 218  52; 219  23; 220   
4; 221  12; 222   2; 223   2; 227   3; 228   2; 229  17; 230   9; 231  22; 232   7; 233  14; 234   4; 235   2; 240   2; 241   4; 242   
3; 243  41; 244  12; 245  12; 246   5; 247   9; 248   2; 249   1; 254   1; 255   2; 256   3; 257   4; 258   1; 259  10; 260   3; 261   
2; 262   3; 263   1; 265   2; 268   2; 269   4; 270   3; 271  45; 272  11; 273   6; 274   2; 275   2; 276   3; 277   1; 278   1; 279   
1; 286   1; 287   1; 289   1; 291   6; 292   2; 293   1; 300   9; 301   2; 302   1; 303   1; 304   1; 305  11; 306   3; 307   2; 317   
3; 318   2; 319  75; 320  23; 321  11; 322   2; 331  14; 332   7; 333   4; 334   1; 337   1; 343   1; 345   2; 346   1; 358   1; 359   
5; 360   3; 361 149; 362  50; 363  25; 364   6; 365   1; 374   2; 376   1; 377   1; 390   3; 391   1; 409   5; 410   2; 411   1; 422   
Hyun_May08 102 507 657.166 2025.4 Myo-inositol Definitive 43   1;  44   7;  45  65;  46   4; 53   4;  54   2;  55   8;  59  18; 60   1;  61   1; 72  10;  73 999;  74  85;  75  23; 81   3;  84   1;  87   
1; 101   4; 102   2; 103  52; 104   5; 105   2; 111   2; 116   2; 117   2; 119   3; 127   3; 129  81; 130   9; 131  23; 132   2; 133  
70; 134   9; 135   5; 141   1; 142   1; 143  17; 144   1; 145   2; 147 341; 148  54; 149  31; 150   3; 157   4; 159   1; 161   9; 
162   1; 163   1; 175   3; 177   5; 189   8; 190  10; 191 221; 192  39; 193  19; 194   2; 201   1; 203   4; 204  67; 205  16; 206   
6; 207   7; 208   1; 215   2; 216   1; 217 307; 218  70; 219  33; 220   4; 221  24; 222   6; 223   3; 229   1; 230   6; 231   5; 232   
1; 235   1; 243   5; 244   1; 245   2; 255   1; 265  76; 266  20; 267  11; 268   2; 271   1; 277   1; 278   1; 279   1; 291  12; 292   
3; 293   4; 294   1; 304   3; 305 122; 306  47; 307  27; 308   6; 309   1; 317   3; 318 107; 319  50; 320  23; 321   7; 322   1; 
331   1; 343   4; 344   1; 345   1; 367  16; 368   5; 369   3; 379   1; 392   1; 393  10; 394   3; 395   2; 419   2; 420   1; 431   1; 
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Appendix F     A Raman spectra of lopinavir 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix G     Additional chemical maps from 670 and 825 cm-1 from E6I, and 680 cm-1 
from E6L 
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